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Abstract
The work presented in this thesis foeuses on the purification, characterisation and
practical applications of an anti-staphylococcal lysin (LysK) and its single-domain
truncated derivative (CHAPk) against pathogenic staphylococci including meticillin
resistant Staphylococcus aureus (MRSA). Both proteins were purified to greater than
90% homogeneity. Affinity chromatography was applied as the optimum method for
LysK purification and ion-exchange chromatography was successfully applied to
CHAPk. The lytic spectrum of LysK was investigated by zymogram analysis where the
enzyme exhibited strong activity against a range of staphylococci regardless of their
origin, sequence type (ST) or antibiotic resistant profile. This analysis included all S.
aureus sequence types in existence in Ireland from the National MRSA Reference
laboratory, Dublin and exopolysaccharide (EPS) producing S. aureus strains associated
with bovine mastitis. Subsequent studies revealed that the LysK enzyme was unstable
and prone to aggregation which ultimately restricted its development for possible
applications in in vitro and in vivo experiments. CHAPk, the truncated single-domain
derivative of LysK was found to be a stable, highly active, highly soluble enzyme.
Purification using cation exchange chromatography regularly yielded up to 10 mg of
pure, soluble, active protein per litre of E. coli culture. The lytic spectrum of CHAPk,
not only included all staphylococci that were susceptible to the native three-domain
LysK protein but also extended to members of the genera Micrcococcus, Streptococcus,
Nesterenkonia, Arthrobacter, Leuconostoc and Camobacterium. Characterisation of
CHAPk over a range of parameters and conditions revealed the enzyme was active from
pH 6 to 11 with an optimum activity at pH 9; from 5°C to 40° C, with an optimum
activity at 15°C and also maintained activity in the presence of 0 to 300 mM NaCl. In
addition CHAPk was analysed in the presence of a variety of inhibitors and the effect of
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repeated freeze-thaw cycles and storage at 4°C and -80°C was also recorded. When
cidture lysis by CHAPKand the metalloendopeptidase lysostaphin were compared over a
concentration range of 2.5 to 10 pg/ml using live S. aureus cells for 5 min at 37°C,
CHAPk gave rise to greater turbidity reduction indicating that it works more rapidly than
lysostaphin. Further studies were performed to investigate the practical applications of
CHAPk for the control and prevention of staphylococcal infection. In one such study
CHAPk was shown to rapidly disrupt and eliminate mature biofilms of S. aureus within
an hour. CHAPk was not only able to disrupt mature biofilms but was also able to
completely prevent biofilm formation. CHAPk was explored as a spray decolonisation
agent to remove S. aureus from skin and the enzyme removed 99% of S. aureus in 30
min. An in vivo trial was performed using CHAPk with an In Vivo Imaging System
(IVIS) and BALB/c mice. Treatment with CHAPk successfully eliminated a lux-labeled
S. aureus strain from the nares of the inoculated animals. Finally, in silico analysis was
undertaken on the enzyme resulting in the predicted three-dimensional structure of the
CHAPk protein. The overall results in this thesis provide new insights into the novel
anti-staphylococcal enzyme CHAPk tind indicate it has significant potential for
development as an effective antibacterial agent against pathogenic staphylococci
including MRSA.
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Chapter 1
Literature Review
Recombinant bacteriophage lysins as antibacterials

Bioengineered bugs (2010). 1(1): 9-16.

Abstract
With the increasing world-wide prevalence of antibiotic resistant bacteria, bacteriophage
endolysins (lysins) represent a very promising novel alternative class of antibacterial in the
fight against infectious disease. Lysins are phage-encoded peptidoglycan hydrolases which,
when applied exogenously (as purified recombinant proteins) to Gram-positive bacteria,
bring about rapid lysis and death of the bacterial cell. A number of studies have recently
demonstrated the strong potential of these enzymes in human and veterinary medicine to
control and treat pathogens on mucosal surfaces and in systemic infections. They also have
potential in diagnostics and detection, bio-defence, elimination of food pathogens and control
of phytopathogens.

This

review discusses the extensive

research on

recombinant

bacteriophage lysins in the context of antibacterials, and looks forward to future development
and potential.

Introduction
Bacteriophage (phage) are considered ubiquitous and estimated to be the most
abundant biological entities on earth. ’ Phages are viruses that specifically infect
bacteria. They were first discovered in the pre-antibiotic era by d’Herelle in 1917
although their antibacterial behaviour was previously described by Hankin in 1896/
and Twort in 1915.'^’^ Since the commercialisation of antibiotics in the 1940’s phage
therapy has been largely neglected in the west until recently with growing concerns
for the increasing prevalence of multi-antibiotic resistant so called “superbugs”
including Meticiilin-Resistant Staphylococcus aureus (MRSA) and the scarcity of
new antibiotics. ’ Over millions of years phage have developed two methods for the
purpose of releasing their progeny from host bacterial cells. Filamentous phage are
released through bacterial cell walls without causing cell death*^ whereas nonfilamentOLis phage use specific lysins to either inhibit the synthesis of peptidoglycan
(single stranded RNA or DNA phage encoded enzymes) or hydrolyse the
peptidoglycan using a holin-endolysin system (double stranded DNA phage encoded
enzymes).'^ Lysins accumulate in the cytosol during the late stage of the lytic cycle
and hydrolyse the peptidoglycan in the bacterial cell wall thus releasing mature phage
progeny." Lysins usually don’t have signal sequences and so are dependent on a
second protein called a holin to reach their substrate. “ At a genetically determined
time (the holing triggering time is allele specific, in that it can be advanced or retarded
by misense mutations) in the terminal stage of the lytic cycle, holins form pores in the
inner membrane of the infected cell resulting in access of lysin to the peptidoglycan '
causing rapid cell lysis. ‘ For phage; both the holin and lysin are essential for host cell
lysis using this system, however when lysins are used as recombinant enzymes and
applied exogenously to Gram-positive bacteria they cause rapid lysis as no membrane

is present to inhibit their access to the cell wall.'"^’''’ It is this potent ability to rapidly
lyse pathogenic Gram-positive cells upon direct contact with peptidoglycan “lysis
from without” that has laid the foundation for exploiting lysins as powerful novel
antibacterials. In the case of Gram-negative bacteria, the outer membrane prevents
access of exogenous lysins to the cell wall peptidoglycan and therefore, their
exploitation as antibacterials is limited. It was in 2001 that a phage lysin was first
shown to successfully prevent and eliminate a bacterial infection in

Unlike

antibiotics, phage lysins can be used to selectively target specific pathogenic bacteria
without effecting surrounding commensal microflora: they are reported to have a
narrow host range similar to that of their phage rendering them generally cither
species'^ '^ or genus specific,although, in at least one case there is evidence that
lysins can target more than a single genus."
There is currently an ever-growing concern over the global spread of antibiotic
resistance among human and animal pathogens and the need for novel effective
antibacterials (like phage lysins) to combat them is recognised.*"'MR.SA is
commonly reported in clinical settings in Europe where there is also a significant level
of antibiotic resistance within the genera of Enterococcus, and Streptococcus."' This
review will focus on the nature of phage lysins and their diverse applications
including; the control and treatment of pathogens on mucosal surfaces and in systemic
infection, there potential in diagnostics and detection, bio-defence, elimination of
food pathogens and control of phytopathogens.

Lysin Structure
In general, lysins studied to date display a two domain modular structure.This
comprises an N-terminal catalytic domain and a C-terminal cell wall binding
domain.

'

The former is categorised into four different groups depending on
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cleavage sites (Fig. 1). The four are (a) N-acetylmuramidases (lysozymes) and (b) Nacetyl-P-D-glucosaminidases (glycosidases), which hydrolyse the B-1-4 glycosidic
bond in the sugar moiety of the cell wall (c) N-acetylmuramoyl-L-alanine amidases,
which cleave the amide bond connecting the sugar and peptide moieties of the
bacterial cell wall (d) L-alanoyl-D-glutamate endopeptidases and interpeptide bridgespecific endopeptidases,

which attack the peptide moiety of the cell

peptidoglycan (See Fig. 1).

" "

wall

Lysins typically comprise of one of these four

muralytic abilities in addition to a cell wall binding domain.’*^ However a number of
lysins have been reported comprising of two catalytic domains including those of
Staphylococcus aureus (LysK, Phil 1 and MV-L) where endopeptidase activity is a
common feature.“

Of all lysins reported to date, the streptococcal phage lysm

PlyC is particularly unique as it displays a multimeric modular structure consisting of
two distinct gene products designated PlyCA (5()-kDa heavy chain) and PlyCB (8kDa light chain).

34

Figure 1. Typical peptidoglycan structure of Gram-positive bacteria, showing lysin cleavage
sites. The cleavage sites are indicated: (1) N-acetylmuramidases; (2) N-acetyl-P-Dglucosaminidases; (3) N-acetylmuramoyl-L-alanine amidases; (4) L-alanoyl-D-glutamate
endopeptidases and interpeptide bridge-specific endopeptidases. Abbreviations: GlcNAc (Nacetyl glucosamine), MurNAc (N-acetyl muramic acid).

The C-terminal binding domain of the majority of lysins is responsible for attaching
the enzyme to its specific substrate in the bacterial cell wall via non-covalent binding
of carbohydrate ligands.“ A recent study on the crystal structure of the pneumococcal
phage lysin Cpl-1 in free and choline-bound states suggested that the choline-binding
domain assists in the correct positioning of the N-terminal catalytic domain." While it
appears that the C-terminal domain

is necessary for lytic activity of some

endolysins,'^’^^’^^ this is not always the case. A number of enzymes have shown
increased lytic activity upon removal of the binding domain.For example, when
LysK was truncated to its N-terminal endopeptidase domain, CHAP (cysteine,
histidine-dependent amidohyrolase/peptidase), it had a two-fold higher lytic activity
than the native enzyme.

It is possible that the C-terminal binding domain in the

native enzyme may be limiting the potential activity of the N-terminal lytic domain by
only allowing it to configure and function when bound to its target in the cell wall.^'^''^^
In contrast to lysins against Gram-positive pathogens, the enzymes associated with
Gram-negative phages are often globular single module enzymesas in the T7 lysin
(lysozyme).

In a recently-reported two-domain lysin KZ144 from a Pseudomonas

phage, the substrate-binding activity was located at the N-terminus.‘^' In recent years,
research on a number of lysins has led to the elucidation of their crystal structure as in
the case ofT7 lysin,"^^ T4 lysin,"^'^ CpL-1,PlyL,'^^ PlyPSA"^"^ and PlyB.'^'"’ The diversity
of enzymztic activities with phage lysins and their association with distinct modules
make it possible to engineer novel lysins with various combinations of binding and
catalytic domains,increasing their antibacterial and therapeutic potential.

12

Critical Properties of lysins as Potential Therapeutics
If these recombinant enzymes are to fulfill their potential as antibacterials a number of
important factors have to be investigated such as drug toxicity, immunogenicity,
efficacy, resistance and synergy. To date a number of in vitro and in vivo trials have
been carried out on various lysins to assess these parameters.

Toxicity
Bacteriophages are the most abundant life forms on the planet and have co-evolved
with bacteria over millions of years. Their lysins specifically target peptidoglycan
bonds present in bacterial cell walls and cannot infect mammalian cells'"'^. Therapeutic
lysin treatment, be it topical, systemic or intravenous is thus far observed to have no
harmful, abnormal or irritant side-effects in pre-clinical trials in mouse models.''^’'^"'’''
53

Immunogenicity
As lysins are proteins, they are capable of stimulating an immune response when
administered mucosally or systemically.

This response could potentially decrease

lysin activity. In vitro and in vivo trials have been conducted to explore this. When
rabbit hyperimmune serum was raised against the pneumococccal lysin Cpl-1, it was
found that lytic activity in vitro was slowed but not blocked.'Similar results were
seen with B. antraciis and S. pyogenes lysins.''''^ In vivo analysis showed that in five
out of six cases, mice that received three intravenous doses of Cpl-1 tested positive
for Immunoglobulin G (IgG) against the enzyme but this only had a moderate
inhibitory effect on activity.

52
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In a study with the Lisleria-spQCiflc lysins, Plyl 18 and Ply500, it was demonstrated
that the affinity of the C-terminal binding domain for its target in the cell wall is in the
nanomolar range, similar to the binding affinity of an IgG molecule for its antigen.

9Q

Fischetti’s group showed that increased cytokine production could also result from
using phage lysin in the treatment of systemic infection.This inflammatory effect is
likely dependent on the amount of lysin delivered in the treatment and may be
reduced with regulated smaller doses of enzyme.

Immunogenicity of lysins in

systemic infection treatment can further be reduced by PEGylation where the protein
is conjugated to polyethylene glycol (PEG), reducing antibody binding, as shown w'ith
lysostaphin.'’^ This also causes a slight reduction in lysin activity but it is compensated
for by greatly improved pharmacokinetics.'^^ While it is clear that lysins can illicit an
immune response, this does not neutralize their activity or prevent their use as
antibacterials in the treatment of systemic infections.

Resistance
For phage lysins, no development of resistance has been reported to date. It has been
suggested by some authors that the occurrence of lysin-resistant bacteria is unlikely
since phage have naturally evolved with their bacterial hosts over millions of years
producing lysins which purposely target specific molecules in the host peptidoglycan
that are essential for bacterial viability.This is supported by the fact that choline,
the cell wall receptor for pneumococcal lysin is essential for cell viability.
Similarly polyrhamnose, the cell wall receptor for Group A streptococcal lysin is also
important for cell viability.Repeated exposure of Streptococcus pneumoniae and
Bacillus cereus to low concentrations of lysin Pal and PlyG respectively on agar
plates and in liquid culture did not result in the emergence of resistant mutants even
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after numerous cycles.The polysaccharide capsule of S. pneumoniae associated
with increased virulence of the bacterial cell did not inhibit lysin activity.'^ A
susceptible B. cereus isolate was demonstrated to develop up to 1,000 to 10,000-fold
increases in antibiotic resistance upon mutagenesis with methanesulfonic acid ethyl
ester while remaining sensitive to PlyG lysin, where no resistant mutants were
found.

In addition the use of lysins with two catalytic domains, each with different

peptidoglycan specificity, may further reduce the likelihood of resistant strains
emerging.'^However, certain bacterial resistance mechanisms to antibiotics suggest
that bacteria are capable of accommodating various changes in their peptidoglycan
structure. Consequently, the occurrence of resistance to lysins, even if considered
unlikely, cannot be ruled out entirely.

Synergy
Studies have demonstrated that some lysins can work in synergy with others or with
certain antibiotics both in vitro and in

When Cpl-1 (lysozyme/muramidase)

and Pal (amidase) were used in combination, the bacteremic titre was reduced to a
greater extent than by either lysin alone, in a murine sepsis model.'’'In another
recent in vitro study, the staphylococcal bacteriophage lysin LysK and lysostaphin
demonstrated antibacterial synergy.^'^ Synergy has also been demonstrated between
lysins and antibiotics in vitro.

Two pneumococcal enzymes, Cpl-1 and LytA

have been used in synergy with a number of antibiotics including penicillin,
gentamicin, cefotaxime and moxifloxacin. In the majority of cases, there was
enhanced activity where an antibiotic was combined with one or other of the
enzymes.The staphylococcal lysin MV-L showed enhanced activity against the
vancomycin-intermediate S. aureus (VISA) strain Mu50 when used in combination
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with glycopeptide antibiotics vancomycin or teicoplanin. ' While these studies have
only been done in vitro, it is clear that the approach of combining lysins with
antibiotics generally gives rise to increased antibacterial activity.

Applications of lysins
Numerous successful pre-clinical trials have revealed the ability of lysins to prevent
pathogenic colonisation of the mucosa,the first being in 2001.'^ The
potential use of lysins as antibacterials against systemic diseases has also been
demonstrated since then by a number of other studies.^^’'’'"'’^ While antibiotics often
kill bacteria indiscriminately, lysins possess high specificity permitting the normal
commensal microflora to be left undisturbed. Moreover, antibiotics such as penicillin
and cephalosporin function by inhibiting pcptidoglycan synthesis, thereby lysing only
dividing cells. Lysins on the other hand destroy the peptidoglycan directly, killing
both growing and non-growing cells. 65

Lysins against Different Pathogenic Bacteria

Streptococci
The pneumococcal lysins Cpl-1 and Pal have been used successfully in pre-clinical
trials in the elimination of antibiotic-resistant S. pneumoniae, the causative agent of
pneumonia, acute otitis media (AOM), septicemia, bronchitis and meningitis.'”’’"'’^’^^ A
2,000 )j.g dose of Cpl-1 when used intravenously in a mouse model one hour after
infection reduced pneumococcal titres from a median of logic 4.70 CFU/ml to
undetectable levels (<logio 2.00 CFU/ml) after 15 minutes. Compared to the lysintreated mice, only a 20% survival rate was seen in untreated mice.'’" The Cpl-1 lysin
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has also been introduced by intraperitoneal injection to mice.^^ In this study 100% of
Cpl-1-treated mice survived otherwise fatal pneumonia and showed rapid recovery
when treatment had been initiated at 24 hours post infection. Cpl-1 prevented
bacteremia, systemic hypertension and reduced pulmonary bacterial counts.In
murine models of infection, Cpl-1 was shown to eliminate and prevent acquired otitis
media, endocarditis and bacterial meningitis.
The Pal lysin was also used successfully to eliminate pneumococcal colonisation of
the nasopharynx in mice. This was achieved with a single dose of the enzyme and no
recolonisation was observed.'^ These studies show that Cpl-1 and Pal lysins have
excellent potential in the prevention, control and treatment of mucosal colonisation
and systemic pneumococcal infection. In addition, bacteria were susceptible to lysis
regardless of the presence of a capsule, indicating that it is not capable the lysins
access to peptidoglycan.
PlyC lysin from the streptococcal bacteriophage Ci has been found to be active
against groups A, C, and E streptococci. Group A streptococcus bacterium
(Streptococcus pyogenes, or GAS) is a common cause of pharyngitis.'^ In one timecourse assay, where cell death of streptococcal cells equated to a spectrophotometric
loss in turbidity, 10 ng of PlyC completely eliminated a culture of ~10^ GAS in 5
seconds. This enzyme was also able to successfully prevent and eliminate upper
respiratory colonisation of mice by GAS.'^ Mice were orally and nasally administered
GAS premixed with either buffer or lysin. 24 hours post treatment, none of the lysin
treated mice were colonised compared to 100% of the control mice. Up to one week
later, only a single colony of GAS from 20 swabs was detected in the lysin-treated
mice. 16
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PlyGBS is another well-studied recombinant streptococcal lysin and is active against
group A, B, C, G and L streptococci.^"^ It has been developed as a prophylactic for
Group B streptococcal (GBS) vaginal colonisation in pregnant women before infant
delivery and also for use as a decontaminant to eliminate GBS from new-borns. This
would potentially reduce the rate of neonatal meningitis and sepsis.Mice models
were successfully used to demonstrate that a single dose of PlyGBS could cause a 3
logio reduction in cell titre in mice that had been vaginally challenged with GBS.
Optimum pH of PlyGBS (~ pH 5.0) is within the range normally found in the human
vaginal tract, and the enzyme did not show activity against vaginal commensal flora
such as Lactohacilliis acidophilus which play a role in defence against pathogens.^"^ In
another study, DNA mutagenesis techniques were used to produce PlyGBS mutants
with up to 28-fold better activity against GBS than the wild-type enzyme.

Staphylococcus aureus including MRSA
S. aureus is responsible for a number of infections ranging from skin infections to
fatal sepsis, endocarditis, septicemia, meningitis and bovine mastitis in dairy herds. ’
MRSA is an important cause of antibiotic resistant healthcare-associated infection
which may result in prolonged hospital stay and higher mortality rates.With the
increasing prevalence of MRSA and increasing incidence of Community-Acquired
MRSA, there is an urgent need for an effective anti-staphylococcal agent. ’

LysK

lysin from staphylococcal phage K has been reported to be active against nine species
of

Staphylococcus

from

both

human

and

bovine

sources.Another

staphylococcal lysin, LysH5, was reported to eliminate S. aureus growing in milk,
which had been present at 10^ CFU/ml.^'^ A third lysin, Phil 1, was active against live
mastitis-causing Coagulase-negative staphylococci.^"^ This enzyme was also shown to

eliminate S. aureus biofilms, which is clinically relevant given the infection problems
associated with biofilm formation on medical devices. 75
The first staphylococcal lysin to be tested in vivo in a mouse infection model is MV-L
from the phage MRll." In one experiment, this was administered intranasally 60
hours post infection with 2 x 10^ MRS A cells in each nasal cavity. Six hours after
lysin treatment, complete elimination of the bacteria was achieved in 1 of 9 mice
treated. The remaining mice had much lower bacterial titres in their nasal cavities
compared to control mice. In a second experiment, mice treated intraperitoneally with
MV-L at 0 minutes and 30 minutes after being challenged with MRSA survived up to
60 days post infection.'^'^ Although an immune response to this lysin was evident, it
did not block lytic activity.
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Enterococci
Enterococci are commonly part of the resident microllora of the lower intestinal tract
in mammals. However, under circumstances where the natural Hora is disturbed, the
bacteria can become invasive and cause nosocomial infections such as endocarditis,
bacteremia and urinary tract infections.-' The majority of these infections are caused
by E. faecalis and E.faecium. Over the past two decades the emergence of particular
clones of both E. faecalis and E. faecium was paralleled by increases in glycopeptide
and aminoglycoside resistance."' The E. faecalis phage lysin PlyV12 showed strong
lytic activity in vitro against a variety of clinical and laboratory strains including VRE
(vancomycin-resistant

enterococcus).

The lysin also showed activity

against

Staphylococcus and Groups A, B, and C streptococci making it one of the first lysins
showing a broad lytic spectrum outside the host range of its parent phage.This is
likely due to a peptidoglycan feature which is common to the genera examined. 76
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Bacillus anthracis
B. anthracis is associated with bio-warfare and is thus classed as a category A
biologieal weapon/^’^^ Two recombinant lysins, PlyG and PlyPH are active against
this pathogen. ’

Since B. anthracis is highly toxic to humans, a B. cereus strain

lacking the B. anthracis virulence plasmid was utilised for in vivo studies. In one
experiment, PlyG was injected into mice 15 minutes after they were infected with 1 x
10^ CPU of an antibiotic resistant B. cereus strain resulting in a 76.9% survival rate
compared to the 100% death rate of infected control mice within 5 hours.PlyPH, is
a putative lysin which was shown to be effective against B. anthracis in; in vitro and
in vivo studies.

These lysins have the potential for exploitation for detection and

treatment of B. anthracis infections.

Clostridium
C. difficile is a major cause of nosocomial-associated diarrhoea and colitis. It usually
presents as a secondary infection where it proliferates in the gastro-intestinal (GI)
tract after the normal commensal Hora has become unbalanced due to antibiotic
therapy.CD27L is a lysin identified from the C. difficile phage CD27^^^ and was
capable of lysing diverse strains of C. difficile. Importantly the lysin did not
negatively effect other commensal gut Hora normally present in the GI tract, including
non pathogenic ClostridiLim-\\V.Q Firmicutes. The lysin demonstrated a broad pH range
(pH 4.5-pH 8.3) and was expressed in a Lactococcus lactis strain which could
potentially be used as a delivery system to the site of infection in the GI tract where
the lysin should remain functional.
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Ply3626 is a lysin with activity against C. perfringens which can cause necrotic
enteritis, gas gangrene and food poisoning. ’ ' This enzyme may be exploited as an
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anti-bacterial for the treatment of C. perfringens infection in humans. In addition it
has been proposed as a hio-control agent in poultry and in food as discussed below. “

Further Applications of Phage Lysins

Veterinary and Food Applications
Lysins may not only be applied and developed to treat human infections. They may
also have applications in veterinary and food sectors as alternative antibacterial agents
in the treatment of infections, prevention and spread of zoonotic disease and pathogen
contamination of food. Bovine mastitis is the most common cause of death in adult
dairy cows and the cause of significant annual economic losses worldwide.

Its

presence can also lead to food contamination particularly in the context of raw milk
cheeses.The Ply7()() enzyme has shown lytic activity against mastitis causing
streptococci in cows’ milk, and another lysin, LysH5, has shown lytic activity against
prevalent mastitis causing staphylococci in pasteurised milk. ’ '
A recent study revealed that a recombinant phage lysin LySMP has a broad lytic
spectrum against the increasingly antibiotic-resistant swine pathogen Streptococcus
suis, which can cause conditions such as endocarditis and septicemia in pigs and is
also an important zoonotic agent.^^’^^ Mortality can approach 20% in pigs carrying or
infected with S. suis, in the absence of treatment.
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The recombinant phage lysin PlyC has been developed as an enzyme disinfectant
against Streptococcus equi, the causative agent of equine strangles.

Serious

complications occur in 20% of infected horses, and an overall mortality rate as high as
8% occurs on farms where infection is endemic.The lysin was assessed for its
ability to help control S. equi spread and transmission in horse stalls and barns and
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was shown to be superior to chemical disinfectants which can be toxic, easily
inactivated, environmentally unfriendly and have a broad bactericidal range. In one
experiment, PlyC remained fully active in a horse stable environment. It was active
against >20 clinical isolates of S. equi, and on a per-weight basis was 1,000 times
more active than the common oxidising chemical Virkon-S, a widely used disinfectant
in the livestock industry for disease prevention and control.
Q

Typically 1 jig of PlyC

was able to sterilize a 10 CFU/ml culture of S. equi in 30 mins.

OQ

Lysins also have a potential role to play in the food industry as can be seen with
Ply3626. This enzyme has shown lytic activity against several strains of C.
perj'ringens, which is a common cause of food poisoning and leads to economic losses
in poultry production. “ It has been proposed that Ply3626 may be exploited as a
control for this pathogen in poultry intestines, as a bio-preservative in raw poultry
products and as a bio-control agent to be added directly to food or feed.^“
Ply511 is a Listeria bacteriophage lysin; cloned into, produced and secreted by L.
lactis to create dairy starter cultures with bio-preservation properties against
pathogenic IJsteria monocytogenes. The lysin caused rapid lysis of this pathogen
when secreted from a lactose-using L. lactis strain that could be employed for
fermentation of milk.*^' A truncated version of Ply511 lysin showed increased lytic
activity over the native enzyme.*^' Recombinant starter cultures have also been
developed to specifically inhibit L. monocytogenes contamination during the ripening
of soft cheese
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In cheese ripening research a phage holin-lysin system was cloned into a lactococcal
starter strain for the controlled release of host intracellular enzymes which are known
to be involved in flavour formation during cheese ripening.
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Plant protection against phytopathogens
Lysins have also been demonstrated to have potential for the control and elimination
of phytopathogenic bacteria. In one study, a transgenic potato plant expressing the
coliphage T4 lysin (lysozyme) was constructed to protect potatoes against Gram
negative Ej-winia carotovora which causes soft rot. The lysin was secreted into the
intracellular spaces of the transgenic plant and shown to kill the invading pathogen
upon contact.In another study, a lysin from bacteriophage Hath was cloned into
an expression vector and expressed in E. coli. When crude preparations of the enzyme
were applied to the surface of pears inoculated with the Gram-negative plant pathogen
Erwinia amylovora, infection was inhibited.Although both enzymes possess
muramidase catalytic activity there is evidence, that the antibacterial effect is due to
binding rather than peptidoglycan hydrolysis."^'^ Further studies may lead to the
development of lysins as a safe alternative to chemical bactericides.

Diagnostics
Lysins can also have applications in pathogen detection. Currently detection methods
for human B. anthracis infection are slow and make successful treatment extremely
difficult, given that the window to treat spore-exposed individuals is only 48 hours.
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Improved detection methods are being developed but to date are impractical for use
outside a lab environment.^^ A novel detection method using PlyG lysin has been
developed which generates a result within 15 minutes.'^ This system is incorporated
into a hand-held illuminator, which detects ATP release from lysed bacilli after
addition of lysin.

In another study, magnetic beads coated with the cell wall-binding

domain of lysins Ply 118 and PlySOO from Listeria phage, were used for
immobilisation and separation of bacterial cells from contaminated food. This novel
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immobilisation and separation technique enabled the recovery of more than 90% of
the L. monocytogenes cells present. 97
The lysin, Plyl 18, has also been developed as a molecular biology tool. Loessner et
a/.''’demonstrated that it could be used for fast, efficient and gentle recovery of DNA,
RNA, or native intracellular proteins from small scale Listeria cultures. Similarly, the
multimeric phage lysin PlyC has proven to be superior to rnutanolysin in efficiently
digesting the cell wall of S. pyogenes for proteome-based studies of cell wallanchored proteins.

Although, the use of lysins may hold considerable potential, to

date, no application has made it to commercial markets.

Additional Lysins
Along with the lysins targeting the Gram-positive pathogens discussed above, a
number of similar enzymes^^^ '^'^ which also have potential to eliminate Gram-positive
pathogens including Streptococcus, Staphylococcus, Actinomyces, Micrococcus and
Enterococcus arc under investigation in different laboratories. These are also included
in Table 1. In the case of the Av-1 lysin against the oral bacteria Actinomyces
naeslundii, its precise catalytic activity is yet to be published.
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Conclusion
Lysins have enormous potential as effective antibacterials in the fight against
infectious disease where multi-drug-resistance is prevalent. As bacteriophages are
considered the most abundant biological entities on earth, they are a rich natural
source of these enzymes. Bioinformatic and proteomic studies are likely to lead to
new opportunities for domain swapping, construction of chimeras and the production
of specifically engineered designer lysins with diverse applications.
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Abstract
With the increasing worldwide prevalence of antibiotic resistant bacteria, new
antimicrobials are urgently needed. Bacteriophage (phage) endolysins are phageencoded enzymes used for the release of the phage progeny from the bacterial host. In
most cases they are peptidoglycan hydrolases which, when applied exogenously to
Gram-positive bacteria, bring about rapid lysis and death of the bacterial cell. A
number of studies have recently demonstrated the strong potential of these enzymes in
human and veterinary medicine to control and treat various pathogens on mucosal
surfaces and in systemic infections. They also have potential in bio-defence,
elimination of food pathogens, diagnostics and detection. Paramount to the
development of these enzymes as therapeutics is the knowledge and capability to
produce them as highly purified recombinant proteins. This chapter reviews the
different chromatographic purification techniques used to date in the study of
endolysins, including ion-exchange, affinity, size exclusion and expanded bed
adsorption. We also outline, in detail, two purification strategies, employed in our
laboratory, in the development of endolysins, as purified recombinant proteins
targeting strains of Mycobacterium and Staphylococcus.
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Introduction
Bacteriophages (phages) were first characterised by Felix D’Herelle [1] and soon
exploited as therapeutics for the control of bacterial infections. However, the general
availability of antibiotics from the 1940s eclipsed the impact of “phage therapy” in the
West. Despite this, phages continued to be utilized for the treatment of infection in the
former Soviet Union and Eastern Europe (2-4].

Phages present a number of unique traits making them attractive biocontrol agents in
terms of phage therapy, phage display, vaccines and pathogen detection. Recently,
there is renewed interest in their potential as natural antimicrobial agents as reviewed
in many publications [5-161. Their role in the treatment of bacterial infections has
been extensively reviewed [3, 17, 181. This return to an almost forgotten antimicrobial
strategy is mainly due to the increasing prevalence of antibiotic resistant strains of
clinically important pathogenic bacteria [19-211 ^tich as Pseudomonas spp. [221
including imipenem-resistant [231 ttnd multidrug-resistant Pseudomonas aeruginosa
[24, 251 vancomycin-resistant enterococci [26, 271, antibiotic-resistant staphylococci
[28, 29], multidrug-resistant Klebsiella pneumoniae [301, antibiotic-resistant strains of
Escherichia coli [31].

Phage cycle
Phages are broadly grouped into virulent and temperate phages. Virulent phages bind
to the cell surface, inject their nucleic acid, which directs a take over of the host
metabolism and molecular machinery resulting in production of phage progeny which
are released upon lysis of the host cell. Temperate phages reported as representing
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between 10-20% of the total phage population present in nature [32], can either
reproduce through a lytic cycle or alternatively initiate a lysogenic cycle during which
the phage genome assumes a quiescent state called a prophage, integrated in the host
chromosome, or sometimes as a plasmid. The molecular mechanisms of phage lysis
have been studied extensively [33-35] and the phage life-cycle is illustrated in Figure

Lysogenic pathway

Figure 1. Lytic vs lysogenic pathways used by virulent and temperate phages.
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Phage proteins of interest

Phage proteins
There are many families of bacteriophage [36]. However, for the purpose of this
chapter, we will use the myoviridae and siphoviridae families as examples. Typically,
structural proteins include the major capsid subunit, portal protein, scaffold proteins,
tail subunits, tapemeasure protein and minor tail proteins [37]. Many phages with
somewhat larger genomes (>125kbp) include a subset of virion internal proteins that
are implicated in adsorption and protection from DNA modification by the host [38].
Phage also encode enzymes which degrade the bacterial host cell membrane and cell
wall in order to release phage progeny at the end of the lytic cycle, including a holin
protein, a pcptidoglycan-degrading enzyme (endolysin) and sometimes additional
proteins targeting bonds within a host-specific layer of the cell wall as described in
more detail later.
Besides the lytic proteins investigated for their potential as antimicrobials, phage
proteins can be exploited for a number of applications as reviewed by Sau et al. [39],
and are of particular interest in the context of antibacterial drug discovery. For
example, certain phage early proteins interact with indispensable bacterial host
proteins involved in replication, cell wall synthesis or transcription, and can therefore
be used as tailoring models for the design of novel antimicrobial compounds [39].
Over the past two decades, phage ]ysis proteins have received considerable attention
for their potential as antibacterial agents [2, 39-48].
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Phage lysis proteins
These proteins are produced late in the lytic cycle and accumulate in the cytosol of the
host cell. At a genetically-defined time, so-called holin proteins will form pores in the
cytoplasmic membrane, thus leaving the endolysin proteins through to reach their cell
wall peptidoglycan target. This leads to disruption of the chemical bonds in the
peptidoglycan causing cell lysis and mature phage progeny release [34, 49, 50].
It is worth mentioning, that phage lysis proteins are not limited to holins and
endolysins. For example mycobacteriophages, whose host bacteria possess an outer
membrane composed of mycolic acids and other lipids, also encode lipolytic enzymes
v,'hich target this structure to facilitate cell lysis [51,52].
In general, endolysins studied to date display a two domain modular structure |48, 53,
54]. This comprises an N-terminal catalytic domain and a C-terminal cell wall binding
domain [45, 55]. The former is categorised into four different groups depending on
cleavage sites. The four are (a) N-acetylmuramidases (lysozymes) and (b) N-acetyl-PD-glucosaminidases (glycosidases) which hydrolyse the P-1-4 glycosidic bond in the
sugar moiety of the cell wall, (c) N-acetylmuramoyl-L-alanine amidases, which
cleave the amide bond connecting the sugar and peptide moieties of the bacterial cell
wall and (d) L-alanoyl-D-glutamate endopeptidases and interpeptide bridge-specific
endopeptidases, which attack the peptide moiety of the cell wall peptidoglycan (Fig.
2).
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Figure 2. Typical peptidoglycan structure of Gram-positive bacteria, showing endolysin
cleavage sites,

indicated as follows:

(1) N-acetylrnuramidases; (2) N-acetyl-(3-D-

glucosaminidases; (3) N-acetylmuramoyi-L-alanine amidases; (4) L-alanoyl-D-glutamate
endopeptidases and interpeptide bridge-specific endopeptidases. Adapted from [47]

Endoivsins

Applications of endolysins
When endolysins are used as purified recombinant proteins and applied exogenously
to Gram-positive bacteria, they cause rapid cell lysis as no membrane is present to
inhibit their access to the cell wall [55]. It is this ability to rapidly lyse pathogenic
Gram-positive cells upon direct contact with peptidoglycan “lysis from without” (Fig.
3) that has laid the foundation for their exploitation as novel antibacterials [2, 40-47].
In the case of Gram-negative bacteria, the outer membrane prevents access of
exogenous endolysins to the cell wall peptidoglycan therefore limiting their
exploitation in this incidence [48].

40

Endolysin Therapy

Phage Therapy

Figure 3. Phage therapy and endolysin therapy applied to Gram-positive pathogens.

The production of recombinant endolysins has been achieved in a number of studies
and their antimicrobial potential against clinically relevant human and animal
pathogens has been well documented (Table 1.). Examples include Staphylococcus
aureus [56-641 Bacillus anthracis [65-69] Streptococcus pneumoniae [70-78]
Streptococcus siiis [79], Streptococcus equi [61], enterococci [80-82], Clostridium
difficile [83], Clostridium perfringens [84-86] and Listeria monocytogenes[^l].
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Table 1. Recombinant phage endolysins targeting pathogenic bacteria published to
date, adapted from [47]
Endolysin, Origin

Reference

Plyl 18, L. moocytogenes O A118

[87]

Ply51 1, L monocytogenes

A511

[87]

Ply50(), L. monocytogenes 0 A500

[99]

Pal, 5. pneumoniae <!> Dp-1

[70, 71]

Cpl-1, S. pneumoniae O Cpl-1

[71,72, 74, 75]

PlyGBS, GBS 0 NCTC 11261

[89]

PlyC, S. pyogenes O C1

[61, 88]

CjBS endolysin, S. agalactiae 4> B30

LambdaSal prophage endolysin, 5. agalactiae LambdaSal prophage.

LanibdaSa2 prophage endolysin, S. agalactiae LanibdaSa2 prophage

PlyTOO, S. uberis (ATCC 700407) prophage

[102]

[103]

[103]

1104]

O SMP

[79]

PlyC I, B. an th rads O y

[65]

PlyPH, B. anthracis Ames prophage

[65, 67]

PlyB, B. anthracis O Bepl

[68]

I.ysl6, S. aureus (D P68

[105]

LysK, S. aureus 4) K

[56]

Phi 1 1 endolysin, S. aureus 4>1 1

[57, 101]

MV-L, S. aureus 4> MRl 1

[58]

LysH5, S. aureus 0 H5

[60]

LysWMY, Y warneri M 0 WMY

[106]

Ply3626, C. perfringens 4> 2626

[84]

CD27 endolysin, C. dijficile O CD27

[83]

Ply V12, E. faecalis <I> 1

[80]

Av-1 endolysin, A. naeslundi 4* Av-1

[107]

LySMP, S.

SLiis
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Table 1, continued
Endolysin, Origin

Reference

LysgaY, L gasseri 0 gaY

[108]

Clys*

[63, 90]

LysGHlS, S. aureus O GH15

[62]

()RF9, £/aeca//5 0 EF24C

[82]

PlyCM, C. perfringens prophage endolysin

[85]

Endolysins of C. perfringens phages phiCP390 and phiCP26P

[86]

EFAL-1, E. faecaUs 4> EFAP-1

[81]

TM4 LysA, M. sniegmatis

TM4

[109]

Ms6 LysA, M. sniegmatis 0 Ms6

[110, 1 11]

Ms6 LysB, M. sniegmatis (t> Ms6

[51,52, 1 12]

D29 LysB, M. sniegmatis (I> D29

[113]

LysA proteins gp69, gp236 and gp32, mycobacteriophages Corndog, Bxzl, Che8 respectively

151]

Ardmore LysB, M. sniegmatis

Ardmore

1114]

* Clys: (chimeric lysin obtained by fusing the N-terminal catalytic dt)main of the S. aureus Twort
phage lysin with the C-terminal cell wall-targeting domain from another S. aureus phage lysin
(phiNM3))

Numerous successful pre-clinical trials have revealed the ability of endolysins to
prevent pathogenic colonization of the mucosa, the first being in 2001 [62, 64, 75, 8890]. The potential use of these enzymes as antibacterials against systemic diseases has
also been demonstrated in a number of systemic studies [58, 62, 71, 72, 74, 78],
Research has also been carried out which displays the potential of certain endolysins
for use in bio-warfare [65, 67], in veterinary applications [57, 60, 61, 79], in the food
industry [87, 91,92] and in diagnostics and detection [65, 93-95].
To date, these studies have revealed several promising features of endolysins as
potential antimicrobial agents. They are economical to produce [47, 65], have a
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distinct mode of action and display rapid bactericidal activity [34, 45]. In general,
they are either species- or genus-specific allowing them, unlike antibiotics, to
selectively

target specific

pathogenic

bacteria without effecting

surrounding

commensal microflora [56, 65, 70, 84, 96]. Their modular structure allows the
creation of chimeric and truncated endolysins with alternate and improved binding
and enzymatic features [90, 97, 98]. In addition, their bactericida] activity is
independent of the antibiotic susceptibility profile of the target pathogen [56]. Studies
have failed to reveal development of bacterial resistance and strongly suggest that it is
unlikely to occur [55, 65, 70]. Therapeutic endoiysin treatment, be it topical, systemic
or intravenous is thus far observed to have no harmful, abnormal or irritant side
effects in pre-clinical in vivo trials [45, 55[. Although endolysins are capable of
stimulating an immune response when administered mucosally or systemically this
does not neutralise their activity or prevent their use as antibacterials in the treatment
of infections [41, 74, 99, 100]. In addition to the above studies, endolysins have also
been shown to be effective against biofilms [ 101 ]. Studies have also demonstrated that
some endolysins can work in synergy with each other or with certain antibiotics both,
in vitro and in vivo, resulting in overall increased antibacterial efficacy [58, 59, 71,73,
76, 90, 100].
These attributes show potential for the use of purified recombinant endolysins as
alternative antibacterials especially where multi-drug-resistance is prevalent in both
clinical and community settings such as hospitals and nursing homes.
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Cloning of endolysins
Where the cloning, expression and purification of phage lysis proteins is considered,
the main concerns faced are the choice of the expression system (bacteria, yeast,
insect cells or human cells), the choice of vector, the length of the protein to he
expressed (full length or fragment thereof), the choice of the most appropriate affinity
tag if required, and the most appropriate purification strategy. As many phage lysis
proteins vary in their characteristics, there is no definititive answer to any of these
questions a priori, thus cloning strategy and purification protocol must be determined
empirically and optimised for each individual protein [102],

Cloning
Different cloning hosts that can be used for recombinant protein production include,
bacteria [ 103-107], yeasts [ 108-1 1 1 j, insect cells [112, 113], mammalian cells [1141 17], filamentous fungi [118, 119], transgenic animals [120, 121 [ or transgenic plants
[122-125]. These systems have been extensively reviewed in recent years ] 126-128].
Where phage endolysins are concerned, bacterial expression systems are more popular
[107]. They are considered the cheapest and fastest but nevertheless, the recombinant
proteins produced are frequently insoluble, forming aggregates or inclusion bodies.
The latter are formed from partially folded protein intermediates and are composed of
aggregates of mostly single types of polypeptide. This is often exploited to help
isolate and purify protein aggregates to homogeneity [129]. Nevertheless, protein
solubilization and refolding requires adjustment and optimisation of different
parameters in order to recover a maximum yield of biologically active enzyme [ 130].
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The majority of cloned phage lysis proteins have been expressed in E. coli strains,
although other cloning hosts can also be used such as Lactococciis lactis in the case of
the S. aureus endolysin LysK [56] and the Listeria monocytogenes endolysin Ply511
[87, 131].

Expression vectors
A range of vectors for different expression host systems are commercially available.
Examples include the bacterial tac and T7 promoter-based systems such as the vector
pRSETB (Invitrogen, Carlsbad, CA) used for expression of the S. aureus endolysin
LysH5 [60] or the pET vectors (Merck/EMD; the pET System manual, 2006), which
drive expression of a recombinant gene under the control of the T7 RNA polymerase
promoter and lac operator [132, 133]. Examples which use pET vectors in phage
protein studies include the Clostridium difficile endolysin CD27L using pET15b
(Novagen) [83], the Pseudomonas aeruginosa phage structural peptidoglycan
hydrolase gpl81 using pET26 and pET23 (Novagen) [134], the Bacillus anthracis
prophage endolysin PlyL using pET22b (Novagen) [66], the group B streptococcal
endolysin using pET21a [135] and the Lactobacillus helveticus endolysin Mur-LH
(pET)

[136].

T5

promoter-based

(https://www.dna2Q.com/pJexpress.php)

vectors
or

[137]

QlAexpress

such

as

pJexpress

pQE

vectors

(The

QIAexppressionist-QIAGEN literature), which employ ampicillin as an antibiotic
selection marker are also commonly used in phage protein cloning [84, 98, 134, 138,
139]. The pBAD and pBAD/Myc-His plasmids are pBR322-derived expression
vectors [140] designed for regulated, dose-dependent recombinant protein expression
and purification in E. coli (Invitrogen user manual), and were used to express the E.
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coli phage N4 endolysin gp61 using pBAD/Myc-His B (Invitrogen) with an ciraBAD
promoter (PBAD) [141] and the Streptococcus uheris prophage endolysin Ply700
using the pBAD 18 prokaryotic expression vector [142],
Nisin-inducible vectors such as pNZ8048 or pUK200 have also been used for
expression of phage proteins in lactic acid bacteria [56, 138, 143]. In addition, the Sep
secretion system [144] was shown to be effective in expressing endolysins in a variety
of lactic acid bacterial hosts. The gene encoding the Listeria monocytogenes
endolysin Ply511 was cloned using the Sep secretion signal and the sep promoter with
a His6 epitope placed between the secretion signal and the start of PI3/511 [131].

Affinity tags
Affinity tags arc useful aids in protein purification and rarely adversely affect
biological or biochemical activity [ 145]. Nevertheless, they can affect solubility [146].
Numerous types of tags are available (Table 2) and have been compared showing their
respective advantages [147, 148]. A study by Arnau et al. showed that no one affinity
tag emerged as significantly more efficacious over others in successfully producing
soluble, active recombinant proteins [149].
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Table 2. Examples of affinity tags for recombinant proteins adapted from Arnau et al. 2006
[159].
Tag

Size (aa)

Comments

His-tag

5 to 15

Purification under Native or Denaturing conditions

FLAG

8

Calcium-dependent, mAb-based purification

Streptag II

8

Modified Streptavidin

HA-tag

9

Influenza virus hemagglutinin tag, Ab-based purification

Softag 1, Softag 3

13 to 8

Recognized by polyol-responsive mAb

c-myc

10

mAb-based purification

T7-tag

11 to 16

mAb-based purification

S-tag

15

S-protein resin affinity purification

Elastin-like peptides

18 to 320

Protein aggregation by temperature shift, intein used to remove tag

Chitin-binding domain

52

Binds only insoluble chitin

Thioredoxin

109

Affinity purification with modified resin

Xylanase lOA

163

Cellulose based capture, elution with glucose

Glutathione S-transferase

201

Glutathione or GST-Ab affinity

Maltose binding protein

396

Amylose affinity purification

NusA

495

Increased solubility in E.coli. Affinity tag needed for purification

One example of a widely used affinity tag is hexahistidine (His-tag) as it allows easy
purification by immobilized metal ion affinity chromatography (IMAC) [150], it
rarely affects protein solubility [102], it does not interfere with crystallography [102],
it does not have a negative impact on the N-terminal structure of the target protein
[151], and unlike other tags such as glutathione ^-transferase, rarely affects the
characteristics of the protein [102]. His-tagging was used in severa] studies on phage
endolysins such as CD27L (N-terminal His-tag) [83], LysH5 (N-terminal His-tag)
[60], the Pseudomonas aeruginosa structural peptidoglycan hydrolase gpl81 (Nterminal (pQE30) and C-terminal His-tag (pET26 and pET23)) [134], E. coli phage
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N4 endolysin gp61 (C-terminal His-tag) [141], Av-1 (N-terminal His-tag) [139],
LysK (C-terminal His-tag) [56] and Ply511 [131].
Generally, the literature on purification of endolysins suggests that addition of a Histag does not prevent enzymatic activity and therefore can be successfully utilized for
downstream characterization studies [139]. Obviously, addition of the tag results in a
slight increase in the molecular mass.

Protein Expression
Small scale preparations are often used to predict the solubility of recombinant
endolysins [152] and to optimise the expression conditions before upscaling
production [153, 154]. Recombinant proteins expressed using a bacterial system often
precipitate when the recombinant strain is incubated at 37°C following induction.
However, this may be remedied if the temperature is reduced to between 15°C and
25°C immediately post-induction, resulting in an increase in production of soluble
proteins. As mentioned earlier, inclusion bodies may facilitate the isolation and
purification of the target protein but necessitate a time-consuming refolding step in
order to recover active enzyme. Here again, reducing the incubation temperature from
37°C at the point of induction can be an important step in facilitating slower bacterial
growth and therefore slower rates of protein production which allow the newly
transcribed recombinant proteins to fold correctly into their active form [155]. For
example, E. coli XL 1-Blue expressing various truncated versions of the LysK
endolysin were incubated at 26°C for 14 h post-induction to successfully avoid
inclusion bodies [98]. Similarly, E. coli DHIOB over-expressing LysH5 were induced
with ImM isopropyl-P-D-thiogalactoside (IPTG) and subsequently incubated for 18 h
shaking at 19°C [60]. Optimization of expression conditions is worth-while as
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efficient over-expression can yield high concentrations of active enzyme. For
example, the gene of a Bacillus anthracis-dmgnosing endolysin cloned in pET22b
resulting in the enzyme being optimally expressed in E. coli BL21 (DE3), accounting
for about 40% of total protein. In a 5 L fermentor the expression level reached 15g/L
[156].

Purification approaches used for phage lysis proteins
Purification of phage lysis proteins is necessary for continued structural and
functional studies along with other applications. However, certain purification
procedures can involve the use of reagents that may impair the structure or activity of
the protein in question. Therefore careful choice of purification technique and an
extensive phase of optimisation are necessary to obtain satisfactory yields of pure
active enzyme 1157].
Among the chromatographic purification techniques available, the most common are
affinity, hydrophobic interaction, ion exchange, expanded bed adsorption, and size
exclusion/gel

filtration.

Companies

such

as

QIAGEN,

Applied

Biosystems,

BioChrom and Amersham Biosciences (now part of GE Healthcare) have introduced
new modifications to improve purity, efficiency and ease of use [158].

Affinity Chromatography

Affinity Chromatography separates proteins on the basis of the reversible interaction
between a protein and a specific ligand attached to a chromatographic matrix [159]
offering high selectivity and high capacity [160]. Crude cell lysate is applied under
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conditions promoting the binding of a target protein to the matrix. Unbound material
is then washed away and the bound protein of interest can subsequently be eluted.
Desorption can be done specifically by using a competitive ligand or non-specifically
by changing the physico-chemical conditions within the column (Fig. 4).

Figure 4. Typical affinity chromatography separation graph.

Immobilized Metal Ion Affinity Chromatography (IMAC)
Immobilized Metal Ion Affinity Chromatography (IMAC) is a robust method for
purifying His-tagged recombinant proteins based on the natural tendency of histidine
to form a complex with divalent metals around neutral pH [161]. There is a broad
array of common resins with slightly different binding capacities and binding
strengths, which all tolerate harsh cleaning procedures [102, 162]. This technique has
been widely applied to the field of phage protein purification, particularly to
endolysins. For example, the recombinant phil 1 and phi 12 endolysins were purified
under

native

conditions

via

nickel-nitrilotriacetic

acid

(Ni-NTA)

affinity

chromatography and each individual purified protein could then be identified by SDS-
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PAGE [101], LysH5 was purified using a 5 ml Ni-NTA (nickel matrix) slurry and
eluted according to the manufacturer's instructions (QIAGEN, Valencia, CA). A
major protein band with an estimated molecular mass of 55 kDa was observed on an
SDS-PAGE gel which correlated with the predicted molecular mass for this endolysin
(53.7 kDa) [60]. Another example is E. coli phage N4 endolysin gp61. The majority
of this 23 KDa endolysin was produced in inclusion bodies so the insoluble fraction
was resuspended in 5 M guanidine-HCl, and applied to a TALON-Co^"^ IMAC resin
column (Clontech) equilibrated with 5 M guanidine-HCl for purification under
denaturing conditions. The column was washed with high-salt and low-salt buffers in
the absence of denaturant, and bound protein was eluted with 20 inM Tris-HCl (pH
8.0), 20 mM NaCl,60 mM imidazole buffer, which yielded pure active protein [141].
Plyl 18 (30.8 kDa), Ply500 (33.4 kDa) and Ply51 1 (36.5 kDa) His-tagged cndolysins
were purified using an XK 16/20 column (Pharmacia) packed with 15 ml of nickelnitrilotriacetic acid (Ni-NTA) resin (QIAGEN) where it was observed that increasing
the NaCl concentration to 500 mM and the imidazole concentration in the binding
buffer to 5 mM returned the highest purity levels. The recombinant enzymes were,
finally, eluted using 100 mM imidazole and the purity, estimated by SDS-PAGE, was
more than 90% [ 163]. An identical procedure was used for the purification of Ply3626
and a total yield of approximately 1.3 mg of purified HPL3626 (Ply3626- 6xHis-tag,
40.2 kDa) per litre of culture was obtained [84].

Other examples include the Streptococcus agalactiae endolysin GBS which was
purified with a 10 ml Ni-NTA affinity column (QIAGEN) washed with 50 ml 50 mM
NaH2P04, 300 mM NaCl, 20 mM imidazole, pH 8-0 and subsequently eluted with
50 ml 50 mM NaH2P04, 300 mM NaCl, 250 mM imidazole, pH 8-0. A single band
with a molecular mass of 51 kDa was observed upon SDS-PAGE analysis [135]. A
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10-ml Ni-NTA affinity column (QIAGEN) was also used for the purification of
Streptococcus agalactiae LambdaSl and LambdaS2 prophage endolysins allowing
the successful recovery of active proteins [164]. Purification of CD27L was only
partially achieved under native conditions by using the nickel-nitrilotriacetic acid (NiNTA) Fast Start kit (QIAGEN), which eluted the endolysin in a final buffer of 50 mM
Na phosphate, 300 mM NaCl, and 250 mM imidazole, pH 8.0 [83].

Finally, LMAC was also used in the purification of LySgav- After encountering
difficulties in purifying the wild type LySgav (310 amino-acid residues) cloned in
pUCl 18 vector due to the formation of inclusion-bodies, lySf,aY was cloned under Pj-j
of pET-15b to yield a His-tagged pHLysgaY with a calculated molecular mass of
35.9 kDa. After purification, the N-terminal His-tag was cleaved off using thrombin to
yield Gly-Ser-His-Lysgav (designated as gshLySgav), with an apparent molecular mass
t:)f about 35.0 kDa on a SDS-PAGE gel. Purification of HLySgav ^ind gshLySgav
endolysins was carried out using the His-bind kit (Novagen, Germany) and Sephacryl
S-200 HR (GE Healthcare) according to the supplier's instructions, to homogeneity, as
evidenced on a SDS-PAGE gel [165]. Generally with IMAC, purification conditions
such as the choice of metal ion, resin type, and the condition of binding and elution
buffers need to be carefully optimized for best results.

Ion Exchange chromatography

Ion exchange is based on the reversible interaction between a charged protein and an
oppositely charged matrix [160]. Charged proteins will bind to the matrix first, and
subsequently conditions such as salt concentration or pH are changed so that the
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bound substances are eluted differentially. The net charge of a protein will vary
depending of the surrounding pH. When the pH is above a protein's isoelectric point,
it will be negatively charged and therefore bind to an anion exchanger; when the pH is
lower than a protein’s isoelectric point, the protein will be positively charged and bind
to a cation exchanger [166] as illustrated in Figure 5.

+
Protein has overall negative charge
and will bind to an anion exchange
column
L

pH

10

u
Protein has overall positive charge
and will bind to a cation exchange
column

Isoelectric Point

Figure 5. Ion exchange purification strategy for protein with a pi of 7. Use purification buffer

at a pH <7 for a cation exchange chromatography column and use a purification buffer at a
pH >7 for anion exchange chromatography columns.

The two most commonly used resins for ion-exchange chromatography of proteins are
carboxymethyl-cellulose (CM-cellulose) and diethylaminoethyl-cellulose (DEAEcellulose). Examples of ion-exchange strategies for phage proteins include the
purification to electrophoretic homogeneity of two Streptococcus mitis endolysins
LytAnER and LytAea using a DEAE-cellulose column [167] and the purification of the
Ply700 (26.5 kDa) using an Econo-Pac High Q Anion Exchange Cartridge from
BioRad [142].
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Ion exchange techniques were also used in the purification of a truncated derivative of
LysK, (Cl65 (CHAPk)) [64, 98] and also for the purification of PlyL [66], In the
latter case, the use of a HITRAP 5 ml SP column on an AKTA automated purification
system (GE Healthcare) yielded elution fractions of PlyL with a purity of more than
90%. Cpl-1 and Pal, were purified as previously described for other choline-binding
proteins [168] using a DEAE-cellulose coiumn (8 x 2.5 cm), washed with three
volumes of 20 mM sodium phosphate buffer pH 6.9 (or pH 6.0 for Cpl-1) containing
1.5 M NaCl. The same buffer containing 2% choline was then added and elution
fractions containing purified endolysin were recovered [71 ]. PlyGBS (49.6 kDa) was
purified using a 40-ml Q-Sepharose column (GE Healthcare) and eluted in a linear
gradient from 0 to 1 M NaCl in 25 mM Tris-HCl (pH 7.4) to a final preparation,
estimated to he >95% pure, by scanning densitometry on the Coomassie-stained SDSPAGE gel |89]. Ion exchange was also used successfully for the purification of/f. coli
phage N4 endolysin gp61 which was subsequently concentrated on HiTrap Q columns
(GE Healthcare) [ 141 ].

Size exclusion chromatography
This technique uses gel filtration to separate proteins on the basis of differences in
their molecular size and is an ideal method as a final polishing stage in protein
purification [102, 162]. In the case of PlyL a gel filtration step using a Superdex 75
column (16/60; GE Healthcare) was found to give a sufficiently high purity for
crystallography studies [66]. Sephacryl S-100 is an example of a gel filtration device
which gives high purity phage protein when combined with other purification steps.
This was also used for the purification of the endolysin LySgav [165].
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Expanded bed adsorption chromatography
Expanded bed adsorption allows the separation of a target protein from a crude,
unclarified lysate without the need for prior removal of suspended solids which would
normally result in the blockage of packed beds. This is achieved using an expanding
resin containing particles of varying size and density in a fluidized state as opposed to
a closely packed solid phase employed in packed bed chromatography. The ability of
expanded bed adsorption to clarify, concentrate and purify target protein in one
operation helps increase overall protein yield while cutting running time, labour and
costs [169][170]. Streamline SP (GE Healthcare) is an example of an expanded bed
adsorption product which was found to yield phage lysin purity at levels greater than
95% [156|.

Combining purification methodologies
It is often necessary to combine several purification approaches to obtain a high level
of purity for certain experimental work such as crystallography studies. For example,
PhiH5 endolysin was purified by immobilized metal chelate affinity chromatography,
dialysed with 20 mM NaH^P04 buffer, pH 6.0, and then processed with an extra
cation exchange chromatography purification step to remove contaminants [171]. In
tne case of PlyL endolysin, ion-exchange (HITRAP 5 ml SP column on an AKTA
(GE Healthcare)) and gel filtration (Superdex 75 (16/60; GE Healthcare)) were
combined to yield protein of a grade suitable for crystallography studies [66].
A purity of higher than 95% was obtained for a Bacillus anthracis phage endolysin
v/hen an SP HP ion exchange method was used in combination with Streamline SP

56

(Expanded Bed Adsorption) and Sephacryl S-100 (gel filtration) [156]. For the
purification of LySgav, tin IMAC technique was followed by a gel filtration step using
Sephacryl S-200 HR (GE Healthcare) [165]. Finally, in the case of the Streptococcus
agalactiae LambdaSl and LambdaS2 prophage endolysins, high concentrations of
purified protein were obtained using a combination of Ni-NTA affinity and size
exclusion chromatography techniques followed by a final ultrafiltration step [164].
An extra chromatographic step may aiso be included after purification in order to
adjust the composition of the buffer in which a purified protein is contained. Indeed,
most purification approaches require the use of buffers containing elements that may
interfere with downstream applications, such as imidazole for IMAC, high
concentrations of sodium chloride for ion exchange or guanidine hydrochloride in the
case of certain protocols involving the refolding of recombinant proteins. Buffer
exchange and protein concentration can be achieved using, membrane filtration, size
exclusion and/or with centrifugal concentrator devises such as Amicon-Ultra
Centrifugal filters (Millipore).

Automated systems
It is relatively straightforward to implement the above protein purification protocols
on automated chromatography systems, which have proven reliable, effective and
simple to use [157]. Most purification steps can be integrated by Fast Protein Liquid
Chromatography (FPLC); and a commonly used device is the AKTA system from GE
Healthcare [102]. A purity of greater than 95% was reported for the peptidoglycan
hydrolase from phage (pKZ using a C-terminal His-tag with Ni^"^ affinity
chromatography in a HisTrapTM HP 1 mL column (GE Healthcare) deployed with an
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AKTA system [134]. Purification of PlyL by ion exchange was also carried out using
the AKTA system (GE Healthcare) [66j.

Case studies with phage lysis proteins which targeting Mycobacterium and
Staphylococcus.

(i) Purification of mycobacteriophage lysis proteins LysA and LysB
Work carried out in our laboratory includes the cloning, expression, purification and
activity testing of different endolysins from the mycobacteriophages D29 and TM4.
Genes encoding the cndolysin A (LysA ) proteins of these two phages (D29 gplO,
TM4 gp29) and the Lysin B (LysB) protein (lipolytic enzyme) of D29 (D29 gpl2)
were cloned into pQE60 vectors in E. coli XL 1-Blue cells and over-expressed
following induction with IPTG. The vector used in these studies allows His-tag Cterminal tagging of the recombinant proteins. Thus purification methods available
included His-tag affinity chromatography. The recombinant proteins were recovered
from the E.coli clones following a lysis step using BugBuster Protein Extraction
Reagent (Novagen).
Initially, work was carried out with the insoluble form of the recombinant proteins.
This involved solubilization of inclusion bodies, purification and subsequent refolding
using a gradient of Urea or Guanidine Hydrochloride. However, this procedure was
laborious and yielded poor results in the absence of an automated chromatographic
system (Lig. 6, A). The proteins were subsequently purified in soluble form. Using
His-tag chromatography, the recombinant proteins were eluted with 500mM
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imidazole buffer or with a step gradient of NaCl (0.05-1.5 M NaCl) using ion
exchange chromatography. His-tag mediated chromatography provided consistently
better results (Fig. 6, B) and was subsequently employed using a variety of His-tag
chromatography columns. Recombinant protein was recovered with satisfactory purity
but low yield using HisGraviTrap columns (GE Healthcare) (Fig. 6, C).
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Figure 6. (A) Attempts of on-column refolding using 1-6 M urea gradient (a.) and 1-6 M
gradient Guanidine Hydrochloride (b.) Biorad Low Range Protein Marker is used, U indicates
unpurified fractions, Lanes with Elution fractions are labelled in both cases and Flowthroughs
(FT) and Wash Fractions (WF) were also run on the gel to detect any loss. (B). His-tag
affinity chromatography for the purification of LysA D29 gplO recombinant protein. Lane 1
was loaded with Biorad Low Range prestained protein Marker; Lanes 2 and 3: unpurified
crude lysate; Lanes 4 to 6: Elution fractions; Lane 7 Flowthrough; Lane 8 Wash buffer. (C).
Purification using HisGraviTrap columns resulted in a satisfactory purity but very low yield.

Among the recombinant proteins, D29 gplO was poorly expressed. This necessitated
the up-scaling of culture volume, which was facilitated by the use of the AKTA Prime
automated chromatography system. His-tag affinity chromatography using HisTrap
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FastFlow Crude 5 ml columns (GE Healthcare) on the AKTA system could be
achieved using a gradient (Fig. 7, a. and b.) or step (Fig. 7, c. and d.) elution. From the
chromatograms showing the fractions collected (Fig. 7, e.), the step elution method
was preferable and yielded a maximum amount of protein in a minimum number of
elution fractions.

Gradient elution

Step elution

b.
2 13,415
^0

«

Figure 7. Purification chromatograms showing a gradient elution pattern (a and b), a step
elution pattern (c and d) and a SDS-PAGE showing the elution fractions for each method. The
green line represents the concentration of elution buffer, the blue line represents the UV
reading (increasing when the protein is eluted), numbers of individual fractions are indicated
in red over the elution peaks. The gel presents different fractions with lanes 1, 2, and 3
representing the elution fractions number 22, 26 and 29 on the gradient elution output (b) and
lanes 4 and 5 representing fractions 2 and 3 of the step elution (d).
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All three recombinant mycobacteriophage enzymes, LysA D29 gplO, LysA TM4
gp29 and LysB D29 gpl2 were subsequently purified successfully to a level allowing
activity testing (Fig. 8, a,b.).

Figure 8. Optimization of the HisTrap purification on the AKTA Prime Plus system for the
purification of LysA D29 gplO, LysA TM4 gp29 and LysB D29 gpl2. (a.) Purification
software output for a HisTrap step elution run with the peak indicating the elution of the
bound fraction of protein over fractions 2 and 3 (b.) SDS PAGE showing the elution fraction
obtained for the 3 recombinant proteins.
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(ii) Purification of an anti-staphylococcal truncated phage endolysin by ionexchange chromatography
This study concerns the cloning, expression, purifieation and subsequent in vitro
aetivity of a phage-derived cysteine, histidine-dependent amidohydrolase/peptidase
designated CHAPk [64, 98]. This enzyme was identified as one of two eatalytic
domains within the LysK endolysin, which is derived from the staphylococcal phage
K genome [172]. DNA encoding the 165 amino acid CHAPk endolysin was cloned
into the pQE60 expression vector (QIAGEN) in E. coli XL 1-Blue [56, 98].

E. coli cultures harbouring the pQE6()-CHAPk expression veetor were grown for 14 h
at 26°C post induction with IPTG. This temperature was important in the over
expression of highly soluble protein by preventing the formation of inclusion bodies
which may form at 37°C. Cells were harvested by centrifugation and lysed by
sonication (Soniprep 150). Ion-exchange chromatography was employed with an
AKTA Prime system, to purify the non-tagged CHAPk. Bioinformatic analysis
revealed a theoretical PI of 8.8 for CHAPk Buffers were prepared at pH 6.5 to confer
a positive charge on the protein prior to its application onto a negatively charged
cation-exchange column (Capto-S, GE Healthcare). After a wash step with binding
buffer (50 mM sodium acetate, pH 6.5), tightly bound CHAPk was released from the
column with a 0-100% elution buffer gradient (50 mM sodium acetate, IM NaCl, pH
6.5) (Pig. 9).
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Figure 9. Typical purification curve for CHAPk on AKTA Prime automated purification
system using ion exchage chromatography, (a.) crude cell lysate peak (b.) purified CHAPk
peak (c.) green line tracking the 0-100% elution buffer gradient.

Purified samples in elution buffer were then concentrated, desalted and exchanged
into storage buffer (10 mM sodium acetate, pH 7.4) via an Amicon-Ultra Centrifugal
Device (Millipore). Samples were sterilized by passage through a 0.45-!im filter and
quantified using the BCA Protein Kit Assay (Pierce) and stored at -80°C. Typically
one litre of E. coli culture yielded 2 to 4 mg of purified CHAPkSamples were assessed for purity and enzymatic activity against staphylococci by
SDS-PAGE and zymogram analysis using a BioRad Mini-PROTEAN 3 dual gel
apparatus as previously described [56]. Results revealed enzymatically active CHAPk
with a purity of up to 99% (Fig. 10).
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Figure 10. SDS-PAGE (a) and zymogram (b) analysis of CHAPk purification, (a) Lane 1:
unpurified crude lysate; Lane 2: sample flowthrough from cation exchange column; Lane 3-6:
eluted fractions of purified CHAPk; Lane 7: Biorad Low Range Protein Marker, (b) Purified
CHAPk activity on zymogram gel (clearing of impregnated staphylococcal cells in the gel is
indicated by black arrow).

CHAPk in vitro activity was assessed against live staphylococci in a turbidity
reduction assay using a rnicrotitrc plate reader. Briefly, S. aureus was grown to earlylog phase at an optical density of 0.3 at 590nm (00590), centrifuged, and then
resuspended to a final OD590 of 0.5 in 10 mM sodium acetate buffer (pH 7.4).
Aliquots of 100 pi of CHAPk (at concentrations ranging from 0.5 pg/ml to 50 pg/ml)
were mixed with 100 pi of the bacterial suspension and incubated at 37°C in the
microtitre plate for between 5 to 15 min. Typically 5 pg/ml of CHAPk reduced the
OD 590 by 70% in 5 min (Fig. 1 1). To confirm that the loss in turbidity equated to a
reduction in cell viability, aliquots of CHAPk treated cells were plated and CPUs
enumerated on Baird Parker agar plates and showed a significant reduction in viable
cell numbers. The reduction in cell numbers varied depending on CHAPk
concentration, with complete elimination being observed at 31.25 pg/ml.
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Figure 11. Bacterial culture optical density (OD590 nm) verses time showing activity of
CHAPk against live S. aureus in vitro. The decrease in optical density (OD) over time
following the addition of CHAPk (5 pg/ml) at time zero

(A)

in 10 mM sodium acetate buffer

was monitored at 59()nm in a Molecular Devices SpectraMax 340 plate reader. Controls (•)
were included under the same conditions with no enzyme added.

Conclusion
In this chapter we have documented different purification techniques used to date in
the study of phage lytic enzymes, which include ion-exchange, affinity, size exclusion
and expanded bed adsorption chromatography methods. We have also outlined in
detail purification strategies employed in our laboratory in the development of
endolysins as purified recombinant proteins which target Mycohacteriiim and
Staphylococcus. This chapter can be used as a guide in protein expression and
purification studies for a range of recombinant phage proteins including new lysis
proteins which may be studied in the future.
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Chapter 3
Purification and lytic spectrum of the three-domain endolysin LysK from
staphylococcal bacteriophage K
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Abstract
In this study, we describe the different approaches used in the purification of the
three-domain

recombinant bacteriophage endolysin

LysK.

This enzyme was

previously cloned from the genome of staphylococcal bacteriophage K and expressed
in Escherichia coli. It was purified from E. coli inclusion bodies by on-column
refolding in conjunction with immobilised metal ion affinity chromatography
(IMAC). The lytic spectrum of the purified enzyme against staphylococci was
determined by zymogram analysis. The range of strains tested included all sequence
types (ST) of S. aureus in existence in Ireland from the National MRSA Reference
laboratory, Dublin. Exopolysaccharide (EPS) producing S. aureus strains of bovine
mastitis origin were also tested as were other species of Staphylococcus. The
zymogram analysis confirmed that the enzyme was inhibitory to all of the above
bacteria.
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Introduction
Staphylococcus aureus is a major cause of nosocomial infections. It is an
opportunistic pathogen which naturally colonises skin and mucous membranes and is
associated with a variety of conditions ranging from soft-tissue infections to more
serious conditions such as septicaemia, pneumonia, meningitis, endocarditis and
osteomyelitis (Lowy 1998; Fitzgerald, O'Gorman et al. 2011). The prevalence of
meticillin-resistant S. aureus (MRSA) is of critical concern with strains becoming
increasingly multi drug-resistant, as seen with the development of vancomycinintermediate (VISA) and vancomycin resistant (VRSA) isolates (Hiramatsu, Hanaki et
al. 1997; Centers for Disease Control 2002; Robinson and Enright 2004; Appelbaum
2007). MRSA infection is commonly acquired in hospital settings where it is
associated with increased length of stay, morbidity, mortality and also a considerable
financial burden on healthcare services (Whitby, McLaws et al. 2001; Shorr, Tabak et
al. 2006; Kock, Becker et al. 2010). In addition, there is growing concern regarding
the increasing prevalence of highly-virulent community acquired MRSA (CA-MRSA)
(Okuma, Iwakawa et al. 2002; Boyle-Vavra and Daum 2007; Bukharie 2010).
Consequently, the need for alternative antibiotics or novel therapeutic agents
belonging to different classes which effectively target MRSA, has become apparent.
A number of new antibacterial agents such as linezolid, quinupristin/dalfopristin,
daptomycin, telavancin, new glycopeptides and ceftobiprole have been introduced or
are under various stages of clinical development (Micek 2007; van Hal and Paterson
2011).
Bacteriophage-encoded

endolysins

[phage

lysins)

are

a

new

class

of

antibacterials that display considerable potential as alternative agents for the
prevention and treatment of Gram-positive infections. Lysins are normally
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produced at the end of the phage lytic cycle to degrade the host cell wall
peptidoglycan, thus facilitating the release of mature phage progeny (Young
1992]. When applied exogenously, to Gram-postitive bacteria, recombinant
lysins bring about rapid lysis and death of the bacterial cell "lysis from without"
[Fischetti 2005). The majority of lysins display a modular structure, usually
comprising of at least one N-terminal catalytic domain which attacks bacterial
peptidoglycan, and a C-terminal cell wall binding domain which binds to a specific
substrate (usually carbohydrate) localising the lytic domain to its site of hydrolysis. In
the case of lysins of pneumococcal phages, the receptor is choline, a component of the
teichoic acids of the pneumococcal cell wall, which is essential for bacterial viability
(Garcia, Garcia et al. 1990; Khosla and Harbury 2001; Loessner, Kramer et al. 2002).
Lysins possess several unique traits which may be exploited in their development as
antimicrobials, such as, rapid lytic activity against both live and dead bacteria, narrow
host range and suggested low likelihood of the development of bacterial resistance
(Schuch, Nelson et al. 2002; Pastagia, Euler et al. 2010). These properties have been
summarised in a number of recent review articles (Loessner 2005; Borysowski,
Weber-Dabrowska et al. 2006; Fischetti 2008; Fenton, Ross et al. 2010).
In this study, we describe the different approaches used in the purification of the
recombinant phage lysin LysK. This enzyme was previously cloned from the genome
of staphylococcal bacteriophage K and expressed in Lactococcus lactis and
Escherichia coli (O'Flaherty, Coffey et al. 2005). BLAST analysis of the LysK
protein sequence (495 amino acids) revealed a three domain modular structure
consisting of a cysteine, histidine-dependent amidohydrolase/peptidase (CHAP)
domain, an amidase-2 domain and a SH3b cell wall-binding domain (Fig. 1)
(O'Flaherty, Coffey et al. 2005).

80

NH-

COOH

LysK (495 amino acid residues)

THAP

Amidase-2
(residues 197 to 3461

SHTt) Binding"
»ii

Figure 1. Modular organisation of the three-domain LysK protein.

Materials and Methods

Plasmids, constructs and strains
Details of bacterial strains used in this study are listed in Tables 1 and 2. All strains
were stored at -8()°C. Staphylococcal strains were grown in brain heart infusion (BHI)
medium at 37°C. All other genera and species were purchased from the German
Collection

of Microorganisms

and

Cell

Culture

(DSMZ)

and

cultured

as

recommended for each individual strain (www.dsmz.de). DNA encoding N-terminal
hexahistidine tagged (His-tag) LysK was previously cloned into the commonly used
pQE60 (QIAGEN) expression vector (Fig. 2) and introduced into E. coli XL 1-Blue
for overexpression (O'Flaherty, Coffey et al. 2005). Lfnless stated otherwise, all media
were supplied by Sigma-Aldrich.

Strain and ST number

^

..........----------------Description

DPC5245 ST71
DPC5246 ST71
DPC5247 ST71
MSS 11
3188 (11) ST5
0220(11) ST5
0.1345 (llv) STS
3596 (llv) STS
3045 (llv) STS
3488 (Ivv) STS
3144 (llv) STS
E1038 (llv)ST8
Ell85(Iv)ST12
E1174(Iv)ST22
0242 (Iv) ST30
3594 (11) ST36
E1139(Iv)ST45
0.1239 (III) ST239
0.0066 (IIlv) ST239
0104 (III) ST239
0073 (111) ST239
M03/0073 (III) ST239
0308 (1 A) ST247
2581 (lA) ST247
0.1206 (Iv) ST250
El202 (II) ST496
ISA79 STl
IS A100 ST 1
ISA49 STS
ISA60 STS
ISA76 STS
IS ASS ST 15
1SA57 ST22
ISA59 ST22
ISA63 ST22
ISA67 ST22
ISA53 ST30
ISA58 ST30
ISA80 ST30
ISA22 ST36
ISA61 ST36
ISA75 ST36
1SA82 ST39

Bovine Staphylococcus aureus
Bovine S. aureus
Bovine S. aureus
Meticillin-resistant S. aureus (MRSA)
MRSA
MRSA
MRSA
MRSA
MRSA
MRSA
MRSA
MRSA
MRSA
MRSA
MRSA
MRSA
MRSA
MRSA
MRSA
MRSA
MRSA
MRSA
MRSA
MRSA
MRSA
MRSA
Meticillin-sensitive S. aureus (MSSA)
MSSA
MRSA
MRSA
MRSA
MSSA
MRSA
MSSA
MRSA
MRSA
MSSA
MSSA
MSSA
MRSA
MRSA
MRSA
MSSA
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-------LysK
activity
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+

Source
1
1
1
1
2
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4

Table 1 continued
Strain and ST number
ISA 108 ST39
ISA51 ST45
ISA54 ST45
ISA86 ST45
BMA/GE/032/384 ST45
BMA/NE/032/163 ST71
BMA/FRy032/366 ST71
BMA/FR/032/088 ST97
BMA/FR/()32/091 ST97
BMA/UK/032/106 ST97
BMA/GE/032/411 ST97
Newbould/MSA/035 STl 15
BMA/FR/032/074 ST 126
BMA/GE/032/385 ST 1229
BMA/GE/032/412 ST 1306

Description
MSSA
MSSA
MSSA
MSSA
Exopolysaccharride producing S. aureus
(EPS)
EPS
EPS
EPS
EPS
EPS
EPS
EPS
EPS
EPS
EPS

LysK
activity
+
+
+
+
+

Source

+
+
+
+
+
+
+
+
+
+

5
5
5
5
5
5
5
5
5
5

Table 2. Lytic spectrum of LysK against genera outside the genus Staphylococcus
LysK
Source
Strain designation
Genus/species
activity
1
Micrococcus lute us
DSM 20030 (ATCC 4698)
1
M. flavus
DSM 19079
1
M. lylae
DSM 20315 (ATCC 27566)
1
Streptococcus miitans
DSM 6178 (ATCC 35668)
1
S. pneumoniae
DSM 11865
1
DSM 20565 (ATCC 12344)
S. pyogenes
1
S. thermophilus
DSM 20259
1
Nesterenkonia halohia
DSM 20541 (ATCC 21727)
1
Arthrohacter agilis
DSM 20550 (ATCC 966)
1
Paracoccus pantotrophus
DSM 65
1
DSM 20343 (ATCC 8293)
Leuconostoc mesenteroides
1
Carnohacterium
DSM 20342 (ATCC 27865)
maltaromanticum
1
Kocuria rosea
DSM 20447 (ATCC 186)
1
Escherichia coli
DSM 10232 (ATCC 128)
1
DSM 10720
E. coli
“ Lytic activity (+) or no lytic activity (-) on zymogram gels
1. Dairy Products Research Centre, Teagasc, Fermoy, Cork, Ireland (1998)
2. Cork Institute of Technology bacterial culture collection, Cork, Ireland (2001)
3. National MRSA Reference Laboratory, St. James Hospital, Dublin (2008)
4. Athlone Institute of Technology collection, Athlone, Ireland (2007)
5. Intervet International BV, Boxmeer, Netherlands (2008)
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4
4
4
4
5

Figure 2. Map of the pQE6() (QIAGEN) expression vector into which DNA encoding the
495-amino-acid LysK protein was cloned.

Purification of LysK

Overpression
A 10 ml culture of E. coli XL 1-Blue harbouring pQE60-LysK was grown overnight in
Luria Bertani (LB) broth supplemented with ampicillin (200 pg/ml) at 37°C. This 10
ml culture was then added to IL of fresh LB broth (1% inoculum) supplemented with
ampicillin (200 pg/ml) and grown at 37°C, with shaking at 150 rpm, to an optical
density at 59()nm (OD590) of 0.5. LysK expression was induced by the addition of
Isopropyl p-D-l-thiogalactopyranoside (IPTG) to a final concentration of 1 mM
followed by incubation at 37°C for 4 h. Cells (containing LysK inclusion bodies) were
harvested by centrifugation in 4 x 250 ml volumes at 10,000 x g, for 10 min at 4°C.
The supernatant was decanted and each pellet was washed once in 20 mM Tris pH 7.5
before storage at -80°C.
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Isolation and solubilization of inclusion bodies
When required cell pellets were thawed, resuspended in 5 ml of 20 mM Tris pH 7.5
and disrupted by sonication (MSE Soniprep 150, Wolf Laboratories Ltd, UK) (4
pulses for 10 s with 10 s intervals) on ice. After centrifugation at 12,000g for 10 min
at 4°C, pellets were resuspended in 3 ml of refrigerated isolation buffer (2 M urea, 20
mM Tris, 0.2 M NaCl, 2 % Triton X-100, pH 7.5) and then sonicated and centrifuged
as described above. This step was repeated two times and the cell pellet was
subsequently resuspended in 5 ml of solubilization buffer (4 M guanidine
hydrochloride, 20 mM Tris, 0.3

M

NaCl,

10 mM

imidazole,

1

mM 2-

mercaptoethanol). This suspension was stirred for 60 min at room temp before
centrifugation at 12,000 g for 15 min (at room temperature). The resulting supernatant
of solubilised protein was passed through a 0.45 pm filter to remove debris and stored
on ice prior to its application onto a His GraviTrap (GE Healthcare) affinity
chromatography column.

On column refolding and purification
A His GraviTrap column (containing precharged Ni sepharose resin) was equilibrated
with 10 ml of binding buffer (20 mM Tris, 0.3 M NaCl, 10 mM imidazole, 1 mM 2mercaptoethanol, pH 7.5). Solubilised protein sample was diluted to a final volume of
10ml in binding buffer and slowly applied to the equilibrated His-Tag affinity
chromatography column. During this step, the His-tagged protein of interest (LysK)
binds to the Ni-sepharoe resin and non-tagged proteins eluted in the flow-through.
The column was washed a second time with 10 ml of binding buffer. A 30 ml linear
gradient of refolding buffer (20 mM Tris, 0.3 M NaCl, 5 mM imidazole, 1 mM 2-
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mercaptoethanol, pH 7.5) containing 6 to 0 M urea was applied to the column with a
flow rate of 1 ml/min to bring about refolding of bound protein. The column was
again washed with binding buffer before the LysK protein was released from the
column and collected in 10 x 1 ml fractions in elution buffer (20 mM Tris, 0.3 M
NaCl, 0.5 M imidazole, 1 mM 2-mercaptoethanol, pH 7.5). Elution fractions (1 ml)
were analysed for purity by 12 % sodium dodecyl sulphate (SDS)-polyacrylamide gel
electrophoresis (PAGE), and stained with 0.05 % Coomassie brilliant blue-R
(Laemmli 1970). Typically, 10 pi of each 1 ml elution fraction was loaded onto SDS
gels for analysis. Tractions containing detectable purified protein were subjected to
protein quantification assays using the BCA Protein Kit Assay (Pierce) and stored at 80°C in sterile microcentrifuge tubes.

Multilocus Sequence Typing (MLST)
Multilocus sequence typing was performed to assign an ST number to un-typed S.
aureus strains according to the method of Enright et al. (Enright, Day et al. 2000).
Briefly, chromosomal DNA was extracted from each S. aureus strain using a QIAamp
DNA mini Kit (QIAGEN) and the sequences of ~450-bp internal fragments of seven
housekeeping genes of each S. aureus strain were amplified by polymerase chain
reaction (PCR). The sequences of the specific primers (arcC, aroE, glpE, gmk, pta, tpi
and yqiL) designed by using the sequences of the highly conserved regions that flank
the more variable regions in each of the seven housekeeping genes and PCR
conditions were obtained from the MLST database (www.saureus.mlst.net) (Enright,
Day et al. 2000). The amplified fragments were then sequenced in both directions
(MWG-Biotech) and the resulting sequences were trimmed to the exact length of a
specific internal fragment region within each housekeeping gene. The seven
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housekeeping gene sequences for each strain were then submitted to the on-line S.
aureus MLST database (www.saureus.mlst.net) where a specific ST number is
generated based on the allelic profile of the query strain when compared to all S.
aureus strains in the database (Enright, Day et al. 2000).

Lytic spectrum of LysK
In order to assess lysin activity and determine the lytic spectrum of LysK, zymogram
analysis was performed, according to the method by Leclerc and Asselin (Leclerc and
Asselin 1989). This involved the incorporation of target bacterial cells into the
polyacrilamide gel. Briefly, an overnight 50 ml BHI culture of the bacterium was
autoclaved and subjected to centrifugation. The pellet of heat-killed cells was
resuspended in the 10 ml of SDS polyacrylamide solution immediately prior to
addition of Temed and ammonium persulphate. After solidification, 3.4 pg samples of
LysK were applied and subjected to electrophoresis at 180 V for 40 min. Enzymatic
activity is indicated as a zone of clearing in the opaque zymogram gel after incubation
of the gel at room temperature for 60 min in renaturation buffer (25 niM Tris, 1%
Triton X-100, pH 8). The location of the clear zone should correspond with the
predicted molecular weight of the protein.

Results

Isolation of LysK
A variety of cell disruption methodologies were evaluated. These included the use of
a MagNA lyser (Roche), Mini-BeadBeater-8 (BioSpec Products, USA) and sonicator
(MSE Soniprep 150, Wolf Laboratories Ltd, UK). All were applied for a wide range
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of times and settings (data not shown). It was found that the optimum method for
isolation of LysK was two rounds of sonication, each involving 4 pulses for 10 s with
10 s intervals as described in the materials and methods. This resulted in efficient
release of crude cell lysate from E. coli (Fig. 3). The optimum sonication treatment
was indicated by the presence of a range of cellular proteins released from disrupted
cells. The efficacy of IPTG induction (ImM) for the overexpression of LysK was
indicated by the presence of a protein band at the predicted molecular weight of LysK
(54 kDa) (O'Flaherty, Coffey et al. 2005) in IPTG-induced samples, in contrast to the
absence of a detectable band at the same position in uninduced controls (Fig 3.). SDSPAGE analysis of the soluble and insoluble fractions of the sonicated induced E. coli
extracts showed that LysK was predominantly expressed as insoluble inclusion bodies
and needed to be solubilized prior to application on a chromatography column.

kDa 1()4.4^
83.2 ►
LysK

Figure 3. SDS-PAGE demonstrating expression and effective sonication of LysK. Biorad
Low Range Protein Marker (Lane I); cmde lysate from uninduced E.coli clones harbouring
pOE60-LysK (Lane 2); crude lysate from induced E.coli clones harbouring pQE6()-LysK.
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Solubilization of LysK
Guanidine hydrochloride (4 M) was used to achieve solubilization of LysK inclusion
bodies. In addition to this, 1 mM 2-mercaptoethanol was included in the solubilization
buffer to maintain the conserved cysteine residue (amino acid number 54 in the 495
amino acid sequence of LysK) in a reduced state and thus prevented non-native inter
disulphide bond formation (De Bernardez Clark, Schwarz et al. 1999). Cysteine
residues are important for enzymatic activity in proteins containing a CHAP domain,
therefore maintaining them in their reduced state is important for recovery of active
protein (Anantharaman and Aravind 2003; Liu, Yang et al. 2007).

On-column refolding of LysK
Proteins expressed as inclusion bodies are largely inactive after solubilization. Thus,
on-column refolding of the solubilised His-Tagged LysK was necessary. This was
performed while the LysK protein was still bound to the affinity column. Optimum
conditions and buffers for refolding and purification were determined empirically
after extensive experimentation which assessed a multiple range of parameters and
conditions. All samples purified from a range of refolding and purification runs, were
analysed for yield, purity and activity by SDS-PAGE and zymogram analysis. The
optimum conditions arrived at were as follows. A His GraviTrap column (containing
precharged Ni sepharose resin) was washed with 10 ml of binding buffer (20 mM
Tris, 0.3 M NaCl, 10 mM imidazole, 1 mM 2-mercaptoethanol, pH 7.5) before
application of protein. The column was washed a second time with 10 ml of binding
buffer after which a 30 ml linear gradient of refolding buffer (20 mM Tris, 0.3 M
NaCl, 5 mM imidazole, 1 mM 2-mercaptoethanol, pH 7.5) containing 6 to 0 M urea
was applied to the column with a flow rate of 1 ml/min. LysK was successfully
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purified to >95% homogeneity as evideneed by the presence of single bands of 54
kDa when elution fractions were analysed by SDS-PAGE (Fig. 4a). Activity was
confirmed by the presence of clear defined zones of clearing on zymogram gels at the
location corresponding to the molecular weight of LysK (54 kDa) (Fig. 4b). Yields of
2 to 4 mg of purified protein per litre of E. coli culture were routinely achieved.

kDa 104.4 ^
83.2 ^

49.3 ^

36.9 ^

.

28.9 k

19.8 ►

b.

a.

Figure 4. SDS-PAGE (Lanes 1-4, a) and zymogram analysis (Lanes 1-2, b) of purified LysK.
Biorad Low Range Protein Marker (Lane 1, a); Empty (Lane 2, a); eluted fractions of purified
LysK (Lanes 3-4, a); LysK activity on zymogram gel with activity causing staphylococcal cell
lysis indicated by zone of clearing (Lanes 1-2, b).

Multilocus Sequence Typing (MLST) of collected S. aureus isolates
MLST analysis was successfully performed on four S. aureus strains including three
dominant bovine mastitis isolates DPC5245, DPC5346, DPC5247 (O'Flaherty, Ross
et al. 2005) and a new human MRSA isolate MS811 (Table 1). This was achieved by
sequencing (forward and reverse) PCR-amplified products of seven housekeeping
genes specific to S. aureus. The resulting sequences were trimmed to the exact length
of the internal fragment region within each housekeeping gene and submitted to the
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web-based MLST database (www.saureus.mlst.net). Here the sequence of each
housekeeping gene was assigned an allelic-profile (ST number). This was achieved by
comparison of the sequences with the alleles of all S. aureus isolates held in the
database. An ST number or allelic profile of each of the four submitted S. aureus
strains was generated. This was the same for the three mastitis isolates, namely ST71.
The MRSA isolate S. aureus MS811 was assigned as STS.

Lytic spectrum of LysK
Zymogram analysis was performed to determine the lytic spectrum of purified LysK.
In total fifty seven strains of S’, aureus were tested (Table 1). Of these, thirty two were
MRSA, eleven were meticillin-sensitive (MSSA), eleven were exopolysaccharride
producers (EPS) and three were bovine mastitis isolates (Table 1). Every ST number
in existence in clinical MRSA collections in Ireland was represented in the analysis.
All were susceptible to lysis by LysK regardless of their origin or antibiotic-resistance
profile (Table 1). LysK was further evaluated to assess if it lysed staphylococci other
than S. aureus and those tested included S. caprae, S. haemolyticus, S. hyicus, S.
hominus, S. chromogenes, S. saprophyticus, S. capitis and S. epidermidis. All were
susceptible to lysis. Eollowing this, it was of interest to explore if the enzyme lysed
genera outside of the genus Staphylococcus. The range of strains tested are shown in
Table 2. LysK did not exhibit lytic activity in zymogram analysis with these genera
and species.

Discussion
In this study, methodology was established for the production of highly pure
staphylococcal phage lysin, LysK. The process included isolation, solubilization and

on-column refolding steps in conjunction with His-tag affinity chromatography.
Purification from inclusion bodies, while usually more labour intensive than working
with the soluble fraction of recombinant proteins, has a number of merits. These
include the fact that proteins are generally highly concentrated in inclusion bodies,
they are generally protected from proteolytic degradation, they can usually be easily
solubulised and inclusion bodies predominantly contain pure protein in different states
of aggregation (Schoner, Ellis et al. 1992). However, it is worthy of mention that
proteins in inclusion bodies are initially produced in an inactive form which
necessitates the application of a downstream re-folding protocol.
Purified LysK was active against all S. aureus strains tested by zymogram analysis. In
total the enzyme lysed fifty seven isolates encompassing twenty different MLST
sequence types including STS, ST22 and ST36 which are the predominant sequence
types recovered from blood cultures in Irish hospitals (Rossney, Lawrence et al.
2006). It is significant that LysK displayed strong lytic activity against EPS producing
S. aureus strains (Table 1). EPS producing ability of bacterial strains can be an
important factor in pathogenesis and also S. aureus biofilm formation. In addition,
EPS-producing S. aureus strains can be responsible for infections with increased
resistance to antibiotic treatments (Hensen, Pavicic et al. 2000; Begun, Gaiani et al.
2007; Coulon, Vinogradov et al. 2010). Interestingly, a variety of coagulase-negative
staphylococci of bovine origin were also susceptible to lysis and these included S.
caprae, S. haemolyticus, S. hyicus, S. hominus, S. chromogenes, S. saprophyticus and
S. capitis. No lytic activity was observed against genera outside the genus
Staphylococcus. This shows that the enzyme is genus-specific with the SH3b cell wall
binding domain responsible for exclusively attaching the enzyme exclusively to its
substrate in the cell wall peptidoglycan of staphylococcal species (Loessner, Kramer
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et al. 2002). In this study, successful purification and lytic spectrum results were very
promising and suggested that the three-domain anti-staphylococcal phage lysin, LysK,
could have widespread applications as an alternative therapeutic against S. aureus
associated infections.
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Appendix to Chapter 3

Subsequent studies revealed that the three-domain LysK enzyme was unstable and
prone to aggregation in both a temperature and concentration dependent manner. This
impacted negatively on the further characterisation of LysK. It also restricted the
development of possible applications in in vitro and in vivo experiments against live
staphylococci. Studies performed by collaborators in our research group reported that
expression of the 165-amino-acid N-terminal CHAP domain of LysK as a non tagged
single-domain recombinant protein, resulted in two fold higher activity than the native
three-domain LysK construct against live staphylococci (Horgan, O'Flynn et al.
2009). All subsequent experimental studies focused exclusively on the single-domain
truncated derivative of LysK, which we designated CHAPk, shown below.
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Abstract

Aims: To develop an efficient purification strategy for the phage derived peptidase
CHAPk- To evaluate its antibacterial spectrum, enzymatic properties, optimal reaction
conditions and lytic activity against S. aureus compared to the commercially available
anti-staphylococcal metalloendopeptidase lysostaphin.
Methods and Results: Recombinant CHAPk was purified to homogeneity by cation
exchange chromatography, with yields of up to 10 mg from 1 litre of E. coli culture.
The lytic spectrum of CHAPk includes all staphylococcal species and also members
of

the

genera

Micrcococcus,

Streptococcus,

Nesterenkonia,

Arthrobacter,

Leuconostoc and Carnobacterium. The enzyme was active from pH 6 to 11 with an
optimum activity at pH 9; from 5°C to 40° C, with an optimum activity at 15°C.
When culture lysis by CHAPk and lysostaphin were compared over a concentration
range of 2.5 to 10 pg ml ’ using live S. aureus cells for 5 min at 37°C, CHAPk
exhibited up to 45-fold better activity on the basis of reduction of optical density.
Conclusions: This study describes in detail the purification and characteristics of the
novel phage-derived enzyme CHAPk demonstrating that it has excellent biochemical
properties as an anti-staphylococal agent.
Significance and impact of the study: Currently there is a need for new
antimicrobials due to the increasing worldwide prevalence of antibiotic resistance.
Our findings demonstrate the potential for development of CHAPk as an antibacterial
agent against pathogenic staphylococci including MRSA.
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Introduction
In recent years, there has been an increasing worldwide prevalence of bacterial
resistance to a wide range of antibiotics, resulting in an urgent need for new
antibacterials. Phage encoded lysins have become a focus of research interest (Fenton,
Ross et al. 2010). Lysins are murien-hydrolases produced at the end of the phage lytic
cycle to digest specific bonds in the host bacterial cell wall, facilitating release of
mature phage progeny (Young, Wang et al. 2000). When applied exogenously as
purified recombinant proteins to Gram-postitive bacteria, hydrolases illicit rapid cell
lysis and bacterial death (Fischetti 2005; Loessner 2005). The majority of lysins
display a modular structure, usually comprising of at least one N-terminal catalytic
domain which attacks bacterial peptidoglyean, and a C-terminal cell wall binding
domain which directs the lytic domain to its site of hydrolysis (Garcia, Garcia et al.
1990; Khosla and Harbury 2001; Loessner, Kramer et al. 2002). The potential for
these enzymes as novel therapeutics against a number of Gram-positive pathogens in
mouse models of mucosal colonisation and systemic infections has previously been
demonstrated (Nelson, Loomis et al. 2001; Cheng, Nelson et al. 2005; McCullcrs,
Karlstrom et al. 2007; Daniel, Euler et al. 2010; Fenton, Casey et al. 2010; Gu, Xu et
al. 2010).
These studies have revealed several distinct features of lysins which facilitates their
further development as antimicrobials. Their modular organisation allows the creation
of chimeric and truncated proteins with improved binding and enzymatic features
(Sheehan, Garcia et al. 1996; Becker, Foster-Frey et al. 2009; Morgan, O'Flynn et al.
2009; Daniel, Euler et al. 2010). In general, lysins are either species- or genusspecific allowing them to selectively target specific pathogenic bacteria without
affecting surrounding commensal microflora (Loessner, Maier et al. 1997; Loeffler,
Nelson et al. 2001; Schuch, Nelson et al. 2002; Zimmer, Vukov et al. 2002;

99

O'Flaherty, Coffey et al. 2005). Their baetericidal activity is independent of the
antibiotic resistance profile of the target pathogen (O'Flaherty, Coffey et al. 2005). In
addition, studies have failed to identify development of bacterial resistance and many
authors suggest that it is unlikely to occur (Loeftler, Nelson et al. 2001; Schuch,
Nelson et al. 2002; Loessner 2005; Pastagia, Euler et al. 2010). These attributes
strongly support the use of purified recombinant lysins in a variety of applications
especially where other antibacterials have failed.
S. aureus is associated with various skin and soft-tissue infections as well as with
serious infections such as endocarditis, toxic shock syndrome, septicaemia, impetigo
and pneumonia, among others (Lowy 1998). Meticillin-resistant S. aureus (MRSA) is
a major cause of antibiotic resistant healthcare-associated (nosocomial) infection
worldwide, which may result in prolonged hospital stay and higher mortality rates
(Shorr, Tabak et al. 2006; EARSS Management Team 2007). In addition to the global
prevalence of MRSA there is also increasing incidence of Community-acquired
MRSA (Eady and Cove 2003). Eurthermore, MRSA carriage is increasingly being
reported in animals, including pigs, horses, cattle, poultry and household pets (Lee
2003; O'Mahony, Abbott et al. 2005; Voss, Loeffen et al. 2005; Nemati, Hermans et
al. 2008; Loefner, Kearns et al. 2009; van Duijkeren, Moleman et al. 2009). S. aureus
and coagulase-negative staphylococci (CoNS) are also leading causes of bovine
mastitis (Eorsman, Tilsala-Timisjarvi et al. 1997). In addition, S. aureus enterotoxins
in food are a common cause of gastroenteritis known as staphylococcal food
poisoning (Dinges, Orwin et al. 2000). New and improved methods of eliminating
staphylococci in both humans and animals are urgently needed.
Our laboratory has previously reported that the truncated phage lysin, CHAPk,
demonstrates activity against S. aureus including MRSA and heterogeneous
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vancomycin-resistant (hVRSA) (Liu and Chambers 2003) strains in the absence of a
lytic amidase domain or cell wall binding domain (Morgan, O'Flynn et al. 2009;
Fenton, Casey et al. 2010). In this study we report the complete purification strategy
and antibacterial spectrum of CHAPk, its enzymatic properties, optimal reaction
conditions, and a comparison of its lytic activity to the commercially available antistaphylococcal metalloendopeptidase lysostaphin.

Materials and methods

Plasmids, constructs and strains
Details of bacterial strains used in this study are listed in Table 1. All strains were
stored at -80°C. Staphylococcal strains were routinely grown in brain heart infusion
(BHI) medium at 37°C. All other strains were purchased from the German Collection
of Microorganisms and Cell Culture (DSMZ) and cultured as recommended for each
individual strain (www.dsmz.de). Unless stated otherwise, all media were supplied by
Sigma-Aldrich. DNA encoding the CHAP domain (designated CHAPk) of the
staphylococcal phage lysin LysK was previously cloned into the pQE60 (QIAGEN)
expression vector and introduced into E. call XL 1-Blue for overexpression (Morgan,
O'Flynn et al. 2009).
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able 1 . Bacterial species and genera tested for sensitivity to CHAPk
jenus/species
staphlyococciis aureus, bovine mastitis isolate
Vleticillin resistant S. aureus (MRSA)
SdRSA
aureus', exoploysaccharide producing strain (EPS)
aureus', EPS
y caprae
S. haemolyticus
S. hyicus
hominis
chromogenes
S. saprophyticus
5'. capitis
S. epidermidis
Vlicococcus species
VI. lute us
VI. flaviis
VI. lylae
Streptococcus mutans
S. pneumoniae
S. pyogenes
S. thermophiliis
Nesterenkonia halohia
\rthrohacter agilis
Faracoccus pantotrophus
Leuconostoc mesenteroides
Carnohacterium maltaromanticurn
Kocuria rosea
Escherichia coli
E. coli

Strain designation
DPC5246
STS ISA 49
ST22 ISA 59
BMA-FR-032-074
Newbould 305 STl 15
M.139
M.140
M.146
M.145
M.143
M.141
M.144
DSM 23269
DSM 1057
DSM 20030 (ATCC 4698)
DSM 19079
DSM 20315 (ATCC 27566)
DSM 6178 (ATCC 35668)
DSM 1 1865
DSM 20565 (ATCC 12344)
DSM 20259
DSM 20541 (ATCC 21727)
DSM 20550 (ATCC 966)
DSM 65
DSM 20343 (ATCC 8293)
DSM 20342 (ATCC 27865)
DSM 20447 (ATCC 186)
DSM 10232 (ATCC 128)
DSM 10720

Source
1
2
o

Overexpression and purification of CHAPk
A 10 ml culture of E. coli XL 1-Blue harbouring the pQE60-CHAPk was grown
overnight in superbroth medium (32 g l ’ tryptone, 20 g l ’ yeast extract, 5 g l ’ NaCl)
(superbroth is a rich medium with elevated levels of tryptone and yeast extract which
contribute to high yields of E. coli cells) supplemented with ampicillin (200 pg ml ')
at 37°C. This 10 ml culture was then added to 1 L of fresh superbroth (1% inoculum)
supplemented with ampicillin (200 pg ml ') and grown at 37°C to an optical density at
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3
3
4
4
4
4
4
4
4
5
5
5
5
5
5
5
5
5
5
5
5
5
5
5
5
5

590nm (OD590) of 0.5. It was then allowed to stand on ice for 30 min before CHAPk
expression was induced by the addition of Isopropyl P-D-l-thiogalactopyranoside
(IPTG) to a final concentration of 1 mmol P' followed by incubation at 26°C for 14 h.
Cells were harvested by centrifugation in 4 x 250 ml volumes at 10,000 x g, for 10
min at 4°C. The supernatant was decanted off and each pellet resuspended in 2 ml of
binding buffer (50 mmol l ' sodium acetate, pH 6.5). These samples were stored at 80°C. When required samples were thawed, and cells lysed by Bugbuster solution
according in manufacturers instructions (Novagen). Cell debris was removed by
centrifugation at 5000 x g, for 15 min at 4°C. The resulting supernatant was removed
and the centrifugation repeated. This supernatent was then applied to a 1 ml HiTrap
Ccipto S (GE Healthcare) strong cation exchange chromatography column attached to
an AKTA Prime automated chromatography system. CHAPk was eluted in a linear
gradient from 0 to 1 mol l ' NaCl in 50 mmol l ' sodium acetate buffer, pH 6.5.
Elution fractions (2 ml) were analysed for purity and lytic activity by SDS-PAGE and
zymogram analysis (O'Flaherty, Coffey et al. 2005). Typically 10 pi of each 2 ml
elution fraction was loaded on zymogram gels. Fractions containing detectable
purified protein were pooled and concentrated in 10 mmol l ' sodium acetate buffer
pH 7 by an Amicon-Ultra Centrifugal Device (Millipore) according to manufacturers
instructions. Finally purified and concentrated CHAPk was sterilised by passage
through a 0.45-pm syringe filter (Millipore), quantified using the BCA Protein Kit
Assay (Pierce) and stored at -80°C in sterile microcentrifuge tubes.
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Turbidity reduction assays
CHAPk activity was monitored in a microtitreplate based assay as previously
described, (Fenton, Casey et cil. 2010), with some modifications. Briefly, 1 litre of .S'.
aureus strain DPC5246 (Table 1) was grown to early log-phase at an OD590 of 0.3, 50
ml aliquots of culture were distributed in sterile Falcon tubes (Sarstedt) and harvested
by centrifugation at 5000 x g, for 15 min at 4°C. Cell pellets were washed twice in 50
mmol r' sodium acetate pH 7 or 20 mmol r' Tris pH 8 and frozen at -20°C. When
required for turbidity reduction assays individual 50 ml pellets were thawed and
resuspended in 50 mmol l ' sodium acetate pH 7 or 20 mmol l ' Tris pH 8 to an OD590
of 0.5 to 0.7. In the assay 100 pi of CHAPk or buffer equivalent (control) was added
to 100 pi of the prepared cell suspension in triplicate (final concentration of enzyme
ranging from 1- 50 pg) in a 96-well plate (Sarstedt). Decrease in 00590 was monitored
for 5 to 25 min at 37°C in a microtitreplate reader (Molecular Devices, Spectra Max
340). To confirm that reduction in turbidity equated to a reduction in cell viability,
bacteria in control and lysin treated wells were plated on Baird Parker (BP) agar
supplemented with egg yolk tellurite and enumerated. Assays were carried out in
triplicate and data was expressed as the mean ± standard deviations.

Lytic spectrum of CHAPk
The susceptibility of a range of staphylococci and other genera to lysis by CHAPk
was assessed in turbidity reduction assays as outlined above. Early log-phase bacterial
cells were treated with 10 pg ml"’ of lysin and the reduction in OD590 (AOD)
monitored at 37°C for 15 min. Assays were carried out in triplicate and data was
expressed as the mean ± standard deviations.
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Influence of temperature on CHAPk activity
To determine the optimum temperature for CHAPk activity, early log-phase S. aureus
DPC5246 cell suspensions and aliquots of CHAPk were pre-incubated at temperatures
of 0, 5, 10, 15, 20, 25, 30, 35, 40, 45 and 50 °C for 5 min. Immediately after, 100 pi
of pre-incubated CHAPk was added to 100 pi of pre-incubated cells in triplicate, at
each of the above temperatures, for a further 5 min. The final concentration of enzyme
in each assay was 5 pg ml '.CHAPk activity was equated with reduction in OD590
(AOD). Assays were carried out in triplicate and data was expressed as the mean ±
standard deviations.

Influence of NaCl concentration on CHAPk activity
Early log-phase S. aureus DPC5246 cell suspensions were prepared in 50 mmol l '
sodium acetate pH 7 buffer containing concentrations of NaCl ranging from 0 to 600
mmol r'. Reduction in the OD^goof 100 pi of each cell solution in the presence of 100
pi of CHAPk, at a final concentration of 5 pg ml ', was monitored for 5 min at 37°C
in the microtitreplate reader. Assays were carried out in triplicate and data was
expressed as the mean ± standard deviations.

Influence of pH on CHAPk activity
S. aureus DPC5246 cells were resuspended in 50 mmol 1"' sodium acetate buffer with
pH values ranging from pH 4-11. A volume of 100 pi of CHAPk was added to 100 pi
of cells at each of the varying pH values, in triplicate. Reduction in OD59o(AOD) was
monitored at 37°C for 5 min, in the microtitre plate reader. The final enzyme
concentration in each sample was 5 pg ml '. Assays were carried out in triplicate and
data was expressed as the mean ± standard deviations.
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Influence of chelating agents, reducing agents and metal ions on CHAPk activity
Assays were carried out with 50 mmol r‘ sodium acetate buffer pH 7 containing early
log-phase S. aureus DPC5246 cells and 5 pg ml"' of CHAPk. Final concentrations of
1, 10 and 100 mmol l ' ethylenediaminetetraacetic acid (EDTA), dithiothreitol (DTT),
P-mercaptoethanol, CaCF and MgCF were contained in individual aliquots (200 pi) of
the enzyme-cell suspension and the reduction in OD590 (AOD) was monitored at 37°C
for 5 min. Results were expressed as percentage residual activity where the reduction
in OD590 (AOD) of cells in the presence of sodium acetate buffer and CHAPk only,
represented 100% activity. Assays were carried out in triplicate and mean values
reported for percentage residual activity.

Minimum

inhibitory

concentration

(MIC)

and

minimum

bactericidal

concentration (MBC)
The MIC of CHAPk against S. aureus DPC5246 was determined according to the
standard broth microdilution method of the National Clinical and Laboratory
Standards Institute (CLSI 2009). Concentrations of CHAPk ranged from 1.95 pg ml '
to 250 pg ml"' in cation-adjusted Mueller Hinton (CAMH) broth containing a starting
inoculum of ~ 5 x 10^ CPU ml"' of S. aureus strain DPC5246 in a 96-well microtitre
plate. Control wells included; sterile broth alone, sterile broth with lysin and broth
inoculated with DPC5246. The end-point of the assay (MIC) was defined as the
lowest concentration of antimicrobial agent which completely inhibits growth of the
microorganism in microdilution wells as detected by the unaided eye (CLSI 2009).
The minimal bactericidal concentration (MBC) was also determined against the same
strain and is defined as the lowest concentration of antimicrobial agent that will
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prevent the growth of an organism after subculture onto antibiotic-free media
(Andrews 2001).

Results

Production and in vitro activity of CHAPk
CHAPk is a 165-amino-acid protein with a predicted molecular mass of 18,586.8
daltons and a theoretical isoelectric point of 8.79 (www.expasv.org). The use of
sonication (MSE Soniprep 150, Wolf laboratories, UK) (144 pulses for 5 s with 10 s
intervals) on ice for lysis of bacterial clones, prior to protein purification, was found
to be as effective as Bugbuster solution (Novagen) (data not shown). This
recombinant phage lysin was purified by cation exchange column chromatography to
>90% homogeneity. When purified protein fractions were examined by SDS-PAGE a
band of approximately 20 kDa was evident, which corresponds to the predicted
molecular mass of 18.6 kDa (Fig. 1). Fractions were also examined for lytic activity
by zymogram analysis where zones of cell lysis were clearly evident at the 20 kDa
position (Fig. 1).
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Figure 1. SDS-PAGE (Lanes 1-3) and zymogram analysis (Lane 4) of purified CHAPk-

Biorad Low Range Protein Marker (Lane 1); eluted fractions of purified CHAPk (Lanes 2-3);
CHAPk-activity on zymogram gel with activity causing staphylococcal cell lysis indicated by

zone of clearing (Lane 4).

Yields of 4 to 10 mg of purified protein per litre of induced E. coli culture were
routinely achieved. In preliminary experiments various concentrations of purified
CHAPk were tested for activity against live cultures of S. aureus DPC5246 in
turbidity reduction assays. Lytic activity was observed at concentrations of lysin as
low as 0.1 |ig and typically a concentration of 1 pg reduced the OD590 (AOD590) of
early log-phase S. aureus by up to 70% in 5 min. To confirm that the observed loss in
turbidity corresponded to a decrease in cell viability, aliquots from sample and control
wells were taken at various time points during turbidity reduction assays, serial
diluted, plated and enumerated (CPU ml ') on BP agar supplemented with egg yolk
tellurite. A greater than three-log decrease in S. aureus was observed after 10 min
when cells were treated with 20 pg of CHAPk (Fig.2).
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Time (min)
Figure 2. Activity of CHAPk against S. aureus in vitro, (a) S. aureus DPC5246 cells were
resuspended in 50 mmol 1 ’ sodium acetate buffer (pH 7) and incubated in a 96-well microtitre
plate with 20 pg of CHAPk (filled squares) at 37°C. Control experiments (filled diamonds)
were performed under the same conditions with buffer and cells alone. The OD590 was
monitored by a spectrophotometer for 60 min. To confirm that reduction in turbidity equated
to a reduction in cell viability, bacteria in control and lysin treated wells were plated on Baird
Parker (BP) agar supplemented with egg yolk tellurite and enumerated.

In addition, a turbidity reduction assay was performed in test-tubes to visually
demonstrate CHAPk activity. In this case 1.5 ml of S. aureus DPC5246 cell
suspension (5x10 CPU ml" ) was aliquotcd into two test tubes. After CHAPk (200
pg mb' final concentration) was added to one test tube, gradual clearing took place,
which was video recorded. Figure 3 shows the tubes at times 0, 3.5 minutes and 7
minutes. All viable cells in the CHAPk tube were eliminated after seven minutes.
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CHAP,

Control

Figure 3. Reduction in turbidity of a S. aureus DPC5246 culture (5 x Kr CFU ml' ) after
addition of 200 ixg ml ' of CHARk- (^) appearance immediately after addition of CHAPk; (b)
appearance 3.5 minutes after addition; (c) appearance 7 minutes after addition. No viable cells
remained in the CHAPk tube after 7 minutes.

Lytic spectrum of CHAPk
A turbidity reduction assay was performed to determine the lytic spectrum of CHAPkA variety of genera and species were tested (Table 1). In all cases, early log-phase
cells were incubated with 10 pg ml ' of enzyme at 37°C for 15 min. CHAPk displayed
strong lytic activity against all staphylococcal species (Fig. 3) irrespective of their
origin, their antibiotic resistance profile, or EPS producing ability, associated with S.
aureus biofilm formation and recalcitrant infection (Hensen, Pavicic et al. 2000;
Coulon, Vinogradov et al. 2010). Modest to weak lytic activity was observed against
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genera which were closely related to the genus Staphylococcus, such as species of

Micrococcus and Streptococcus. Of the other Gram-positive species tested moderate
lytic activity was observed against Nesterenkonia halobia, and weak lytic activity
against Arthrohacter agilis,

Leuconostoc mesenteroides and

Carnohacterium

maltaromanticum. No lytic activity was detected against Gram-positive Kocuria
rosea, Paracocus pantothrophus or against Gram-negative bacteria (Fig. 4).
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Figure 4. Lytic spectrum of CHAPk. Log-phase cultures of different bacterial species
and genera were exposed to 10 pg ml ' of enzyme for 15 min at 37°C and the decrease in
OD590 was monitored by a spectrophotometer. Lysin activity was expressed as the reduction
in turbidity in 15 min (AOD590/I5 min). This measurement allowed direct comparison of
CHAPk activity among the bacteria tested. Reduction in turbidity indicates cell death. A
reduction value of 0 on the vertical axis equates to no killing of bacterial cells and a reduction
value of 0.3 equates ~ 4-log reduction in bacterial cell numbers.

Enzymatic properties of CHAPk
Using the turbidity reduction assay, the activity of CHAPk was evaluated over a range
of pH, temperature and salt concentrations (Fig. 5, a, b, c). Decrease in turbidity of the
substrate {S. aureus DPC5246) in varying conditions over 5 min (AOD590/5 min) in
the presence of 5 pg ml ’ of enzyme was monitored spectrophotometrically for each
assay. The optimum pH for lysin activity was pH 9, however, high activity was
evident over a broad pH range from pH 6 to 11 (Fig 5, a). CHAPk was active over a
broad temperature range from 5°C to 40° C, with optimum activity observed at 15°C
and no activity above 45°C (Fig 5, b). Activity was maintained over a broad range of
NaCl concentrations (Fig. 5, c). A linear increase in enzyme activity was seen with
reduction in NaCl concentration from 300 - 0 mmol l '. In the presence of more than
300 mmol f' NaCl, enzyme activity decreased considerably. The effects of chelating
agents, reducing agents and metal ions on CHAPk activity was also determined
(Table 2). The metal chelating agent EDTA completely inhibited enzyme activity at
concentrations above 10 mmol l '. At a concentration of 1 mmol 1 ' EDTA enzyme
activity was reduced by 46%. The reducing agent DTT had no effect on CHAPk
activity at 1 mmol f' and gave rise to slightly enhanced enzyme activity at
concentrations from 10 to 100 mmol f'. P-mercaptoethanol did not inhibit enzyme
activity by more than 13% across a concentration range of 1 to 100 mmol f'. In the
presence of CaCE or MgCE at concentrations greater than 10 mmol f' enzyme
activity was inhibited by up to 50%. At a concentration of 100 mmol l ', MgCE
caused complete inhibition of lysin activity.
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Figure 5. Characterisation of CHAPk activity. Reduction in turbidity of S. aureus strain
DPC5246 after treatment with 5 jig ml ' of CHAPk for 5 min. (a) pH profile of lysin activity,

(b) Temperature profile of lysin activity, (c) NaCl concentration profile of lysin activity.
Reduction in turbidity indicates cell death. A reduction value of 0 on the vertical axis equates
to no killing of bacterial cells and a reduction value of 0.3 equates to a ~ 4-log reduction in
bacterial cell numbers.

Table 2. Inlluence of chelating agents, reducing agents and metal ions on CHAPk
activity
Compound
1 mmol P'

Residual activity
(%)
10 mmol P’

100 mmol P'

54
100
92
84
88

28
103
87
50
55

1
112
90
2
0

EDTA
DTT
p-rnercaptoethanol
CaCH
MgCb

Stability of CHAPk in solution
CHAPk was stored as a 10 pg ml ’ solution (in sterile H2O) at 4°C for two months and
its activity assayed fortnightly by turbidity reduction assay. It was found that after one
month CHAPk still retained up to 70 % of its activity. After this period, lytic activity
diminished rapidly. When aliquots of a solution of CHAPk (in 10 mmol P' sodium
acetate pH 7) were stored at -80°C and assayed periodically there was no reduction in
activity for up to a period of one year (after which the experiment was stopped).
Enzyme aliquots (in 10 mmol P' sodium acetate pH 7) which were stored at -80°C
and which were repeatedly thawed and refrozen 12 times over a period of 2 months
did not exhibit reduced activity.
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Minimum

inhibitory

concentration

(MIC)

and

minimum

bactericidal

concentration (MBC)
An MIC value of 31.25 |ig ml ' was recorded for CHAPk against S. aureus strain
DPC5246 using the standard broth microdilution method under CLSI guidelines
(CLSI 2009). The same result was recorded when the assay was carried out in Brain
Heart Infusion (BHI) broth and Tryptic Soya broth (TSB) (data not shown). The MBC
for CHAPk against strain DPC5246 was determined to be 31.25 pg ml ' as no
bacterial growth occurred after wells containing cells with this concentration of lysin
were subcultured onto fresh antibiotic-free media and incubated @ 35 ± 2 °C
overnight.

I^ytic activity of CHAPk compared to lysostaphin against live S. aureus in vitro
Both CHAPk and lysostaphin were made up as 0.5, 2.5, 5 and 10 pg ml ' solutions in
sterile H2O and each was incubated with live S. aureus DPC5246 cells for 5 min at
37°C (Fig. 6). At 0.5 pg ml ', lysostaphin caused no reduction in turbidity while the
same concentration of CHAPk brought about a 52% reduction. At 2.5 pg ml ',
CHAPk mediated a 70% drop in OD590 which was 45-fold greater than that caused by
lysostaphin (1.5%). Finally, at a concentration of 10 pg ml"', CHAPk brought about an
85% reduction in OD590 corresponding to a 3-log drop in S. aureus cell numbers in 5
min.

1 15

Cone (ug ml )

P'igure 6. Comparison of CHAPk (plain columns) and lysostaphin (striped columns) lytic
activity against live S. aureus by turbidity reduction assay. Reduction in OD590 was monitored
over 5 min using 0.5 to 10 ug ml ’ coneentrations of both enzymes. Reduction in turbidity
equates to cell death. A reduction value of 0 on the vertical axis equates to no killing of
bacterial cells and a reduction value of 0.3 typically equates to a ~ 4-log reduction in bacterial
cell numbers.

I)i.scussion

The current study has revealed important characteristics of the phage derived
peptidase, CHAPk, enhancing its potential development as a novel antimicrobial. This
is the first report of a single domain truncated phage lysin with lytic capabilities
against live bacteria broader than the host range of the original LysK enzyme. It
retains strong catalytic activity over a varied range of environmental conditions that
would otherwise inactivate phage lysins. CHAPk also has more rapid activity against
S. aureus compared to the commercially available, metalloendopeptidase, lysostaphin.
In our laboratory, we have previously studied the antibacterial activity of the phage
lysin, LysK (O'Flaherty, Coffey et al. 2005). This enzyme, originating in
staphylococcal phage K, was found to have a modular organisation with three
domains; a cysteine, histidine-dependent amidohydrolase/peptidase (CHAP), an
amidase, and thirdly a SH3b cell-wall binding domain. The latter facilitates
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attachment of the enzyme to the bacterial cell wall peptidoglycan. The former two
domains catalyse the degradation of the peptidoglycan, mediating rapid bacterial cell
death. Deletion analysis of LysK (495 amino acids) showed that lytic activity was
enhanced at least 2-fold against live antibiotic-resistant staphylococci when the lysin
was truncated to only its CHAP domain (165 amino acid, designated CHAPk)
(Horgan, O'Flynn et al. 2009). A possible explanation might be that the C-terminal
domain inhibits the catalytic activity of the N-terminal domain when not bound to its
substrate in the bacterial cell wall. Therefore, in the case of CHAPk, this effect might
be relieved upon removal of the SH3b binding domain resulting in production of the
enzyme in a highly active state.
In this study CHAPk was successfully purified to homogeneity by cation exchange
chromatography. SDS-PAGE analysis of the lysin indicated a monomer of ~2() kDa in
size and of >90% purity (Fig. 1). This size compared well to the predicted molecular
mass of 18.6 kDa. The ability of CHAPk to inflict log-fold death on live S. aureus
cultures within minutes was also demonstrated (Fig. 2 and 3). In turbidity reduction
assays 20 pgof CHAPk routinely reduced lO^CFU ml ' S. aureus by 3-log fold in 10
min (Fig. 2).
In addition to killing bovine and multi-drug resistant human isolates of S. aureus,
CHAPk was highly effective against coagulase negative strains S. epidermidis, S.

saprophyticus, S. chromogenes, S. capitis, S. hominis, S. haemolyticus, S. caprae and
S. hyicus and EPS producing S. aureus Newbold 305 and BMA-FR-032-074 (Pig. 4).
The native LysK enzyme also displayed lytic activity against these staphylococcal
strains (O'Plaherty, Coffey et al. 2005). Interestingly, when the study was extended
outside the genus of Staphylococcus, only CHAPk demonstrated lytic activity against
eleven other bacterial species (Pig. 4). Most notably lytic activity was observed
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against live S. pyogenes which is a common cause of pharyngitis (Nelson, Loomis et
al. 2001); against S. pneumoniae a causative agent of pneumonia, acute otitis media
and meningitis (Jado, Lopez et al. 2003; Loeffler, Djurkovic et al. 2003) and against
S. mutans a contributor in the development of dental caries (Hamada and Slade 1980;
loannidis, Kakoutis et al. 2011). These results suggest that in the absence of a SH3b
cell wall binding domain, CHAPk may recognise, a common moiety in the
peptidoglycan cross-bridge of staphylococcal and streptococcal pathogens. The
endopeptidase cleavage site of CHAPk was previously reported to be between Dalanine and the first glycine in the pentaglycine cross-bridge of S. aureus
peptidoglycan (Becker, Dong et al. 2009), whereas the cross-bridge of streptococcal
peptidoglycan contains a D-alanine-L-alanine bond and no glycine residues
(Pritchard, Dong et al. 2004). Although lytic activity was moderate to weak against
streptococci, further investigation is worthwhile, for example, a recent study by
Becker et al (2009) reported that the fusion of a streptococcal phage lysin, displaying
weak activity against S. aureus, to a staphylococcal SH3b cell wall binding domain
resulted in the lysin displaying increased staphylolytic and streptococcal activity. All
genera/specics tested in this host range study were Gram-positive, apart from two
strains of E. coli against which no lytic activity was detected (Table 1 and Fig. 4).
Lfsing the turbidity reduction assay an impressive profile of CHAPk enzyme activity
was determined against live cells under various conditions. CHAPk was shown to
maintain high lytic activity over a broad pH range (pH 6-11) (Fig. 5, a) comparable to
that of the Bacillus anthracis lysin, PlyPH (Yoong, Schuch et al. 2006). In general the
pH profile of lysins, where activity is optimal, is pH 5-7 (Loeffler, Djurkovic et al.
2003). Strong lysin activity was retained when examined over a broad temperature
range from 5°C to 40°C, with a marked reduction in activity at 45°C (Fig. 5, b).

CHAPkIs active at high salt concentrations (Fig. 5, C), including at physiological salt
concentrations of 150 mmol 1“' (Yoong, Schuch et cil. 2006). In contrast to the native
three-domain LysK enzyme which shows increasing activity at concentrations of
-150 mmol T' NaCl to maximum activity approaching 400 mmol 1"' NaCl (Becker,
Foster-Frey et al. 2008), the single domain CHAPk demonstrates decreasing activity
at concentrations greater than 250 mmol 1"' NaCl with increasing activity at lower salt
concentrations (Fig. 5, c).
Effects of CaCF and MgCl2 on CHAPk activity were consistent with that reported for
other lysins where enzyme activity was maintained at the 3 mmol 1* free calcium ion
concentration of bovine milk (Donovan, Lardeo et al. 2006) and at the 1 mmol 1"'
physiological concentration of magnesium ions (LoefOer, Djurkovic et al. 2003).
FDTA strongly inhibited enzyme activity, whereas activity was unaffected by the
reducing agent (I-mercaptoethanol and slightly enhanced in the presence of DTT.
CHAPk retains strong enzymatic activity for up to one month when stored at 4°C and
up to one year under storage at -80°C.
The MIC value for CHAPk against S. aureiLs bovine mastitis strain DPC5246 was
31.25 (ig ml '. This value is within the range of MICs previously reported for the
streptococcal phage lysins Cpl-1 and Pal (Loeffler and Fischetti 2003) and for the
staphylococcal phage lysins C-His-LysK (Becker, Foster-Frey et al. 2008) and ClyS
(Daniel, Euler et al. 2010). Interestingly, when Becker et al. made a deletion
derivative of LysK encompassing the CHAP domain alone as a truncated amino acid
peptide, no activity was detected in MIC assays (Becker, Dong et al. 2009).
With the increasing prevalence of antibiotic resistant pathogens there has been a
renewed interest in the possibility of using recombinant lysostaphin for the treatment
of S. aureus infections including MRS A (Climo, Patron et al. 1998; Yang, Li et al.
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2007). The potential of lysostaphin, a 27 kDa antistaphylococcal endopeptidase, has
been examined in many in vitro and in vivo studies over a number of years as
reviewed by Kumar (Kumar 2008). However a considerable drawback to the potential
of this antimicrobial are reports outlining the development of bacterial resistance
(Boyle-Vavra, Carey et al. 2001; Climo, Ehlert et al. 2001; Grundling, Missiakas et
al. 2006). For phage lysins however, no development of bacterial resistance has been
reported. It is suggested that resistance is unlikely because it requires the cell to
change the structure of essential components of its cell wall (Loeffler, Nelson et al.
2001; Schuch, Nelson et al. 2002; Loessner 2005; Pastagia, Euler et al. 2010). In the
study comparing the lytic activity of various concentrations of CHAPk to lysostaphin
against live S. aureus, CHAPk demonstrated superior lytic activity, in a concentration
dependent manner over 5 min at 37°C (Fig. 6). At a concentration of 2.5 pg ml ',
CHAPk displayed lyti^-' activity 45-fold higher than that of lysostaphin (Fig. 6).

In the current report we have performed initial characterisation studies on the CHAPk
lysin highlighting its potential

use as a novel antimicrobial

agent against

staphylococci in a wide range of applications.
In summary, CHAPk is a unique truncated phage lysin with excellent biochemical
properties, high specificity and strong, rapid lytic activity against all staphylococci
regardless of their origin or antibiotic resistance profile. Characterisation of this
enzyme has revealed its broad host range and stable nature. It maintains high lytic
activity at the calcium ion concentration of bovine milk and at physiological temp,
pH, salt and magnesium ion concentrations. Finally, the superior lytic activity of
CHAPk compared to lysostaphin was demonstrated against live S. aureus. Further

detailed studies on the structure and function of the CHAPk enzyme are now in
progress.
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Chapter 5
Bacteriophage-derived peptidase CHAPk disrupts and prevents S. aureus
biofilms
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Abstract
The cysteine, histidine-dependent amidohydrolasc/peptidasc, CHAPk, is derived from
the multi-domain lysin (LysK) of staphylococcal bacteriophage K. Following
purification,

CHAPk

was

shown

to

rapidly

disrupt

and eliminate

mature

staphylococcal biofilms in one hour. Futhermore, it was more effective than the
metalloendopeptidase, lysostaphin. CHAPk was also able to completely prevent
biofilm formation. In addition CHAPk reduced/eliminated S. aureus in a skin
decolonization model. Our data demonstrates the potential of CHAPk as a promising
agent for the rapid elimination of highly antibiotic resistant biofilm-related infections.
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Introduction
Staphylococcus aureus commonly colonizes the skin and mucosal membranes of both
humans and animals. It is also the causative agent in a number of diseases, ranging
from a variety of skin conditions to more serious infections such as scepticemia,
endocarditis, osteomyelitis, pneumonia and meningitis in humans in addition to
bovine mastitis in dairy herds (Lowy 1998; Gruet, Maincent et al. 2001). Along with
the urgent requirement for novel antibacterials to combat the prevalence of meticillin
resistant S. aureus (MRSA) in healthcare settings and the increasing incidence of
community-acquired MRSA (CA-MRSA) there is a need for effective therapeutics to
prevent and treat staphylococcal biofilm infections (Donlan and Costerton 2002; Eady
and Cove 2003; Lowy 2003). Biofilms are multilayered communities of sessile cells
protected by an extracellular matrix which, in cases of infection, often adhere to
damaged tissue or indwelling medical devices such as catheters (Dunne 2002;
O'Grady, Alexander et al. 2002). Once formed, biofilms may be up to 1,000 times
more resistant to antibiotics than planktonic cells alone making them particularly
difficult to eliminate. This can ultimately lead to increased risk of persistent infections
and complications, resulting in a need for removal of medical implants (Costerton,
Stewart et al. 1999; Aparna and Yadav 2008). Although the precise mechanisms of
biofilm antibiotic resistance have yet to be fully resolved, inability to successfully
treat infections with conventional therapies necessitates the investigation and
development of novel treatment strategies (Costerton, Stewart et al. 1999; Donlan and
Costerton 2002; Stewart 2002).
In recent years bacteriophage endolysins (phage lysins) have been the focus of
research against a range of clinically relevant Gram-positive pathogens including
multidrug resistant strains, both in vivo and in vitro, as summarised in the following
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reviews (Fischetti 2005; Loessner 2005; Fenton, Ross et al. 2010). These cell wall
peptidoglycan hydrolases possess a number of advantages over conventional
antibiotics including, target strain specificity, rapid lytic activity against both
planktonic and dead bacterial cells, low probability of developing bacterial resistance
and have no negative impact on beneficial commensal microflora (Schuch, Nelson et
al. 2002; Fischetti 2005; Loessner 2005; Pastagia, Euler et al. 2010).
To date a number of phage lysins have been described which demonstrate activity
against staphylococci including LysK (O'Flaherty, Coffey et al. 2005), LysWMY
(Yokoi, Kawahigashi et al. 2005), 011 lysin (Sass and Bierbaum 2007), MV-L
(Rashel, Uchiyama et al. 2007), LysH5 (Obeso, Martinez et al. 2008), LysGH15 (Gu,
Xu et al. 2010), SAL-2 (Son, Lee et al. 2010) and SAL-1 (Jun, Jung et al. 2011). To
our knowledge only two of these lysins, 011 lysin (Sass and Bierbaum 2007) derived
from a siphoviridae phage and SAL-2 (Son, Lee et al. 2010) derived from a
podoviridae phage, have been reported to lyse staphylococcal biofilms.
CHAPk is a truncated derivative of a three-domain phage lysin (LysK) derived from

the myoviridae staphylococcal phage K (O'Flaherty, Coffey et al. 2005). This
endopeptidase specifically cleaves the peptide bond between p-^lanine and the first
glycine in the pentaglycine cross-bridge of staphylococcal cell wall peptidoglycan
(Becker, Dong et al. 2009). We have previously reported that purified CHAPk
exhibits stronger activity than the original three-domain lysin (LysK) (Morgan,
O'Flynn et al. 2009) and displays rapid lytic activity against all pathogenic
staphylococci including MRSA strains, both in vitro and in vivo (Morgan, O'Flynn et
al. 2009; Fenton, Casey et al. 2010).
Here we examine the efficacy of the phage-derived CHAPk enzyme in eliminating S.
aureus biofilms and compare it to another peptidase previously used for this purpose.
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the metalloendopeptidase lysostaphin (Wu, Kusuma et al. 2003). We also demonstrate
its effectiveness in the removal of S. aureus from skin.

Materials and Methods

Bacterial strains
The strains used in this study were S. aureus strain Xen29 (Caliper Lifscienees, UK)
and S. aureus strain DPC5246 (Moorepark Food Research Centre, Teagasc, Fermoy,
Cork, Ireland). Strain Xen29 is a confirmed biofilm producing pleural fluid isolate
derived from the parental strain S. aureus ATCC 12600. It has been engineered to
emit luminescence when metabolically active by the introduction of a modified
Photorhahdus luminescens luxABCDE operon at a single integration site on the
bacterial chromosome (Kadurugamuwa, Sin et al. 2003; Kadurugamuwa, Sin et al.
2003; Kadurugamuwa, Sin et al. 2004). Strain DPC5246 is an S. aureus bovine
mastitis isolate (O'Flaherty, Coffey et al. 2005). If not otherwise indieated, both
strains were stored at -80°C and grown on tryptic soya agar (TSA), in tryptic soya
broth (TSB) or TSB supplemented with 1% D-(+)-glucose (TSBg) at 37°C in
agreement with previous biofilm studies (Christensen, Simpson et al. 1985; Wu,
Kusuma et al. 2003). All media were supplied by Sigma-Aldrich.

Production of CHAPk
CHAPk

is

comprised

solely

of

the

cysteine,

histidine-dependent

amidohydrolase/peptidase (CHAP) domain of the anti-staphylococcal bacteriophage
endolysin, LysK (O'Flaherty, Coffey et al. 2005). The truncated phage lysin gene, was
cloned into a pQE60 expression vector (QIAGEN) and overexpressed in Escherichia
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coli (E. coli) XL 1-Blue as previously described (Morgan, O'Flynn et al. 2009). Highly
active CHAPk (18.6 kDa) was purified to >90% homogeneity by cation exchange
chromatography and stored at -80°C. The lytic activity of CHAPk against live
planktonic cells of staphylococci including multi-antibiotic resistant strains of clinical
origin has been demonstrated previously (Morgan, O'Flynn et al. 2009; Fenton, Casey
et al. 2010).

Biofilm formation and treatment with CHAPk
A modified static microtitre plate assay, based on previous studies (Christensen,
Simpson et al. 1985; Wu, Kusuma et al. 2003), was used to analyse biofilm formation
and treatment with CHAPk- Brielly, overnight colonies of S. aureus Xen29 from a
TSA plate were suspended in TSBg to an optical density equivalent to 0.5 McFarland
standard and subsequently diluted 1:100 in TSBg to give a starting inoculum of 5 x
lO"' CFU/ml. In the biofilm disruption assay, 200 pi volumes of the prepared culture
were aliquoted into wells of a sterile 96-well microtitre plate (Sarstedt) and incubated
at 37°C for 24h, which was sufficient for biofilm formation (Fig. 1).

A

B

Figure 1. Formation of S. aureus Xen29 biofilm, from a starting titer of 1 x 10^ CFU/ml, post
incubation at 37°C for 24h. (A) negative control wells, which contained growth media alone
(TSBg), post washing and staining with 0.5% crystal violet. (B) confirmation of Xen29
biofilm formation, as indicated by dark staining in wells, post washing and staining with 0.5%
crystal violet.
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After this incubation period, wells were washed twice with 100 pi of sterile H2O
using a multichannel pipette (Gilson) to remove media and planktonic cells. Biofilm
containing wells were then treated with 100 pi of various concentrations of CHAPk
(1.95 to 250 pg/ml) in sterile H2O or with 100 pi of sterile H2O alone (control), at
37°C for 1 h. At the end of treatment all wells were washed again before the plate was
inverted and left to dry for 1 h at 60°C. The biofilms were then fixed and stained with
200 pi of 0.5% crystal violet solution for 10 min. The stain solution was removed and
the wells were gently washed as before. The biofilm disrupting ability of CHAPk was
determined by visually comparing differences in the degree and intensity of staining
in CHAPK-treated and untreated biofilm wells where faint or no staining indicates the
removal and elimination of the biofilm. In addition these wells were also examined
spectrophotometrically in a microtitreplate reader (Molecular Devices, Spectra Max
340) at an optical density (OD) setting of 590nm (OD^qq).
For comparison of CHAPk with a documented biofilm disrupting enzyme, namely
lysotaphin, the disruption assay was carried out with a starting inoculum of 1x10^
CFU/ml (5. aureus Xcn29) (The starting inoculum of 1 x lO^CFU/ml was previously
used in a study (Wu, Kusuma et al. 2003) assessing the biofilm disruption activity of
lysostaphin). Biofilm containing wells received 200 pi of either CHAPk or
lysostaphin (Sigma-Aldrich: L9043) at concentrations of 62.5, 125, 250 and 500
pg/ml in phosphate buffered saline (PBS) or 200 pi of PBS alone (control).
In order to investigate the ability of CHAPk to prevent the formation of S. aureus
biofilms on artificial surfaces, the plate assay, as described above was carried out with
the following modification. At the beginning of the assay 100 pi of CHAPk at
concentrations ranging from 0.78 to 50.0 pg/ml was added to 100 pi of 1 x lO''
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CFU/ml of Xen29 cells in a sterile 96-well microtitre plate and incubated for 24 h at
37°C.

Skin decolonization assay
This study was carried out using a modified version of a recent spray test method
(Hoopes, Stark et al. 2009). Briefly, three individual areas, 25 cm in size, were
marked out on a coupon of porcine skin (obtained fresh from an abattoir). Each area
was disinfected with 70% isopropyl alcohol wipes and allowed to dry at room
temperature for up to 30 min. All three marked areas were then seeded with 100 pi of
6.2 X 10^ CPU of S. aureus DPC5246 by pipette, distributed evenly within each area
with a sterile plastic spreader (Sarstedt) and allowed to dry for 30 min. CHAPk (200
pg/ml in sterile H2O) was then misted 20 cm above one of the 25 cnr areas, in two
passes. The two remaining sections served as controls where one 25 cm*" area was
misted with sterile H2O and the other was left untreated. The skin was then left to dry
at room temperature for 30 min. Sterile cotton tipped swabs (Deltalab sterile swabs,
Fisher Scientific, Ireland) were moistened in sterile Ringer’s solution and used to
sample each section of skin by rotating and rubbing the swab, in a zigzag pattern, and
repeating at right angles. The tips of each swab were placed in 10 mis of Ringers
solution and vigorously mixed using a vortex mixer to dislodge cells. The suspensions
were serially diluted and plated on Baird Parker agar supplemented with egg yolk
tellurite for enumeration of surviving cells. Experiments were carried out in duplicate
using S. aureus DPC5246. The work was also similarly done using the bioluminescent
producing S. aureus Xen29 strain.
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Results

Biofilm disruption using CHAPk
Preliminary studies confirmed the biofilm-forming capacity of .S. aureus Xen29 in 96well plates when incubated for 24 h at 37°C (Fig. 1). Strong biofilms were routinely
formed with bacterial titers ranging from 1 x 10'^ to 1 x lO^CFU/ml and grown in TSB
supplemented with either 0.25 or 1 % D-(+)-glucose. The addition of 200 pi of 0.5%
crystal violet solution to wells, for 10 min, was sufficient for staining and visualising
mature biofilms and allowed the direct examination and comparison between control
and enzyme treated wells (Fig. 1).
In the biofilm disruption assay, the effect of CHAPk treatment on established Xen29
biofilms was determined. Mature biofilms (24 h) were treated with enzyme at
concentrations ranging from 1.95 to 250 pg/ml, for 1 h at 37°C. CHAPk successfully
disrupted the S. aureus biofilms, in a concentration dependent manner (Fig. 2). Visual
inspection of the degree and intensity of staining in the CHAPk treated wells
compared to untreated biofilm wells revealed that 32.25 pg/ml of CHAPk caused a
clear reduction in biofilm mass and a concentration of 250 pg/ml resulted in the
complete elimination of the S. aureus biofilm, with CHAPK-treated wells showing
only faint or no staining (Fig. 2). Faint residual staining in CHAPK-treated wells is
likely to be biofilm debris and contain no intact staphylococci, as was the case in a
similar study by Wu et al. (2003). when examining the biofilm disrupting activity of
lysostaphin (Wu, Kusuma et al. 2003).
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Figure 2. CHAPk disruption assay against 24h biofilms of S. aureus Xen29. Microtitre plate
wells displaying the biofilm reducing effects of CHAPk treatment for Ih at 37°C are shown
directly below the corresponding concentration of enzyme used. Absorbance readings at
59()nm of each well were also recorded in a microtitreplate reader and displayed on the bar
chart. Assays were carried out in triplicate and OD590 data was expressed as the mean ±
standard deviations.

Biofilm prevention by CHAPk
To investigate the eapaeity of CHAPk to inhibit the formation of S. aureus biofilms,
various coneentrations of the enzyme were incubated with strain Xen29 for 24 h at
37°C in the microtitre plate assay. When a relatively low concentration of CHAPk
was employed (6.25 ug/ml), inspection of the degree and intensity of crystal violet
staining in microtitre plate wells, showed biofilm partial inhibition by comparison
with untreated control wells where biofilm growth had occurred (Fig. 3). Increasing
degrees of biofilm prevention were evident in the presence of increasing
concentrations of enzyme. When a concentration of 50 pg/ml of CHAPk was used,
complete inhibition of biofilm formation was observed (Fig. 3).

34

2.5

1.5

im

li

0

0.78

1.6

3.1

6.25

12.5

Concentration of CHAPk ((ig/ml)

25

50

Control
medium

Figure 3. CHAPk biofilm prevention assay. Coneentrations of enzyme ranging from 0-50
|ig/ml were incubated with S. aureus Xen29 in TSBg at 37°C for 24h. Optical density
readings at 590nm (OD590) of all wells were afso recorded in a microtitreplate reader and
displayed on the bar chart. Assays were carried out in triplicate and OD.sw data was expressed
as the mean ± standard deviations.

Comparison of biofilm disrupting activity by CHAPk with lysostapin
We compared the S. aureus biofilm disrupting ability of CHAPk to the documented
biofilm disrupting enzyme, lysostaphin (Wu, Kusuma et al. 2003). S. aureus Xen 29
biofilms were treated with concentrations of 62.5 to 500 pg/ml of either CHAPk or
lysostaphin at 37°C for 1 h. The biofilm-disrupting activity of both enzymes was
observed by comparing differences in staining intensity of CHAPK-treated versus
lysostaphin-treated biofilm wells (Fig. 4). Faint or no staining in CHAPK-treated wells
across all concentrations contrasted with strong biofilm staining in all lysostaphintreated wells (Fig. 4). CHAPk thus displayed superior biofilm disrupting ability
compared to lysostaphin, rapidly eliminating mature staphylococcal biofilms in one
hour (Fig. 4).
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Fig. 4. Comparison of the biofilm-disrupting activity of CHAPk with lysostaphin. All wells
contained 24h biofilms of S. aureus Xen29 and were treated for Ih with 200 pi of various
concentrations of either enzyme at 37°C

Removal of X. aureus from skin using CHAPk

The potential of CHAPk as

skin decolonization agent was assessed by incorporation

of the enzyme into a spray. Coupons of porcine skin (25 cm“) were seeded with 2.5 x
lO'’ CFU/cnC of S. aureus strain DPC5246 and misted with 200 pg/ml solution of
CHAPk for two seconds. Water-treated and untreated skin sections had similar CPU
values when enumerated after 30 minutes. This contrasted with a significant reduction
in CPUs on the CHAPK-treated skin, which received approximately 60 pg of enzyme.
This was found to be sufficient to remove 99% of S. aureus DPC5246 in 30 min.
Similar results were achieved when CHAPk was employed against the bioluminesent
strain S. aureus Xen29 (Pig. 5).
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Fig. 5. Reduction of S. aureus Xen29 on porcine skin using CHAPk. Two sections of skin
were seeded with 2.4 x 10^ CFU/cm^ of the bacterium. One area of skin was treated with
sterile H2O as a control (a) and the other area treated with 100 pg CHAPk (b). Skin was
imaged (Exposure; 15 seconds, Binning: medium. Color-scale 36-67) 30 min after treatment
with CHAPK/H2O using the in vivo Imaging System (IVIS) (Xenogen, Ca). This system
enabled direct monitoring of the effect of CHAPk treatment in real time. The colour bar
represents bacterial bioluminesent signal intensity, with red to blue indicating high and low
bioluminescence, respectively.

Discussion

New control agents are needed for the elimination of biofilm associated infections
such as those caused by S. aureus. These are generally difficult to disrupt, they
survive in suboptimal environmental conditions, display widespread resistance to
antibiotics, establish chronic infections and often render it necessary to remove
biomedical implants (Raad, Darouiche et al. 1998; Chamis, Peterson et al. 2001;
Ando, Monden et al. 2004). In this study we demonstrated that the phage-derived
peptidase, CHAPk, specifically disrupts S. aureus biofilms in one hour. In the biofilm
context it is likely that CHAPk rapidly lyses sessile staphylococcal cells with an
efficiency that brings about destabilization of the biofilm matrix leading to their

37

subsequent detachment from solid surfaces. Treatment of staphylococcal biofilms
with CHAPKmay have numerous advantages over traditional regimens such as the use
of high concentrations of antibiotics for prolonged periods of time. This can
ultimately be ineffective, frequently leading to the necessity to remove medical
implants (Costerton, Stewart et al. 1999; Aparna and Yadav 2008). CHAPk also has
the potential

to rapidly eliminate biofilms, at relatively low to

moderate

concentrations in one hour. As CHAPk is derived from a phage lysin there is also low
likelihood of the development of bacterial resistance (Schuch, Nelson et al. 2002;
Fischetti 2005; Loessner 2005; Pastagia, Euler et al. 2010) as frequently seen with
conventional antibiotics which are employed in medical practice for biofilm
elimination (Raad, Darouiche et al. 1998; Chamis, Peterson et al. 2001; Ando,
Monden et al. 2004). Another additional benefit is, unlike antibiotics, phage lysins do
not negatively impact on commensal microHora (Fischetti 2005; Loessner 2005, O
Flaherty, Coffey et al. 2005).
At a concentration of 50 ug/ml, CHAPk completely prevented the formation of S.
aureus biofilms (Fig. 3). This result demonstrates the potential of possibly applying
CHAPk as a coating agent on medical implants such as catheters to prevent the
adherence of staphylococci and subsequent biofilm formation and infection. Previous
studies have shown that coating medical implants with antibacterial agents can be
effective in preventing formation of biofilms (van Heerden, Turner et al. 2009;
Bernthal, Stavrakis et al. 2010; Bruellhoff, Fiedler et al. 2010).
The anti-staphylococcal enzyme, lysostaphin, has previously been evaluated for the
removal of staphylococcal biofilms (Wu, Kusuma et al. 2003). In this study, CHAPk
was compared to lysotaphin and found to be more effective at disrupting and
removing 24 h S. aureus biofilms. In the comparison assay, a final concentration of
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62.5 |ig/ml of CHAPk was sufficient to completely eliminate mature S. aureus
biofilms in just one hour whereas lysostaphin at the same and at higher concentrations
was ineffective over the one hour treatment period (Fig. 4). It is worthy of mention
that the study by Wu et al (2003) applied lysostaphin for three hours.
The two main reservoirs of S. aureus on the human body are the skin and mucosal
membranes. Infection can often originate from a person’s own flora, especially in
hospital and healthcare settings (Kluytmans, van Belkum et al. 1997; Gong, Lin et al.
2006). We have previously reported the ability of CHAPk to eliminate S. aureus in the
nares of mice in vivo (Fenton, Casey et al. 2010). The present study demonstrated the
potential of CHAPk as a decolonization agent for the removal of S. aureus from the
surface of skin (Fig. 5). When applied as a spray, CHAPk eliminated 99% of S.
aureus DPC5246 from skin in 30 min. Effective removal of S. aureus from patients’
skin with CHAPk prior to surgery may help prevent serious nosocomial infections.
The results of the skin disinfection experiment also suggest that CHAPk could be
included in bovine teat-dip solutions for reduction of mastitis causing staphylococci
on the udder prior to and after milking in dairy farms. In conclusion, our data
demonstrates the potential of CHAPk as a novel antibacterial with the ability to
prevent, and eliminate staphylococcal biofilms in vitro as well as its potential as a skin
decontaminant.
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The truncated phage lysin CHAPk eliminates Staphylococcus aureus in
the nares of mice
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Abstract
The endolysin LysK derived from staphylococcal phage K has previously been shown
to have two enzymatic domains, one of which is an N-acetylmuramoyl-L-alanine
amidase and the other a cysteine, histidine-dependent amidohydrolase/peptidase
designated CHAPk- The latter, when cloned as a single-domain truncated enzyme, is
conveniently over-expressed in a highly-soluble form. This enzyme was shown to be
highly active in vitro against live cell suspensions of S. aureus. In the current study,
the In-Vivo Imaging System (IVIS) (Xenogen, Ca) was used to demonstrate the
effective elimination of a lux labeled S. aureus from the nares of BALB/c m.ice.
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Introduction
Staphylococcus aureus {S. aureus) is responsible for a variety of infections ranging
from skin conditions to fatal sepsis, endocarditis, septicemia, pneumonia and
meningitis.' Meticillin resistant S. aureus (MRSA) is frequently the cause of
nosocomial infections,“ which can lead to prolonged hospital stays and increased
mortality. It has been shown that a substantial proportion of these serious nosocomial
infections originate from the patients own flora, nasal carriage of S. aureus in
particular being a considerable risk factor.'^’"^ Currently, the topical application of
mupirocin ointment is used to eliminate staphylococcal nasal carriage in clinical
settings.'^ Although successful in removing S. aureus from the nose when applied
twice daily for up to 5 days, bacterial resistance to this agent is nonetheless increasing
and so new antimicrobials arc required.'’

Lysins

are

phage-encoded

pcptidoglycan

hydrolases,

which,

when

applied

exogenously as purified recombinant proteins to Gram-positive bacteria, bring about
rapid lysis and death of the bacterial cell.^’^ Unlike antibiotics, phage lysins can be
used to selectively target specific pathogenic bacteria without affecting surrounding
commensal microflora; they are reported to have a narrow host range similar to that of
their phage producers; rendering them generally either species^'^ or genus specific.
The potential for these enzymes as novel therapeutics against a number of Gram
positive pathogens on mucosal surfaces and in systemic infections has previously
been demonstrated.

In relation to bacterial resistance, no strains have yet been

identified with resistance to phage lysins.^’^’'^ It has been suggested that these
enzymes have evolved for the purpose of targeting specific molecules in the host
peptidoglycan that are essential for cell viability, making resistance an unlikely
event.

' In general, S. aureus phage lysins display a multi-domain modular structure
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comprising of a C-terminal cell wall binding domain and two N-terminal catalytic
domains. Examples include LysK, MV-L, phil 1, and LysH5.

10,20,24,25

Native lysins of S. aureus, with the exception of MV-L, have typically shown poor
expression, insolubility and low activity when generated as recombinant proteins.
However, their modular structure has enabled the construction of truncated
(CHAPk),^^ and chimeric versions of lysins (ClyS, PI6-17)“'’^^ to help circumvent
these problems. We previously showed that the activity of CHAPk (18.6 kDa) against
live S. aureus including MRSA was twofold higher than that of the native enzyme,
LysK (54 kDa).^^ To date, the multi-domain MV-L lysin from phage MRl 1 and the
chimeric two-domain lysin, ClyS, are the only anti-staphylococcal lysins which have
been evaluated in viv()?^'~^ In this study we demonstrate the effectiveness of the
highly-soluble, high-activity single-domain lysin, CHAPk to eliminate S. aureus from
the nares of artificially inoculated BALB/c mice.

Methods and Results
Bacterial Strain
The staphylococcal strain used in this study was S. aureus Xen29 (Caliper
Lifesciences, UK). This strain is derived from the parental strain S. aureus ATCC
12600, a pleural fluid isolate which has been engineered with a stable copy of the
modified Photorhabdus luminescens luxABCDE operon at a single integration site on
the bacterial chromosome.'

When metabolically active this strain emits

luminescence, which can then be rapidly detected and quantified for evaluating the
efficacy of therapeutics, in animal infection models, using an In-Vivo Imaging System
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(IVIS) (Xenogen, Ca)

30,31,32

This enabled us to monitor the nasal colonization of

individual mice in real-time and to directly compare the effect of the therapeutic agent
with appropriate controls. S. aureus Xen29 was selectively grown at 3TC in
trypticase soy broth (TSB) and trypticase soya agar (TSA) in the presence of 200
pg/ml kanamycin. CHAPr has been cloned into the pQE60 (QIAGEN) expression
system and heterlogously overexpressed in Escherichia coli XL 1-Blue cells as
previously described.

Unless stated otherwise, all media was supplied by Sigma-

Aldrich.

CHAl’Km vitro activity
CHAPk was purified by ion-exchange chromatography to high purity and quantified
with the BCA Protein Assay Kit (Pierce Scientific). CHAPk in vitro activity was
assessed against live S. aureus Xen29 in a microtitreplate based assay. Briefly, S.
aureus Xen29 was grown to early log phase at an optical density of 0.3 at 590 nm
(OD590), centrifuged, and then resuspended to a final OD590 of 0.5 in lOmM Sodium
acetate buffer (pH 7.4). 100 pi aliquots of CHAPk (at concentrations ranging from 1.0
pg/ml to 50 pg/ml) were mixed with 100 pi of the bacterial suspension and incubated
at 3TC in a microtitreplate reader (Molecular Devices, Spectra Max 340) for between
5 to 15 min. Typically 5 pg/ml of CHAPk reduced the OD590 by 70% in 5 min (Fig.
1). To confirm that the loss in turbidity equated to a reduction in cell viability,
aliquots of lysin treated cells were plated and CPUs enumerated on TSA plates
containing 200 pg/ml kanamycin (selective for S', aureus strain Xen29).
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Figure 1. Activity of CHAPk against live S. aureus Xen29 in vitro. The decrease in optical

density (OD) over time following the addition of CHAPk (5 pg/ml) at time zero (A ) in lOmM
sodium acetate buffer was monitored at 590nm in a Molecular Devices SpectraMax 340 plate
reader. Controls (•) were included under the same conditions with no enzvme added

CHAPk

vivo nasal decolonization

Experiments were undertaken with the approval of the University College Cork
Animal Experimentation Ethics Committee. S. aureus Xen29 was grown overnight at
37°C with shaking at 170 rpm in TSB medium containing 200 pg/ml kanamycin. The
culture was diluted 1:50 in fresh media and grown as above, to mid-log, centrifuged at
6000g, washed twice in PBS pH 7.4 and re-suspended in the same buffer to a
predefined titer of 3.53 x lO'^^ CEU/ml. Inoculum titers were confirmed by serial
dilution and plating on TSA containing 200 pg/ml kanamycin. Six to eight week old
female BALB/c mice (Harlan, UK) were anesthetized using isofluorane gas (Abbott
Laboratories, Kent, UK) to ensure accurate instillation of the inoculum. A total
volume of 15 pi of 3.53 x lO'*^ CEU/ml of X aureus Xen29 was intranasally instilled
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with a Gilson P20 pipette in a dropwise fashion distributed equally in each nostril.
One hour post-inoculation the mice were again anesthetized and imaged (Exposure: 5
minutes, Binning: medium, Color-scale: 70-500) using the FVIS system (Xenogen,
Ca). The luminescence from the nasal area of each animal (expressed as Relative
Light Units (RLU)) was quantified using the Living Image software package
(Xenogen, Ca). Strong luminescence was detected in the nares of all mice, indicating
successful colonization by S. aureus Xen29.
Mice were divided into two groups {n = 1) and administered either 60 pi (20 pi per
nostril and 20 pi orally) of 925 pg/60pl CHAPk in enzyme buffer (lOmM Sodium,
acetate pH 7.4) or 60 pi of buffer alone. One hour post-treatment, mice were
anesthetized by intraperitoneal injection with a mixture of ketamine (65 mg/kg) and
xylazine (13 mg/kg) (Vctoquinol, Dublin, Ireland). This enabled the simultaneous
visualization of an entire group at one time (n = 7) as opposed to the limit of 5 mice at
a time using the gas method. Animals were imaged as described earlier. The RLU
readings from the nasal area of each mouse in both groups were recorded. The mice
were then euthanized, noses aseptically dissected, weighed, macerated in 500 pi of
PBS and vigorously vortexed for 60 seconds. CPU counts for each nose were
recorded by plating out dilutions of each suspension on TSA plates containing 200
pg/ml kanamycin.
One hour post-treatment, it was observed that luminescence was drastically reduced
in the nares of the CHAPK-treated group compared to strong luminescence in the
buffer-treated control group (Fig. 2). The mean RLU value of the CHAPK-treated
group was 2996 ± 254 while the mean RLU value of the buffer-treated control group
was 23366 ± 3436. This represents approximately a 7-fold difference, which indicated
a significant reduction

in S.

aureus Xen29
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in the enzyme-treated group.

Bacteriological analysis by plating confirmed that the single treatment with CHAPk
brought about a 2-log reduction in S. aureus Xen29 numbers in the nares of the
treated mice within one hour {p <0.001). The mean logio value of the CHAPK-treated
group was 5.29 ± 0.26 CFU/g compared to a mean logio value of 7.35 ± 0.10 CFU/g
for the buffer-treated control group. The RLU and bacterial counts from both groups
of animals were statistically analyzed using the Mann-Whitney rank sum test.

Figure 2. BALB/c mice following S. aureus Xen29 inoculation imaged using the IVIS
system (Xenogen, Ca). A. Buffer-treated control group, imaged 1 hour post treatment with
lOmM Sodium acetate pFl 7.4: the Mean RLU value of this buffer-treated control group was
23366 ± 3436. B. CHAPK-treated group imaged 1 hour post treatment with 60 pi CHAPk in
lOmM Sodium acetate pH 7.4: the mean RLU value of the CHAPK-treated group was 2996 ±
254. The color bar indicates the signal intensity, with red to blue representing the high and
low bioluminescent signals, respectively.
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Conclusion
In conclusion, a single treatment with CHAPk brought about a two-log reduction in S.
aureus Xen29 cells in one hour from the nasal mucosa of mice. This single-domain
truncated lysin demonstrates high solubility, rapid lytic activity and high specificity
against staphylococci. These attributes strongly support the use of this enzyme as a
potent alternative therapeutic option.In particular it should be efficacious for the
elimination of multidrug-resistant S. aureus in both clinical and community settings
such as hospitals and nursing homes. A single application of CHAPk administered
intranasally as a spray may potentially be able to reduce the reservoir of pathogenic
staphylococci in the nasal mucosa of humans and thus be a valuable tool in the
prevention and spread of life-threatening multi-drug resistant S. aureus. This would
be particularly relevant in high-risk groups such as immunocompromised patients,
chronic disease cases and patients requiring surgery, medical implants, hemodialysis
etc."^’'’ CHAPk may also have potential to be used in a single application for the
eradication of S. aureus from the nares of patients who require emergency surgery.
This is a capacity that is currently unavailable as multiple applications of mupirocin
are required for up to five days to effectively remove S. aureus from the nose.'*’
Further investigation, development and evaluation of CHAPk is needed (e.g. study
detailing direct comparison with mupirocin in-vivo) along with preclinical and clinical
trials before this anti-staphylococcal enzyme can be used as an alternative
antibacterial agent.
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Chapter 7

In silica modelling of the staphylococcal bacteriophage-derived peptidase
CHAPk

Bacteriophage. Accepted
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Abstract
The aim of this study was to use comparative modelling to predict the threedimensional

structure

of

the

CHAPk

protein

(cysteine,

histidine

amidohydrolase/peptidase domain of LysK). Iterative PSI-BLAST searches against
the Protein Data Bank (PDB) and non-redundant databases (nr) were used to populate
a multiple alignment for analysis using the T-Coffee Expresso server. A consensus
Maximum Parsimony phylogenetic tree with a bootstrap analysis setting of 1,000
replicates was constmcted using MEGA4. Structural templates relevant to our target
(CHAPk) were identified, processed in Expresso and used to generate a 3D model in
the alignment mode of SWISS-MODEL. These templates were also processed in the
I-TASSER web server. A Staphylococcus saprophyticiis CHAP domain protein,
2K3A, was identified as the structural template in both servers. The I-TASSER
alignment generated the most accurate predicted CHAPk structure when analysed
using a Ramachandran plot and examined in DeepView and PyMOL molecular
visualisation systems. The predicted 3D model indicates that CHAPk has a papain
like fold with CATH analysis (hierarchical domain classification of protein structures)
predicting alpha-beta classification and alpha-beta-alpha architecture. The putative
active site maintained a highly conserved Cys54-Hisl 17-Glul34 charge relay and an
oxyanion hole residue Asnl36. The residue triplet, Cys-His-Glu, is known to be a
viable proteolytic triad in which we predict the Cys residue is used in a nucleophilic
attack on peptide bonds at a specific site in the pentaglycine cross bridge of
staphylococcal cell wall peptidoglycan. Comparative modeling can approximate the
3D structure of target proteins for which only the sequence is available and determine
valuable information in relation to structure, binding and active sites towards their
development as alternative antibacterial agents.
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Introduction
Staphylococcus aureus is a common pathogen that plays a major role in various
human and animal diseases ranging from skin and soft tissue infections to more
serious eases of pneumonia, endocarditis, meningitis and osteomyelitis (Lowy, 1998).
Treatment of these infections has become increasingly difficult due to the worldwide
prevalence of multidrug-resistant strains including meticillin resistant S. aureus
(MRSA) which is a cause of serious nosocomial infections (EARSS, 2007). As a
consequence it is critical to develop new and effective antibacterials with the potential
of eliminating such infections irrespective of their antibiotic sensitivity.
Over the past decade numerous studies have focussed on developing recombinant
bacteriophage-encoded cell wall hydrolases, termed lysins, as novel antibacterial
agents as recently reviewed by Loessner (2005), Fischetti (2005) and Fenton et al.
(2010). When applied exogenously as purified recombinant proteins to Gram-postitive
bacteria, lysins bring about rapid cell lysis and bacterial death (Fischetti, 2005,
Loessner, 2005, Borysowski et al., 2006). It is this ability to rapidly lyse pathogenic
Gram-positive cells upon direct contact with pcptidoglycan, also termed “lysis from
without”, that has laid the foundation for their exploitation as novel therapeutics
(Fischetti, 2005).
The majority of lysins display a modular structure, usually comprising of at least one
N-terminal catalytic domain which attacks bacterial cell wall peptidoglycan,
combined with a C-terminal cell wall binding domain which directs the lytic domain
to its site of action (Garcia et ai, 1990, Loessner et al., 2002). In the case of
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Staphylococcal lysins the presence of three domains, comprising an N-terminal
cysteine, histidine-dependent amidohydrolase/peptidase (CHAP) domain and an
amidase-2 domain linked to a C-terminal SH3b cell wall binding domain, is a
common feature. This structure has been observed in LysK (O'Flaherty et aL, 2005),
LysWMY (Yokoi et ai, 2005), 011 lysin (Sass and Bierbaum, 2007), MV-L (Rashel
et al., 2007), LysH5 (Obeso et ai, 2008), LysGH 15 (Gu et al., 2010), and SAL-1 (Jun
et al., 201 1).
Studies have shown that of the two lytic domains contained within staphylococcal
lysins, the CHAP domain confers the principle enzymatic activity of the protein,
whereas the amidase domain contributes minimal detectable activity (Navarre et al.,
1999, Becker et al., 2009, Rigden et al., 2003, Horgan et al., 2009). Furthermore, a
recent study in our laboratory showed that the activity of the single-domain truncated
CHAP (later designated CHAPk), was two-fold higher than the native three-domain
LysK protein (Horgan et al., 2009). Studies have also demonstrated that the CHAP
domain of staphylococcal lysins acts as a o-Ala-Gly endopeptidase, specifically
cleaving the peptide bond between n-iiGnine and the first glycine in the pentaglycine
cross-bridge of staphylococcal cell wall peptidoglycan (Navarre et ai, 1999, Becker
etal., 2009) (Fig. 1).
— GlcNac —MurNac —GlcNac —MurNac —
GlcNac—MurNac—

L-Ala
^

L-Ala

D-Glu

D-Glu

L-Lys—Gly—Gly—Gly—Gly—Gly—D-Ala

L-Lys—(Gly)g —D-Ala
D-Ala

CHAPj^ cleavage site

Figure 1. CHAPk cleavage site of staphylococcal cell wall peptidoglycan.
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CHAP proteins contain three highly conserved amino acid residues, two of which are
an invariant cysteine (Cys) and histidine (His) along with a third, polar residue such as
asparagine (Asn), aspartic acid (Asp) or glutamic acid (Glu) (Anantharaman and
Aravind, 2003). These residues are principally involved in catalytic activity, forming
part of the active site of the enzyme as well as being equivalent to the catalytic triad of
papain-like thiol proteases (Anantharaman and Aravind, 2003, Bateman and
Rawlings, 2003). Site-directed mutagenesis studies on these conserved residues within
the CHAP domain of the LysWHM staphylococcal lysin resulted in reduced activity,
suggesting that a Cys-His-Asn catalytic triad is crucial for enzymatic function (Yokoi
et ai, 2005).
The CHAP domain is a member of the NlpC/P60 family of peptidases and can be
found in proteins from bacteria, archaea and eukaryotes of the Trypanosomidae
family (Bateman and Rawlings, 2003). However, very little structural information is
available in relation to the CHAP domains of phage lysins. To date the crystal
structure of only five lysins has been elucidated, Cpl-1 (Hermoso et ai, 2003), PlyL
(Low et ciL, 2005), PlyPSA (Korndorfer et ciL, 2006), PlyB (Porter et ai, 2007) and
Ply500 (Korndorfer et aL, 2008), none of which are derived from staphylococcal
phage and none of which contain a CHAP domain.
In the current study a comparative modelling approach is employed to generate the
predicted three dimensional (3D) structure of the 162-amino-acid CHAP domain
protein, CHAPk, derived from the staphylococcal phage lysin LysK (O'Flaherty et aL,
2005). The potential of CHAPk as an alternative antibacterial agent which displays
rapid lytic activity against pathogenic staphylococci including MRSA, both in vitro
and in vivo, has previously been demonstrated by our group (Horgan et aL, 2009,
Fenton et aL, 2010).
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Comparative modelling allows accurate prediction of the 3D structure of a target
protein (CHAPk) based on its similarity to a related template protein whose structure
has been experimentally resolved by either X-ray crystallography or Nuclear
Magnetic Resonance (NMR) spectroscopy (Baker and Sali, 2001). The basis of this
approach is that evolutionary related proteins share similar 3D structures if they have
a statistically significant sequence similarity (generally >25% identity over at least
100 residues long) (Claverie and Notredame, 2007). The model prediction process
consists of four consecutive steps starting with template selection, followed by targettemplate alignment, model building and finally model evaluation (Marti-Renom et ciL,
2000).
Resolution of the 3D structure of CHAPk by comparative modelling can provide a
valuable insight into the structural basis of interaction with its cell wall peptidoglycan
substrate and mechanism of catalytic activity. This knowledge may subsequently be
used in the design of novel lysins with altered and improved catalytic domains, or the
creation of designer lysins with unique capabilities (e.g. enhanced turnover rate,
altered specificity) furthering the development of these unique enzymes as alternative
antibacterial agents in the fight against multi-drug resistant bacterial infections.

Methods
The following web-based servers, suites, molecular analysis and visualisation
programs were used in the comparative modelling process for CHAPk structure
prediction. Basic Local Alignment Search Tool (BLAST)
(www.ncbi.nlm.nih.gov/BLAST/), T-Coffee (www.tcoffee.org), MEGA4 (Tamura et
ciL, 2007), SWISS-MODEL (www.swissmodel.expasy.org) (Kiefer et ai, 2009),
iterative threading assembly refinement (I-TASSER) (Zhang, 2008), PyMOL
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(DeLano, 2002), Swiss-PdbViewer (aka DeepView) (Guex and Peitsch, 1997),
PROCHECK (Laskowski et ai,

1996) and the CATH hierarchical domain

classification program (www.cathdb.info.. Version 3.4).

Results and Discussion

Template selection
The first step in the comparative modelling of the target protein, CHAPk, was to
identify potential templates whose structure has been resolved by either X-ray
crystallography or NMR. The two main criteria for selecting suitable templates for the
target were sequence length (choosing proteins of similar length to CHAPk) tind a %
identity between the target and template sequence of >25% over the entire length of
the sequence. Generally, proteins with >25% sequence identity can be labelled
homologous and share at least 80% of their structure (Ginalski, 2006, Claverie and
Notredame, 2007). With the aim of collecting the most suitable template sequences to
form a strong multiple alignment in the second step of comparative modelling, a PSIBLAST (Position-Specific iterated BLAST) search was performed against the Protein
Data Bank (PDB) over a number of iterations. This bank is a repository of the 3D
structural data of proteins and nucleic acids which has been experimentally obtained
by X-ray crystallography or NMR. The most suitable template obtained from the PDB
search was the enzyme 2K3A; a 155-amino-acid secreted CHAP protein from
Staphylococcus saprophyticus (Rossi et ai, 2009) with 28% sequence identity to
CHAPk. This template returned the lowest (E)-value (0.01) and largest % coverage
(58%). The BLAST search converged after three iterations and no known structure
received a significantly high score, over a range of scoring matrix and gap penalties
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settings. This suggested that not many CHAP domain structures with similarity to
phage-derived CHAP domains have been experimentally resolved to date.
In order to populate the multiple alignment in step two, iterative PSI-BLAST searches
were also carried out in the non-redundant (nr) database. Although the inclusion of
homologous sequences

from the nr database does not contribute structural

information, it aids in constructing a better quality multiple alignment, which is
generally regarded as more reliable than a pair-wise structural alignment alone (MartiRenoin et ciL, 2000).

Target-template alignment and model building
In the second step of comparative modelling, the combination of selected template
structures from the PDB and sequences from the nr-database, collected in step one,
were uploaded to the T-Coffee Expresso server together with the amino acid sequence
of the target (CHAPk). The Expresso suite is a multiple sequence alignment server
which accurately aligns sequences that include structural information (Armougom et
al., 2006). The resulting multiple alignment of the CHAPk target and template
proteins was used to construct a phylogenetic tree and identify templates which were
most closely related to the target. A consensus maximum parsimony phylogenetic tree
with bootstrap analysis inferred from 1,000 replicates was constructed using the
MEGA4 software suite (Tamura et al., 2007) and taken to represent the evolutionary
history of the protein sequences analyzed (Pig. 2). Upon examination of the tree,
proteins in close proximity to the target, including the protein 2K3A (with
experimentally derived 3D structure), were selected and processed again using the
Expresso alignment algorithm.
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• YP 239884 ORF017 Stap>hylococcus phage
• ZP 04824947 amldase S epidermidis
■ ZP 06343995 amldase S aureus
1JMM protv region S mulans P IjmmA mol:p
2A48 amFP486 Anemonia majano P 2a48A mol
■ YP 238716 ORF015 Staphylococcus phage
2VPS amldase lelshmania trypanothlone P
■ 2K3A CHAP S saprophyticus P 2k3aA mol:pr
• 2AVW Mac 1 Group A Streptococcus P 2a\MvA
■ 2106 amldase Apo protein E Coll P 2lo7A
■ CAA69022 hydrolase Ply 187 Staphylococcus
1JQP peptidase I cathepsin C P IjqpA mol
CHAPMruncated_endoh^sin^ta£h^lococci^
1PVJ exotoxln B Streptococcus P IpvjA mo
1W5D (jentcillln birtding protein B subtil
3BB7 prrointerpain A Prevotella intermedi
' ZP 03614343 amidase S capitis
YP 241096 ORF042 Staphylococcus phage
ADR02788 endolysin Staphylococcus phage
' CBI50050 phage amldase S aureus TW20
■ YP 002633617 amldase phage associated S
YP 189215 puophage amidase S epidermidls
• YP 024461 lysin Staphylococcus phage K
ABL87142 truncated endolysin Staphylococ
■ YP 254248 amidase S haemolyticus
' BA083402 lysin phage phi
■ YP 003472450 Phage amidase S lugdunensis
YP 239469 ORF009 Staphylococcus phage
NP 817310 amidase Staphylococcus phage
■ YP 001491539 amidase Staphylococcus phag
■ 2HBW endopeptidase cyanobacteria Anabena
• 2P1G xylanase Bacteroides fragills P 2p1
2Z84 mouse UfSPI P 2z84A mol;proteln len
• YP 254251 protein SH2336 S haemolyticus
' ZP 03614366 glucosaminidase S capitis
2IM9 pirotein LPG0564 Legionella pneumoph
YP 240176 ORF003 Staphylococcus phage
YP 950686 hydrolase Staphylococcus phage
ZP 06614671 amidase S epidermidls
2EVR endopeptidase Nostoc Punctelorm P 2

Figure 2. Phylogenetic tree showing evolutionary relationship of 40 CHAPk homologues (15

from PDB BLAST and 25 from nr BLAST databases). The Maximum Parsimony tree was
obtained using the Close-Neighbor-Interchange algorithm level 3 in MEGA4 with a bootstrap
consensus setting of 1,000 replicates. CHAPk and the 2K3A CHAP domain protein are
underlined.

For the third step in the process (model building), the above alignment was submitted
to the Alignment mode of the web-based homology modelling server, SWISSMODEL (Kiefer et ai, 2009). This program facilitates the construction of 3D models
of a target protein using experimentally determined structures of related family
members (Bordoli et ai, 2009). 3D models were constructed using the 2K3A protein
and each structurally resolved protein from the clade containing CHAPk in the
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phylogenetic tree (Fig. 2). Inspection of predicted 3D CHAPk models in relation to
structural compatibility between the target and template, sharing of conserved amino
acids (Fig. 3) and the location of these residues in the overall structure, resulted in the
identification of the 2K3A protein as the most promising candidate for accurate
modelling of CHAPk.
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SYinflHtN 155

Figure 3. T-Coffee Fxpresso alignment of CHAPk target sequence and 2K3A structural
template sequence. Highly-conserved cysteine (C), histidine (H) and glutamic acid (E) active
site residues present in both proteins have been identified and are shown in black boxes.

In model building, accurate alignment of the target sequence with selected template is
a crucial step and poor alignments are commonly responsible for inaccurate models
(Bordoli et al., 2009). In order to examine the quality of the target-template alignment
and the models created in SWISS-MODEL Alignment mode, CHAPk was submitted
to an additional web-based server, I-TASSER (Zhang, 2008). The results from ITASSER independently identified the 2K3A protein as the most suitable template for
constructing an accurate 3D model of CHAPk. Nevertheless, upon inspection and
comparison of the predicted models from both I-TASSER and SWISS-MODEL
servers, which used the 2K3A protein as the template, it was obvious that I-TASSER
had generated a better quality alignment. The I-TASSER model displayed similar
structure and fold to the NMR resolved 2K3A protein whereas the SWISS-MODEL
server produced a predicted protein whose structure (and catalytic residue position)
was not consistent with function (Eig. 4).
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Figure 4. Cartoon images of the 2K3A template protein and predicted CHAPk models, (a)
2K3A protein structure from PDB. (b) Predicted CHAPk structure from SWISS-MODEL
Alignm.ent m.ode. (c) Predicted CHAPk structure from I-TASSER alignment.

Model F>aluation
In the fourth step, the accuracy of the predicted CHAPk model using the superior ITASSER alignment was evaluated using Swiss-PdbViewer (Guex and Peitsch, 1997)
(aka DeepView) and PyMOL (DcLano, 2002), molecular visualisation software.
PROCHECK (Laskowski et al., 1996) structural analysis program was used for the
generation of a Ramachandran plot to assess the stereochemical plausity of the
predicted model. The CHAPk protein sequence was also analysed in the web-based
CATH hierarchical domain classification system.

When the predicted CHAPk model from the I-TASSER alignment was constructed
and visualized in PyMOL, It displayed two short alpha helices packed against a sixstrand beta sheet saddle, which is a typical feature of NplC/P60 papain-related
peptidases (Anantharaman and Aravind, 2003) (Fig. 5).
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Tyrll2

Tyrl4Q

Figure 5. Predicted 31) structure of CHAPKas visualised in PyMOL. Highly conserved active
site cysteine residue (Cys54) is highlighted in orange and conserved histidine residue
(Hisl 17) is highlighted in blue. Two exposed tyrosine aromatic groups, Tyrl40 and Tyrl 12,
either side of the active site, which possibly function as rails to anchor the substrate in
position are highlighted in green.

A comparison between the newly constructed CHAPk model and the 2K3A CHAP
protein template was also assessed in PyMOL. Superposition of the two proteins
demonstrated that the CHAPk target model had a high degree of similarity to the
2K3A template (Fig. 6). Both proteins had highly-conserved cysteine and histidine
residues with Cys54-Hisll7 residues of CHAPk (magenta in Fig. 6) located
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approximately in the same position as the Cys57-Hisl09 residues in the active site of
2K3A (cyan in Fig. 6).

Figure 6. Structural comparison by superposition of the experimentally resolved 2K3A
protein (cyan) and predicted CHAPk structure (magenta). Highly conserved active site
residues are identified and labelled for both proteins. CHAPk Cys54 (orange) and Hisll7
(light blue), 2K3A Cys57 (yellow), His 109 (blue). Model created in PyMOL.
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The distance between the highly conserved cysteine and histidine residues within the
active site of each model was measured (PyMOL program) and reported in Angstroms
(A) (Fig. 7).

Figure 7. Close-up view of highly conserved Cys-His active site residues of CHAPk
(magenta) and 2K3A (cyan). CHAPk Cys54 (orange) and Hisl 17 (light blue), 2K3A Cys57
(yellow), His 109 (blue). Broken lines with labels indicate distance between residues,
measured in Angstroms

(A). Model created in PyMOL.

The distance between the Cys57 and His 109 catalytic residues of 2K3A was found to
be 3.3

A, which

is within hydrogen bond distance. This distance is a critical feature in

imparting enzymatic activity to CHAP proteins. Typically, the presence of a substrate
in the Cys-His active site, triggers the deprotonation of cysteine by the histidine
residue, resulting in a nucleophilic attack by the deprotonated cysteine on a substrate
acyl carbonyl carbon, releasing a fragment of the substrate with an amine terminus.
This leads to the formation of a tetrahedral ionic intermediate, restoration of the
histidine residue to its deprotonated form and finally the release of the carboxylic acid
moiety from the cysteine residue via hydrolysis. This results in the regeneration of the
Cvs-His active site (Lau and Bruice, 1999, Lin et al., 1997). The distance of 3.7
68

A

between the corresponding Cys54-Hisl 17 active site residues in the CHAPk model
are comparable with the active site of the 2K3A template (Fig. 7). It is therefore
plausible that the CHAPk Cys54-Hisll7 highly conserved residues have a similar
catalytic mode of action. When localized to their staphlylococcal peptidoglyan
substrate, they initiate a rapid nucleophilic attack on the peptide bond between dalanine and the first glycine in the pentaglycine cross-bridge, resulting in cleavage of
the bacterial cell wall and rapid cell death.
In total, eight conserved residues, Cys54, Hisl 17, Glul34, Asn 136, Glyl 16, Gly74,
Thr59 and Gln55 at or near the surface of the predicted CHAPk model are essential
for enzymatic activity. These residues coordinate the formation of a broad and
shallow cleft which encompasses the active site of the enzyme (Fig. 8).

Active site cleft

Figure 8. Electrostatic surface representation of CHAPk with the active site cleft indicated by

black arrow. The protein surface is coloured according to its electrostatic potential from
regions of red (negatively charged) to blue (positively charged). The fold of the protein.
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visible through the surface, is coloured according to secondary structure (a-helix in red, 13strand in yellow, and coil in green). Model created in PyMOL using the Adaptive Poison
Boltzmann Solver (APBS) program.

This was consistent with the 2K3A template protein structure (Rossi et ai, 2009). In
the 2K3A protein, active site residues Cys57-Hisl09-Cilul26 are arranged in a viable
proteolytic triad both in a sequence order and a topology typical of cysteine
peptidases, with Asnl28 acting as an additional stabilizing group (Rossi et ai, 2009).
Analysis of the CHAPk model revealed corresponding highly conserved residues
constituted by a Cys54-Hisl 17-Glul34 charge relay and an oxyanion hole
(stabilizing) residue Asnl36, near the surface of the active site cleft (Fig. 9).

Figure 8. Electrostatic surface representation of CHAPk with the active site cleft indicated by
black arrow. The protein surface is coloured according to its electrostatic potential from
regions of red (negatively charged) to blue (positively charged). The fold of the protein,
visible through the surface, is coloured according to secondary stmcture (a-helix in red, (3strand in yellow, and coil in green). Model created in PyMOL using the Adaptive Poison
Boltzmann Solver (APBS) program.
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The exact mechanism of binding of CHAPk to its peptidoglycan substrate remains
unknown. However, it was suggested that in the case of 2K3A, two exposed tyrosine
(Tyr) aromatic groups, TyrlOV and Tyrl29, either side of the active site possibly
function as rails to anchor the substrate in position (Rossi et al., 2009). This may also
be the case for CHAPk as it maintains a similar protein fold, core active site
formation, and catalytic triad as the 2K3A protein. In addition, CHAPk also has two
tyrosines (Tyrl 12, Tyr 140) on either side of its active site (Fig. 5).
The CHAPk model was assessed in PROCHECK, where a Ramachandran plot was
constructed to help identify amino acid conformations deviating from expected phi
and psi torsion values, for structural features such as bond lengths and angles. To
improve the Ramachandran values the model was processed through a minimized run
on CNSsolve (Brunger et al., 1998). This is a sophisticated program that can adjust
side chain positions to minimize collisions and help molecular dynamics to improve
the overall model. The resulting plot confirmed that a valid 3D model had been
constructed for CHAPk, with 92% of its residues positioned in most favoured and
allowed amino acid conformations.
A CATH analysis was also performed on CHAPk (162 amino acids), using default
parameters. This identified a 2iv0A00 domain (E-value 0.40, 21.8% sequence identity
over 64 residues) with an Alpha-Beta classification, Alpha-Beta-Alpha architecture
(both common in papain-like protease folds) and an isopropylmalate dehydrogenase
topology.
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Conclusion
In the present study, comparative modelling was used to construct a 3D model of the
phage derived peptidase, CHAPk. This is the first in silico 3D model of a lytic domain
from a staphylococcal phage lysin. Analysis of the 3D model provided a structural
basis for CHAPk activity and probable mechanism of its highly conserved Cys54Hisl 17-Glul34-Asnl36 active site residues, in the hyrolysis of a o-Ala-Gly substrate,
in the pentaglycine cross-bridge of staphylococcal cell wall peptidoglycan. The
proposed nucleophilic-attack mechanism of the conserved Cys54 residue on the
peptide bond in an acid-base reaction is thought to be the most likely catalytic
mechanism for all members of the CHAP NplC/P60 family of proteases.
Further exploration and investigation of phage lysins and their various domains,
particularly at a structural and bioinformatic level, can provide important information
for understanding biochemical function and specific substrate interaction mechanisms.
This in turn may contribute to specifically engineered designer lysins with diverse and
improved applications for development as novel antibacterials.
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Chapter 8
Discussion and conclusions
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In recent years, there has been an increasing worldwide prevalence of multi
antibiotic

resistant

so-called

“superbugs”

including

meticillin-resistant

Staphylococcus aureus (MRSA). This has caused significant treatment difficulties and
along with the scarcity of new antibiotics, resulted in an urgent need for alternative
antibacterials. This thesis explores an alternative antibacterial agent derived from a
staphylococcal bacteriophage namely a bacteriophage endolysin (phage lysin). In this
thesis the purification, characterisation and practical applications of an antistaphylococcal lysin (LysK) and its single-domain truncated derivative (CHAPk)
against pathogenic staphylococci including MRSA were investigated.
Chapter 1 reviewed the extensive research on recombinant bacteriophage lysins
and their future development in the context of antibacterials in different laboratories
around the world. The potent ability of lysins to rapidly lyse pathogenic Gram
positive cells upon direct contact with peptidoglyean “lysis from without” has laid the
foundation for their exploitation as powerful antibacterials. A number of studies have
demonstrated their potential in human and veterinary medicine to control and treat
various pathogens on mucosal surfaces and in systemic infections. Promising features
of lysins include their distinct mode of action, rapid bactericidal activity and the fact
that they are generally either species- or genus-specific allowing them, unlike
antibiotics, to selectively target specific pathogenic bacteria without effecting
surrounding commensal microflora. In addition, lysins have a modular structure
which allows the creation of chimeric and truncated proteins with alternate and
improved binding and enzymatic features.
Chapter 2 reviews a range of different cloning, expression and purification
techniques, used to date in the study of lysins by different research groups. The
purification techniques outlined included ion-exchange, affinity, size exclusion and
expanded bed adsorption chromatography. Two protein purification case studies are
described which incorporate His-tag affinity chromatography and Ion-exchange
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chromatography. This chapter can be used as a guide in protein expression and
purification studies for a range of recombinant phage proteins including new lysis
proteins which may be studied in the future.
Chapter 3 describes the methodology developed in this project for the
production of pure staphylococcal phage lysin, LysK. The process involved isolation,
solubilisation and on-column refolding steps in conjunction with His-tag affinity
chromatography where LysK was successfully purified to >95% homogeneity.
Purification from inclusion bodies can be more labour intensive than working with
proteins which remain in a soluble form after expression. Working with inclusion
bodies necessitates additional steps in the purification process such as isolation,
solubilisation and on-column refolding. However, this method also has a number of
merits. These include the fact that proteins are generally highly concentrated in
inclusion bodies, they are generally protected from proteolytic degradation, they can
usually be easily solubulised and inclusion bodies predominantly contain pure protein
in different states of aggregation (Schoner, Ellis et al. 1992). Investigation of the lytic
spectrum of purified LysK revealed it was active against all staphylococci regardless
of their origin, sequence type (ST) or antibiotic resistant profile including all S.
aureus sequence types in existence in Ireland from the National MRSA Reference
laboratory, Dublin. Significantly, LysK also displayed strong lytic activity against
EPS producing S. aureus strains. These are often associated with S. aureus biofilm
formation and infections with increased resistance to antibiotic treatments (Hensen,
Pavicic et al. 2000; Begun, Gaiani et al. 2007; Coulon, Vinogradov et al. 2010). No
lytic activity was observed against genera outside the genus Staphylococcus. This
demonstrated that the enzyme is genus-specific with the SH3b cell wall binding
domain responsible for exclusively attaching the enzyme to its substrate in the cell
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wall peptidoglycan of staphylococcal species (Loessner, Kramer et al. 2002). These
successful purification and lytic spectrum results were very promising and suggested
that the three-domain anti-staphylococcal phage lysin, LysK, could have widespread
applications as an alternative therapeutic against S. aureus associated infections.
Unfortunately, subsequent studies revealed that LysK was unstable and prone to
aggregation in both a temperature and concentration dependent manner. This
impacted negatively on further characterisation of the enzyme. It also restricted the
development of possible applications in in vitro and in vivo experiments. As a result
of these findings the focus of all subsequent studies switched to exploiting the 165amino-acid

N-terminal

cysteine,

histidine-dependent

amidohydrolase/peptidase

(CHAP) domain of LysK. This non tagged single-domain truncated derivative, was
designated CHAPkThe work presented in Chapter 4 revealed the stable, soluble and active nature
of CHAPk. The lysin derivative displayed strong, rapid lytic activity against live
staphylococci regardless of their origin or antibiotic resistance profile. The lytic
spectrum of CHAPk not only included all staphylococci that were susceptible to the
native three-domain LysK protein but also extended to members of the genera
Micrcococcus,

Streptococcus,

Nesterenkonia,

Arthrobacter,

Leuconostoc

and

Carnobacterium. Most notably, lytic activity was observed against live cells of S.
pyogenes which is a common cause of pharyngitis and rheumatic fever (Nelson,
Loomis et al. 2001); against S. pneumoniae a causative agent of pneumonia, acute
otitis media and meningitis (Jado, Lopez et al. 2003; Loeffler, Djurkovic et al. 2003)
and against S. mutans a contributor in the development of dental caries (Hamada and
Slade 1980; loannidis, Kakoutis et al. 2011). These results suggested that in the
absence of a SH3b cell wall binding domain, CHAPk may recognise, a common
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moiety in the peptidoglycan cross-bridge of staphylococcal and streptococcal
pathogens. The endopeptidase cleavage site of CHAPk was previously reported to be
between D-alanine and the first glycine in the pentaglycine cross-bridge of S. aureus
peptidoglycan (Becker, Dong et al. 2009), whereas the cross-bridge of streptococcal
peptidoglycan contains a D-alanine-L-alanine bond and no glycine residues
(Pritchard, Dong et al. 2004). Although lytic activity was moderate to weak against
streptococci, further investigation is worthwhile, for example, a recent study by
Becker et al (Becker, Foster-Frey et al. 2009) reported that the fusion of a
streptococcal phage lysin, displaying weak activity against S. aureus, to a
staphylococcal SH3b cell w'all binding domain resulted in the lysin displaying
increased staphylolytic and anti-streptococcal activity. Characterisation of CHAPk
over a range of parameters and conditions revealed the enzyme had unique properties
compared to previously reported lysins as it was able to maintain strong activity over
a wide range of pH (6 to 1 1), temperature (5°C to 40° C) and salt (0 to 300 rnM)
concentrations. The MIC value for CHAPk against S. aureus bovine mastitis strain
DPC5246 was 31.25 pg/ml. This value was within the range of MICs previously
reported for the streptococcal phage lysins Cpl-1 and Pal (Loeffler and Fischetti 2003)
and for the staphylococcal phage lysins C-His-LysK (Becker, Foster-Frey et al. 2008)
and ClyS (Daniel, Euler et al. 2010). Interestingly, when Becker et al. (2009) made a
deletion derivative of LysK encompassing the CHAP domain alone as a truncated
amino-acid peptide, no activity was detected in their assays (Becker, Dong et al.
2009). This contrasting observation may be due to either the different length of their
CHAP peptide (221 amino acids), the different vector expression system used
(pET21a) and different E. coll expression host used (strains DH5a and BL21). With
the increasing prevalence in antibiotic resistant pathogens there has been a renewed
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interest in the possibility of using recombinant lysostaphin for the treatment of S.
aureus infections (Climo, Patron et al. 1998; Yang, Li et al. 2007). The potential of
lysostaphin, a 27 kDa anti-staphylococcal endopeptidase, has been examined in many
in vitro and in vivo studies over a number of years as reviewed by Kumar (Kumar
2008). However a considerable drawback to the potential of this antimicrobial are
reports outlining the development of bacterial resistance (Boyle-Vavra, Carey et al.
2001; Climo, Ehlert et al. 2001; Grundling, Missiakas et al. 2006). For phage lysins
however, no development of bacterial resistance has been reported. It is suggested that
resistance is unlikely because it requires the cell to change the structure of essential
components of its cell wall (Loeffler, Nelson et al. 2001; Schuch, Nelson et al. 2002;
Loessner 2005; Pastagia, Euler et al. 2010). Chapter 4 of the thesis study proceeded to
compare the lytic activity of various concentrations of CHAPk to lysostaphin against
live S. aureus, CHAPk demonstrated superior lytic activity. At a concentration of 2.5
pg/ml, CHAPk displayed lytic activity 45-fold higher than that of lysostaphin, which
is highly significant. The enzyme thus may have potential to replace lysostaphin as an
enzymatic aid to lyse cells in various commercial kits.
Chapter 5 describes the investigation of the practical applications of CHAPk for
the treatment and prevention of staphylococcal associated infections. These included
studies on the potential of CHAPk to disrupt S. aureus biofilms and also its potential
use as a skin decolonisation agent. Significantly CHAPk was able to rapidly eliminate
mature biofilms and also able to prevent biofilm formation. Treatment of
staphylococcal biofilms with CHAPk may have numerous advantages over traditional
regimens such as the use of high concentrations of antibiotics for prolonged periods of
time. This can ultimately be ineffective, frequently leading to the necessity to remove
medical implants (Costerton, Stewart et al. 1999; Aparna and Yadav 2008). As

CHAPk is derived from a phage lysin there is low likelihood of the development of
bacterial resistance (Schuch, Nelson et cil. 2002; Fischetti 2005; Loessner 2005;
Pastagia, Euler et al. 2010) as frequently seen with conventional antibiotics which are
employed in medical practise for biofilm elimination (Raad, Darouiche et al. 1998;
Chamis, Peterson et al. 2001; Ando, Monden et al. 2004). Another additional benefit
is, unlike antibiotics, phage lysins do not negatively impact on commensal microOora
(Fischetti 2005; Loessner 2005). When applied as a spray, CHAPk eliminated 99% of
S. aureus DPC5246 from skin in 30min. Effective removal of S. aureus from patients’
skin with CHAPk prior to surgery may help prevent serious nosocomial infections.
The results of the skin disinfection experiment also suggest that CHAPk could be
included in bovine teat-dip solutions for reduction of mastitis causing staphylococci
on the udder prior to and after milking in dairy farms.
Chapter 6 of the thesis investigated the application of CHAPk as a nasal
decolonisation agent in vivo. In this study, a single treatment with CHAPk brought
about a two-log reduction in S. aureus Xen29 cells in one hour from the nasal mucosa
of mice. This result demonstrated that a single application of CHAPk administered
intranasally as a spray may potentially be able to reduce the reservoir of pathogenic
staphylococci in the nasal mucosa of humans and thus be a valuable tool in the
prevention and spread of life-threatening multi-drug resistant S. aureus. CHAPk may
also have potential to be used in a single application for the eradication of S. aureus
from the nares of patients who require emergency surgery. This is a capacity that is
currently unavailable as multiple applications of mupirocin are required for up to five
days to effectively remove S. aureus from the nose (Coates, Bax et al. 2009). In
addition, as with many other antibiotics, resistance to mupiricin is emerging (Coates,
Bax et al. 2009).
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In Chapter 7, comparative modelling was used to predict the 3D structure of
CHAPk. Significantly, this chapter generated the first in silica 3D model of a lytic
domain from a staphylococcal phage lysin. Analysis of the model provided a valuable
insight into the structural basis for CHAPk activity and probable mechanism of its
highly conserved Cys54-Hisl 17-Glul34-Asnl36 active site residues, in the hyrolysis
of a D-Ala-Gly substrate, in the pentaglycine cross-bridge of staphylococcal cell wall
peptidoglycan. Further exploration and investigation of phage lysins and their various
domains, particularly at a structural and bioinformatic level, can provide important
information for understanding biochemical function and specific substrate interaction
mechanisms. Studies of this nature contribute to the design of improved engineered
phage lysins with more diverse applications.
In summary, this thesis reports the purification, characterisation and potential
applications of a single-domain phage-derived lytic enzyme with improved enzymatic
properties over the native three-domain lysin. We have demonstrated the excellent
lytic activity of CHAPk against all staphylococci including MRSA, and its
effectiveness when used as a biofilm disruption/prevention agent aswell as a potent
decolonisation agent in the removal of S. aureus from the skin and nasal mucosa.
CHAPk provides an alternative therapeutic option and may be a valuable tool to
combat the increasing problem of infections caused by multidrug-resistant S. aureus.
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Appendix I
Ex vivo immune response study
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Introduction
The work presented in this thesis has detailed the potential of phage lysins including
CHAPk as promising antibacterial agents. One of the potential obstacles to the use of
lysins as therapeutics may concern endotoxins and antigens either present in purified
lysin solution or released during the destruction of bacteria in vivo. This may
stimulate an inflammatory immune response that can result in significant morbidity.
Therefore, a preliminary ex vivo study to assess the ability of CHAPk to induce an
inflammatory response was conducted. This study was carried out using primary
human umbilical vascular endothelial cells (HUVECs). Gene expression of the
adhesion molecules Inter-Cellular Adhesion Molecule 1 (ICAMl), Vascular Cell
Adhesion Molecule 1 (VCAMl), endothelial-leukocyte adhesion molecule 1 (Esclectin), the transcriptional activator Cyclooxygenase-2 (Cox-2), and the cytokines
Chemokine (C-X-C motif) ligand 1 (CXCLl), Interleukin 32 (IL32) or Interleukin 8
(IL8) in response to CHAPk stimulation was investigated. Tumor Necrosis Eactoralpha (TNF-a), Lipopolysaccharide (EPS), and CHAPk storage buffer (10 mM
sodium acetate) were included as controls.
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Materials and Methods

Chemicals /Reagents
LPS (Sigma, Dorset, UK) was reconstituted in sterile PBS used at 100 ng/ml. Human
TNF-a (R&D Systems, Abingdon, UK) was reconstituted in sterile PBS containing 1
% BSA, and used at a concentration of 10 ng/ml.

Cells and Cell Culture
HUVECs (Prom.ocell, Heidelberg, Germany) were maintained at 37°C from passage
number 2- 7 in EGM-2 media (EGM-2 growth supplements to Endothelial Basal
medium (EBM-2), (Lonza, Cambridge, UK). Cells were seeded at lx loVml for all
assays unless otherwise stated. CHAPk (250 ng and 10 ng) LPS and TNF-a were
added to the HUVECs for 6 Hrs.

Direct cell real-time polymerase chain reaction (qRT-PCR)
Sidestep™ lysis buffer was used to lyse HUVECs and cDNA synthesis was
performed on the lysates by reverse transcription using RT reagents (Roche).
Hydrolysis real time RT-PCR reactions (PCRs) were performed using primers
designed for the Universal Probe library (Table 1) on a Roche LC480 (Roche
Diagnostics, West Sussex, UK) to test for inflammatory gene induction and
expression. Relative mRNA expression was calculated by the AACt method (Livak et
ai, 2001).
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Table 1. Primers for gene amplification.
Gene

Gene

symbol

description

ACTS
CXCL1
iCAMI
IL32
IL8

PTGS2

SELF
VCAM1

beta actin (House
keeper control)
CXCL1 ,
chemokine
ICAM1 adhesion
molecule
IL32, Interleukin
32
IL8 Interleukin 8
PTGS2, Also
known as Cox-2,
inflammatory
intermediary
SELF, or Eselectin, .adhesion
molecule
VCAM1, adhesion
molecule

Primer forward sequence

Primer reverse sequence

GGCCAGGTCATC.ACCATT

GGATGCCACAGGACTCCAT

TCCTGCATCCCCCATAGTTA

CTTCAGGAACAGCCACCAGT

CCTTCCTCACCGTGTACTGG

GGTAAGGTTCTTGCCCACTG

CATGTGCTTCCCGAAGGT
TAGCCAGGATCCACAAGTCC

TCTATGGCCTGGTGCATTC
CTGTGAGGTAAGATGGTGGCTA

CGCTCAGCCATACAGCAA

TCATACATACACCTCGGTTTTGA

CCTCCTGACATTAGCACCATT

AGCTGCTGGCAGGAACAA

GAAGTTTAACACTTGATGTTCAAGGA

GGATGCAAAATAGAGCACGAG

Results and Discussion
Although a slight increase in ICAMl levels was observed for CHAPk at a
concentration of 250ng (Fig. 1, a), overall the results indicate that CHAPk is not
inducing any inflammation in the HUVECs (endothelial cells) (Fig. 1, b-f). The low
dose of LPS as a control does not seem to induee a response in the cells either but a
high TNF-a stimulation does. It is a good sign that there is no induction especially of
the adhesion molecules SELF (E-selectin) and VCAM-1, of the cytokines IL-8, IL32,
and CXCLl, (which induce cell recruitment) and of the transcriptional activator Cox2. Future work would be to re screen CHAPk for LPS and to try a functional human
blood assay study to see if the enzyme induces an immune response to blood PBMC’s
(peripheral blood mononuclear cells).
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Figure 1. Relative expression of the adhesion molecules ICAMl (a), VCAMl (b),
IL8 (c), IL32 (d), CXCLl (e), Cox-2 (f) after stimulation with CHAPk (250 ng and
lOng) in 10 mM sodium acetate buffer, 10 mM sodium acetate buffer alone, LPS (100
ng/ml) and TNFct (10 ng/ml) were used as controls.
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Appendix II
Properties and applieations of a cloned bacteriophage enzyme for the
elimination of antibiotic-resistant Staphylococcus aureus including
MRSA

The following paper was selected for the National Final of Roche
Researcher of the Year competition 2010
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Abstract.
In recent years, there has been an increasing worldwide prevalence of antibiotic
resistant bacteria, including MRSA. Bacteriophages (phage) are natural antibacterial
parasites and their associated lytic enzymes (lysins) represent a novel class of agents
which have the potential to eliminate problematic bacteria such as MRSA. Lysins
degrade bacterial cell-wall peptidoglycan resulting in rapid bacterial death. We cloned
the lysin-encoding gene from the genome of staphylococcal phage K. The lysin
enzyme was comprised of three domains, one of which binds to the cell wall
peptidoglycan and two of which catalyse the destruction of the peptidoglycan, namely
an amidase and a cysteine, histidine-dependent amidohydrolase/peptidase (CHAP).
Deletion analysis of the lysin gene showed that full activity against live MRSA was
retained when the lysin was truncated to its CHAP domain (designated CHAPk). This
enzyme domain, when purified by ion-exchange chromatography, was highly active
and exhibited stronger activity than the native three-domain lysin. Purified CHAPk
was evaluated and shown to work over a wide range of pH, temperature and salt
concentrations. In addition, it was analysed in the presence of a variety of inhibitors.
The effect of repeated freeze-thaw and storage over long periods was also monitored
demonstrating the enzyme’s robust nature. CHAPk lytic capabilities against S. aureus
were compared to the commercially-available recombinant enzyme lysostaphin and
significantly, CHAPk exhibited superior activity. CHAPk was also demonstrated to
effectively disrupt staphylococcal biofilms. This is highly significant as biofilms are
responsible for many catheter-associated antibiotic-resistant hospital infections. The
enzyme was evaluated in vivo (in mouse models) where it eliminated MRSA
colonization in the nasal cavity, the primary source of MRSA in nosocomial
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infections. The CHAPk domain of the bacteriophage lysin has considerable potential
as an alternative to conventional antibiotics in the elimination of infections.

Introduction.
Staphylococcus aureus {S. aureus) is responsible for a variety of infections ranging
from skin conditions to fatal sepsis, endocarditis, septicemia, pneumonia and
meningitis.' Methicillin resistant S. aureus (MRSA) is frequently the cause of
nosocomial infections globally, which can lead to prolonged hospital stays and
increased mortality. It has been shown that a substantial proportion of these serious
nosocomial infections originate from the patients own flora, nasal carriage of S.
aureus in particular being a considerable risk facter.'^’'^ Currently, topical application
of mupirocin ointment is used to reduce staphylococcal nasal carriage in clinical
settings, albeit requiring several applications.''
Lysins are bacteriophage-encoded peptidoglycan hydrolases, which, when applied
exogenously as purified recombinant proteins to Gram-positive bacteria, bring about
rapid lysis and death of the bacterial cell.^’^ Unlike antibiotics, phage lysins can be
used to selectively target specific pathogenic bacteria without affecting surrounding
commensal microHora; they are reported to have a narrow host range similar to that of
their phage producers; rendering them generally either species^’^ or genus specific.'®'"
The potential for these enzymes as novel therapeutics against a number of Gram
positive pathogens on mucosal surfaces and in systemic infections has previously
been demonstrated.

In relation to bacterial resistance, no strains have yet been

identified with resistance to phage lysins.®'^’'® Native lysins of S. aureus, have
typically shown poor expression, insolubility and low activity when generated as
recombinant proteins in a heterlogous host.
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However, in our laboratory, their

modular structure previously enabled the construction of a truncated lysin
(scientifically designated as a cysteine,histidine-dependent amidohydrolase/peptidase,
or CHAPk for short) in our laboratory to help circumvent these problems . We
optimized purification of this cloned truncated lysin, CHAPk, using cation exchange
chromatography and demonstrated CHAPk activity against cultures of every official
sequence-type of MRSA in Ireland (obtained from the MRSA reference laboratory, St
James’s Hospital, Dublin) in a wide range of relevant applications.
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Structure of bacteriophage endolysin
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Figure /. Above: modular organization of the bacteriophage endolysin ahowing cysteine histidinedependent amidopeptidase-hydrolase peptidase (CHAP), amidase and cell-wall-binding domains.
Below: peptidoglycan targets of the enzymatic domains of the bacteriophage lysin.

The complete endolysin was 495 amino acids in length. Full enzymatic activity was
displayed by the cysteine, histidine-dependent amidohydrolase/peptidase (CHAPk).
As shown in Figure 1, CHAPk disrupts the chemical bond between alanine and
glutamine in the peptide bridge in the peptidoglycan cell wall.
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Purification of the CHAPk lysin

CHAPk gene

Figure 2. Cloning vector used to over-express CHAPk bacteriophage lysin (left) and Aktaprime ion
exchange chromatography system at Cork Institute of Technology (right) used to purify the anti-MRSA
agent.

CHAPk has been cloned in our laboratory into the pQE6() (QIAGEN) plasmid
expression system (previously described" ) where it could be heterologously
overexpressed in Escherichia coli XL 1-Blue cells. The E. coli was routinely grown in
Tryptone/Yeast Extract/NaCl; induced with IPTG over 14 h and harvested by
centrifugation. The cell pellet was sonicated and CHAPk protein was purified by
cation-exchange chromatography using the Aktaprime system (GE Healthcare, US).
The final yield of CHAPk was 2 to 4 mg of CHAPk from 1 litre of E. coli culture,
which is considered substantial. CHAPk was quantified with the BCA Protein Assay
Kit (Pierce Scientific). All media was supplied by Sigma-Aldrich. It is noteworthy
that several other methods including affinity chromatography were also used over a
two and a half year period at the outset of the PhD project to purify the protein, but
the system above was the best. The lysin was stable for several weeks at 4°C and
activity was not reduced after freeze-thaw.
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Figure 3. Stages in the purification of CHAPk. Lane 10 shows the
purified 165-amino-acid product, which was used subsequently in this
study.

Bacterial strain for challenge tests
The staphylococcal strain used in this study was S. aureus Xen29 (Caliper
Lifesciences, UK). This strain has been engineered with a modified Photorhahdus
luxABCDE operon on the bacterial chromosome. ' ’“When metabolically active this
strain emits luminescence, which can then be rapidly detected and quantified using an
In-Vivo Imaging System (IVIS) (Xenogen, Ca)........“This enabled us to monitor the
presence of MRSA in real-time and to directly compare the effect of the CHAPk
agent with appropriate controls. A non luminescent MRSA strain (DPC5246) was
used for routine enzyme and other activity assays. In these cases, enzyme activity was
quantified as change in culture absorbance after addition of CHAPk.

Host range
CHAPk was effective in rapidly killing all ST-groups of MRSA in existence in
Ireland. The death profile of all staphylococci was similar as shown in Figure 4. In
addition, it was equally effective in killing aU other species of staphylococci. It
showed activity against closely related genera including Micrococcus and
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Streptococcus {pyogenes, thermophilus mutcins and pneumoniae), albeit at lower
levels in the latter genus.

Enzymatic properties
The enzymatic properties of the CHAPk enzyme were elucidated in triplicate using
live cells as substrate and equating a reduction in optical density with enzyme
activity. The data can be summarized as follows. It had a pH range of pH 3 to 11.5; a
temperature range of 4°C to 40°C; a salt (NaCl) concentration range up to 0.5 M. It
was inhibited by 100 mM MgCO, 100 mM EDTA and 100 niM CaCO.

CHAPk in vitro activity
CHAPk in vitro activity was assessed against live S. aureus Xcn29 in a
microtitreplate based assay. Briefly, S. aureus Xen29 was grown to early log phase at
an optical density of 0.3 at 590 nm (OD590), centrifuged, and then resuspended to a
final OD590 of 0.5 in 10 mM Sodium acetate buffer (pH 7.4). 100 pi aliquots of
CHAPk (at concentrations ranging from 1.0 pg/ml to 50 pg/ml) were mixed with 100
pi of the bacterial suspension and incubated at 3TC in a microtitreplate reader
(Molecular Devices, Spectra Max 340) for between 5 to 15 min. Typically 5 pg/ml of
CHAPk reduced the OD590 by 70% in 5 min (Fig. 3). To confirm that the loss in
turbidity equated to a reduction in cell viability, aliquots of lysin treated cells were
plated and CPUs enumerated on TSA plates containing 200 pg/ml kanamycin.
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Figure 4. Bacterial culture optical density (OD590nm) vs time showing activity oj CHAPagainst live
S. aureus Xen29 in vitro. The decrease in optical density (OD) over time following the addition of
CHAPk (5 pg/ml) at time zero (A) in 10 mM sodium acetate buffer was monitored at 590nm in a
Molecular Devices SpectraMax .140 plate reader. Controls (•) were included under the same
conditions with no enzxme added.

Activity against biofilms and against staphylococci on skin

Figure 5. Skin sections (5x5 cm^) treated 100 pi containing 5x 10^ CFU of S. aureus in PBS, after
which CHAPk was sprayed onto the right section. Left: natural photograph. Centre: In vivo Imaging
System Capture, showing elimination of S. aureus from the treated skin panel. Right Spray vessel used
to apply CHAPk
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Brietly, 100 |il containing 5x 10^ CPU of .S. aureus in PBS was applied individually to
three SxScm^ sections of pig skin. After an hour, one section was sprayed with sterile
water, one section was sprayed with sterile water containing CHAPk (300 pg/ml) and
the third section was not treated. 30 minutes later, each section was swabbed and plate
counts carried out. The section that was not treated returned a bacterial count of 1.3 x
1 o'’CPU. The section treated with sterile water returned a bacterial count of 1.1 x 10'^
CPU. The section treated with CHAPk (300 pg/ml) returned a bacterial count of 41
CPU. This represents a 4-log reduction (99.99%) in S. aureus counts.
Biofilms were also cultivated in micro-titre dishes. After addition of CHAPk, biofilms
were eliminated (Pigure 6).

Biofilm on microtitre plate
post 2-hrs treatment with CHAP

Untreated staphylococcal biofilm

Figure 6. Biofilm removal using CHAP/^. Left panel shows a natural photograph. Right panel shows an
Invitro Imagaing System Capture, with S. aureus glowing. Lower three wells on either side show
established staphylococcal biofilms. Upper wells on either side where established biofilms have been
removed by application of CHAP Similar results were obtained for S. epidermidis.

CHAPk in vivo nasal decolonization
Experiments were undertaken with the approval of the University College Cork
Animal Experimentation Ethics Committee. S. aureus Xen29 was grown overnight at
37°C with shaking at 170 rpm in TSB medium containing 200 ug/ml kanamycin. The
culture was diluted 1:50 in fresh media and grown as above, to mid-log, centrifuged at
6000g, washed twice in PBS pH 7.4 and resuspended in the same buffer to a
predefined titer of 3.53 x 10'° CPU/ml. Six to eight week old female BALB/c mice
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(Harlan, UK) were anesthetized using isofluorane gas (Abbott Laboratories, Kent,
UK) to ensure accurate instillation of the inoculum. A total volume of 15 [il of 3.53 x
lO’^CFU/ml of S. aureus Xen29 was intranasally instilled with a Gilson P20 pipette
in a dropwise fashion distributed equally in each nostril. One hour post-infection the
mice were again anesthetized and imaged (Exposure: 5 minutes. Binning: medium.
Color-scale: 70-500) using the IVIS system (Xenogen, USA). The luminescence from
the nasal area of each animal (expressed as Relative Light Units (RLU)) was
quantified using the Living Image software package (Xenogen, Ca). Strong
luminescence was detected in the nares of all mice, indicating successful colonization
by S. aureus Xen29 (Figure 7).

Image
Mm- -26
Max-768

CotorBai
Mm-70
Max-500:

Figure 7. BALB/c mice following S. aureus Xen29 inoculation imaged using the IVIS system (Xenogen,
Ca). A. Buffer-treated control group, imaged 1 hour post treatment with 10 mM Sodium acetate pH
7.4: B. CHAPictreated group imaged 1 hour post treatment with 60 pi CHAPk in 10 mM Sodium
acetate pH 7.4. The color bar indicates the signal intensity, with red to blue representing the high and
low bioluminescent signals, respectively.

Mice were divided into two groups {n = 1) and administered either 60 pi (20 pi per
nostril and 20 pi orally) of 925 pg/60pl CHAPk in enzyme buffer (lOmM Sodium
acetate pH 7 .4) or 60 pi of buffer alone. One hour post-treatment, mice were
anesthetized by intraperitoneal injection with a mixture of ketamine (65 mg/kg) and
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xylazine (13 mg/kg) (Vetoquinol, Ireland). Animals were imaged as described earlier.
The RLU readings from the nasal area of each mouse in both groups were recorded.
The mice were then euthanized, noses aseptically dissected, weighed, macerated in
500 |il of PBS and vigorously vortexed for 60 seconds. CPU counts for each nose
were recorded by plating out dilutions of each suspension on TSA plates containing
200 pg/ml kanamycin.
One hour post-treatment, luminescence was drastically reduced in the nares of the
CHAPK-treated group compared to strong luminescence in the buffer-treated group
(Fig. 6). The mean RLU value of the CHAPK-treated group was 2996 ± 254 while the
mean RLU value of the control group was 23366 ±3 436. This represents
approximately a 7-fold difference, which indicated a significant reduction in S. aureus
Xen29 in the enzyme-treated group. Bacteriological analysis by plating confirmed
that the single treatment with CHAPk brought about a 2-log reduction in S. aureus
Xcn29 numbers in the nares of the treated mice within one hour (p<0.001). The mean
logio value of the CHAPK-treated group was 5.29 ± 0.26 CFU/g compared to a mean
logio value of 7.35 ± 0.10 CFU/g for the buffer-treated control group.

Comparison of CHAPk with lysostaphin
CHAPk was also compared to another anti-staphylococcal peptidase, produced by
Staphylococcus simulans, namely lysostaphin in terms of its activity. It was found that
CHAP had greater than three-fold higher activity than lysostaphin in reducing the
optical density of staphylococcal cultures (Figure 8). Data was recorded as the change
in optical density (AOD) per ml per minute. These assays were carried out using
concentrations of 5 pg/ml of each enzyme at 37°C for 10 minutes.
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Lysostaphin versus CHAP Live Activity
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Figure 8. Comparison of activity of CHAPk with commercially available lysostaphin enzyme. Above,
OD readings as recorded in real-time in a microtitre plate system at 495 nm: CHAP reduces the OD
instantly on addition, Lysostaphin causes a gradual decline. Below, change in OD (ADD) caused by
lysostaphin (green) and four different batches of CHAP^ (red).

206

Conclusion
In conclusion, this single-domain truncated lysin demonstrates high solubility, rapid
lytic activity and high specificity against staphylococci in a variety of realistic
settings. These attributes, along with the low probability of bacterial resistance,^’^’'^
strongly advocates the use of this enzyme as a potent alternative therapeutic option. In
particular it should be efficacious for the elimination of multidrug-resistant S. aureus
in both clinical and community settings such as hospitals and nursing homes. A single
application of CHAPk administered intranasally or on skin as a spray has the potential
to rapidly reduce the reservoir of pathogenic staphylococci in the nasal mucosa of
humans and thus may be a valuable tool in the prevention and spread of lifethreatening multi-drug resistant S. aureus. It would be particularly relevant in highrisk groups such as immunocompromised patients, chronic disease cases and patients
4,5

requiring surgery ".

Acknowledgement
This work was financed by Science Foundation Ireland Ref 05/RF/BIM004.

207

References
1.

Lowy FD. Staphylococcus aureus infections. N Engl J

Med

1998;

339(8):520-32.
2. European

Antimicrobial

Resistance

Surveillance

System

(EARSS)

management team, members of the advisory board, and national
representatives of EARSS 2007. EARSS annual report 2006. EARSS,
Bilthoven, the Netherlands.
3. Van Rijen ML, Bonten M, Wenzel RP, Kluytmans J. Intranasal mupirocin for
reduction of Staphylococcus aureus infections in surgical patients with nasal
carriage: a systemic review. J Antimicrob Chemother 2008;61:254-261.
4. Kluytmans J, Van Belkum A, Verbrugh H. Nasal carriage of Staphylococcus
aureus: epidemiology, underlying mechanisms and associated risks. Clin
Microbiol Rev 1997; 10(3):505-20.
5. Coates T, Bax R, Coates A. Nasal decolonization of Staphylococcus aureus
with mupirocin: strengths, weaknesses and future prospects. Antimicrob
Agents Chemother 20()9;64( 1 ):9-15.
6. Loessner MJ.

Bacteriophage endolysins-current state of research and

applications. Curr Opin Microbiol 2005;8(4):480-7.
7. Fenton M, Ross RP, McAuliffe O, O’Mahony J, Coffey A. Recombinant
bacteriophage lysins as antibacterials. Bioengineered bugs 201();1( 1 ):9-16.
8. LoefOer JM, Nelson D, Fischetti VA. Rapid killing of Streptococcus
pneumoniae with a bacteriophage cell wall hydrolase. Science 2001;
294(5549):2170-2.
9. Zimmer M, Vukov N, Scherer S, Loessner MJ. The murein hydrolase of the
bacteriophage phi3626 dual lysis system is active against all tested
Clostridium perfringens strains. Appl Environ Microbiol 2002;68(11):5311-7.
10. O'Flaherty S, Coffey A, Meaney W, Fitzgerald GF, Ross RP. The recombinant
phage lysin LysK has a broad spectrum of lytic activity against clinically
relevant

staphylococci,

including

Methicillin-Resistant

aureus. J Bacteriol 2005;187(20):7161-4.

208

Staphylococcus

11. Loessner MJ, Maier SK, Daubek-Puza H, Windlinger G, Scherer S. Three
Bacillus cereus bacteriophage endolysins are unrelated but reveal high
homology to cell wall hydrolases from different bacilli. J Bacteriol
1997;179(9):2845-51.
12. Cheng Q, Nelson D, Zhu Z, Fischetti VA. Removal of group B streptococci
colonizing the vagina and oropharynx of mice with a bacteriophage lytic
enzyme. Antimicrob Agents Chemother 2005;49( 1): 111 -117.
IS.Entenza JM, Loeffler JM, Grandgirard D, Fischetti VA, Moreillon P.
Therapeutic effects of bacteriophage Cpl-1
pneumoniae

endocarditis

in

rats.

lysin against Streptococcus

Antimicrob

Agents

Chemother

2005;49(11):4789-92.
14. Grandgirard D, Loeffler JM, Fischetti VA, Leib SL. Phage lytic enzyme Cpl-1
for antibacterial therapy in experimental pneumococcal meningitis. J Infect
Dis 2008; 197:1519-1522.
15. Jado I, Lopez R, Garcia E, Fcnoll A, Casal J, Garcia P. Phage lytic enzymes as
therapy for antibiotic-resistant Streptococcus pneumoniae infection in a
murine sepsis model. J Antimicrob Chemother 2003;52(6):967-73.
16. LoefOer JM, Djurkovic S, Fischetti VA. Phage lytic enzyme Cpl-1 as a novel
antimicrobial for pneumococcal bacteremia. Infect Immun 2003;71(11):6199204.
17. McCullers JA, Karlstrom A, Iverson AR, et al. Novel strategy to prevent otitis
media caused by colonizing Streptococcus pneumoniae. PLoS Pathog
2007;3(3):e28.
18. Nelson D, Loomis L, Fischetti VA. Prevention and elimination of upper
respiratory colonization of mice by group A streptococci by using a
bacteriophage lytic enzyme. Proc Natl Acad Sci USA 2001; 98(7):4107-12.
19. Schuch R, Nelson D, Fischetti VA. A bacteriolytic agent that detects and kills
Bacillus anthracis. Nature 2002;418(6900):884-9.

209

20. Rashel M, Uchiyama J, Ujihara T, Uehara Y, Kuramoto S, Sugihara S et al.
Efficient elimination of multidrug-resistant Staphylococcus aureus by cloned
lysin derived from bacteriophage 0MR11. J Infect Dis 2007;196:1237-47.
21. Daniel A, Euler C, Collin M, Chahales P, Gorelick KJ, Fischetti VA.
Synergism between a novel chimeric lysin and oxacillin protects against
infection by Methicillin-Resistant Staphylococcus aureus. Antimicrob Agents
Chemother 2010;54(4): 1603-12.
22. Garcia P, Lopez R, Ronda C, Garcia E, Tomasz A. Mechanism of phage
induced lysis in pneumococci. J Gen Microbiol 1983;129(2):479-87.
23. Fischetti VA. Bacteriophage endolysins: a novel anti-infective to control
Gram-positive pathogens. Int J Med Microbiol 2010 May 6. [Epub ahead of
print].
24. Donovan DM, Lardeo M, Foster-Frey J. Lysis of staphylococcal mastitis
pathogens

by

bacteriophage

phi 11

endolysin.

FEMS

Microbial

Lett

2006;265(1): 133-9.
25. Obeso JM, Martinez B, Rodriguez A, Garcia P. Lytic activity of the
recombinant staphylococcal bacteriophage phiH5 endolysin active against
Staphylococcus aureus in milk. Int J Food Microbiol 2008; 128: 211-218.
26. Becker SC, Foster-Frey J, Donovan DM. The phage K enzyme LysK and
lysostaphin act synergistically to kill MRSA. FEMS Microbial Lett 2008;
287(2): 185-91.
27. Manoharadas S, Witte A, Blasi U. Antimicrobial activity of a chimeric
enzybiotic towards Staphylococcus aureus. J. Biotechnol 2009; 139(1): 1 18-23
28. Sass P, Bierbaum G. Lytic activity of recombinant bacteriophage phil 1 and
phi 12 endolysins on whole cells and biofilms of Staphylococcus aureus. Appl
Environ Microbiol 2007;73(l):347-52.
29. Morgan M, O'Flynn G, Garry J, Cooney J, Coffey A, et al.. The phage lysin,
LysK, can be truncated to its CHAP domain and retain lytic activity against
live antibiotic-resistant staphylococci. Appl. Environ Microbiol 2009;75(3):8724.

210

30. Xiong YQ. Willard J, Kadurugamuwa JL, Yu J, Francis KP, Bayer AS. Real
time in vivo bioluminescent imaging for evaluating the efficacy of antibiotics
in a rat Staphylococcus aureus endocarditis model. Antimicrob Agents
Chemother 2005;49( 1 ):380-7.
31. Yu J, Wu J, Francis KP, Purchio TF, Kadurugamuwa JL. Monitoring in vivo
fitness of rifampicin-resistant Staphylococcus aureus mutants in a mouse
biofilm infection model. J Antimicrob Chemother 2005;55(4):528-34.
32. Kadurugamuwa JL, Sin LV, Yu J, Francis KP, Purchio TF, Contag PR.
Noninvasive optical imaging method to evaluate postantibiotic effects on
biofilm infection in vivo. Antimicrob Agents Chemother 2004;48(6):2283-7.

211

Acknowledgements

212

Acknowledgements
Firstly, I would like to express sincere thanks to my supervisor Dr. Aidan Coffey. It
has been a pleasure and a privilege to work with you and to have had the opportunity
to complete my PhD under your guidance. Thank you for your support, belief and
limitless patience, it was and is, very much appreciated. Thank you also for
encouragement and allocation of funding that enabled me to attend and present my
work at a number of excellent and enjoyable conferences over the course of my PhD,
particularly the Edinburgh and Paris phage conferences and for the opportunity to
attend the up-coming phage meeting at Evergreen.
I would also like to thank the following for their help, advice and support; Prof. Paul
Ross and Dr. Olivia McAuliffe in Moorepark, (Teagasc), Dr. Jim O Mahony and Dr
Roy Sleator in CIT and last but not least Dr. Jakki Cooney in University of Limerick.
I thank Science Eoundation Ireland who provided the funding for this project. I wish
Aidan and the other postgraduate supervisors continued success in future applications
to secure funding so as the excellent research already underway can continue, and that
future undergraduate students will be as fortunate as I was, and have the opportunity
to study as a postgraduate in research.
Sincere thanks to the technicians, staff and friends who have been of great support
and help to me over the course of my studies; Priscilla, Dolores, Marian, Donal, Dave,
Fiona, Irene and all in the Biology Department.
I also wish to thank all my colleagues in the postgrad research labs who I have
worked alongside and with over the course of my PhD. Thank you all for your help,
advice and friendship.
Finally, I wish to say a very special “thank you” to the Fenton and Legnani Families.
Your support and kindness has been and continues to be immeasurable. Thank you
Noreen (Mam), Thomas (Dad), Paul, Mary, Carolina, Gianni, Paola, Valeria, Luigi,
Cristina e il piccolo Thomas. Grazie Francesco, per il suo consiglio semplice ma
indispensabile in questo periodo “prega, spera e non preoccuparti”

^Mar^

213

